

BIOMARKERS IN MEDICINE



Editors:

Pınar Atukeren

Hafize Uzun

Bentham Books

Biomarkers in Medicine

Edited by

Pınar Atukeren

*Department of Medical Biochemistry,
Cerrahpasa Faculty of Medicine,
Istanbul University-Cerrahpasa,
Istanbul, Turkey*

*Faculty of Pharmacy,
Istanbul University-Cerrahpasa,
Istanbul, Turkey*

&

Hafize Uzun

*Department of Biochemistry,
Faculty of Medicine
Istanbul Atlas University,
Istanbul, Turkey*

Biomarkers in Medicine

Editors: Pinar Atukeren & Hafize Uzun

ISBN (Online): 978-981-5040-46-3

ISBN (Print): 978-981-5040-47-0

ISBN (Paperback): 978-981-5040-48-7

© 2022, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2022.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

PREFACE	i
LIST OF CONTRIBUTORS	ii
CHAPTER 1 NEW BIOMARKERS AND IMMUNOTHERAPY DECISION	1
<i>Abdurrahman Yigit, Berkay Kuscu, Ali Kirik, Ruhsen Ozcaglayan and Cigdem Usul Afsar</i>	
NEW BIOMARKERS AND IMMUNOTHERAPY DECISION	2
Principles of Cancer Immunotherapy	2
Tumor Immunology	2
Therapeutic Approaches	3
Immune Checkpoint Inhibitors (ICI)	3
THE PREDICTIVE AND PROGNOSTIC MARKERS OF IMMUNOTHERAPY	4
Immunotherapy Toxicity	9
CONCLUSION	10
CONSENT FOR PUBLICATION	10
CONFLICT OF INTEREST	10
ACKNOWLEDGEMENT	10
REFERENCES	10
CHAPTER 2 BIOMARKERS IN GYNECOLOGIC TUMORS	16
<i>Selim Afsar</i>	
INTRODUCTION	16
Ovarian and Fallopian Tube Cancers	16
<i>Carbohydrate Antigen 125 (CA125)</i>	16
<i>Screening</i>	17
<i>Prediction Models</i>	19
<i>Prognosis</i>	19
<i>Recurrence</i>	20
<i>Human Epididymis Protein 4 (HE4)</i>	20
<i>Diagnosis</i>	21
<i>Prognosis</i>	21
<i>Risk of Ovarian Malignancy Algorithm (ROMA)</i>	21
<i>Circulating Cell-Free DNA (cfDNA)</i>	21
<i>DNA Methylation</i>	22
<i>Metabolites</i>	22
<i>MicroRNAs</i>	23
<i>Carcinoembryonic Antigen (CEA)</i>	23
<i>Alpha-Fetoprotein (AFP)</i>	23
<i>Inhibin B</i>	23
<i>Human Chorionic Gonadotropin (hCG)</i>	24
<i>Kallikreins</i>	24
<i>Other Markers</i>	24
Uterine Cancer	25
<i>CA125</i>	25
<i>HE4</i>	25
<i>Genomic Classification</i>	26
<i>Other Markers</i>	26
Cervical Cancer	27
<i>Squamous Cell Carcinoma Antigen (SCC-Ag)</i>	27
<i>Other Markers</i>	27

CONCLUSION	27
CONSENT FOR PUBLICATION	27
CONFLICT OF INTEREST	27
ACKNOWLEDGEMENT	28
REFERENCES	28

CHAPTER 3 BIOMARKERS IN UROLOGICAL CANCERS 37

Bulent Onal, Mehmet Hamza Gultekin, Muhammed Fatih Simsekoglu, Berin Selcuk and Ahmet Gurbuz

BIOMARKERS IN BLADDER CANCER	37
Blood-based Biomarkers	38
<i>Tumor Cells</i>	38
<i>CD8 Count and Immune Cells</i>	38
<i>Matrix Metalloproteinase</i>	38
<i>Epigenetic Markers</i>	38
Tissue-based Biomarkers	39
<i>Cell Cycle-based Markers</i>	39
Transmembrane- and Signaling-based Markers	39
<i>PDL/PDL1</i>	39
<i>mTOR</i>	39
<i>MDR1</i>	40
<i>Human Epidermal Growth Factor Receptor 2 (HER2)</i>	40
Apoptosis- and DNA Repair-Based Markers	40
Multiplexed Markers	41
<i>Twenty-Gene Panel, GenomeDX Gene-Expression Assay</i>	41
Urine-based Biomarkers	41
<i>Fluorescence In situ Hybridization (FISH)</i>	42
Bladder Tumor Antigen (BTA) Tests	42
Nuclear Matrix Protein-22 (NMP-22) Test	43
ImmunoCyt Test	43
CxBladder Test	44
SUMMARY	44
BIOMARKERS IN PROSTATE CANCER	44
Blood-Based Biomarkers	45
<i>PSA or hK3</i>	45
Free PSA (fPSA)	46
Prostate Health Index (PHI)	46
4Kscore Test	46
Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA)	46
Prostate-Specific Membrane Antigen (PSMA)	47
Urine-Based Biomarkers	47
<i>PCA3</i>	47
<i>Gene Fusion</i>	47
<i>SelectMDx</i>	48
<i>Annexin A3</i>	48
Tissue-Based Biomarkers	48
<i>α-Methylacyl Coenzyme A Racemase (AMACR)</i>	48
<i>Epigenetic Modifications</i>	48
<i>Genomic Expression Profiles</i>	49
<i>Inherited Genetic Markers</i>	49
SUMMARY	49

BIOMARKERS IN RENAL CELL CARCINOMA	49
Diagnostic Biomarkers	50
<i>Carbonic Anhydrase IX (CAIX)</i>	51
<i>Gene Expression Profile</i>	51
<i>Urine Biomarkers</i>	51
<i>Tissue Biomarkers</i>	52
<i>Prognostic Biomarkers</i>	52
<i>Routine Blood Biomarkers</i>	52
<i>Von Hippel-Lindau (VHL) Gene</i>	52
<i>VEGF</i>	53
<i>Survivin</i>	53
<i>p53</i>	53
<i>Ki-67</i>	53
<i>Phosphatase and Tensin Homolog (PTEN)</i>	54
Predictive Biomarkers	54
<i>Immune Checkpoint Inhibitors</i>	54
<i>mTOR Inhibitors</i>	54
Pediatric Renal Tumors:	54
SUMMARY	55
BIOMARKERS IN TESTICULAR CANCER	56
Alfa-fetoprotein (AFP)	58
Human Chorionic Gonadotropin (HCG)	58
Lactate Dehydrogenase (LDH)	58
Potential Biomarkers in Future	59
Placental Alkaline Phosphatase (PLAP)	59
Oct-3/4, Sall 4, and CD 117	60
miRNAs	60
SUMMARY	60
NEXT GENERATION SEQUENCING	61
CONCLUSION	64
CONSENT FOR PUBLICATION	64
CONFLICT OF INTEREST	64
ACKNOWLEDGEMENT	64
REFERENCES	64
CHAPTER 4 CIRCULATING BIOMARKERS IN THYROID CANCER	77
<i>Lebriz Uslu-Besli</i>	
INTRODUCTION	77
THYROID GLAND	78
CLASSIFICATION OF THYROID CANCER	79
MEDICAL MANAGEMENT OF THYROID CANCER	80
Differentiated Thyroid Cancer	80
Medullary Thyroid Cancer	81
Anaplastic Thyroid Cancer	81
SEROLOGICAL BIOMARKERS	82
Thyroglobulin	82
Anti-thyroglobulin Antibodies	83
Calcitonin and Procalcitonin	84
Carcinoembryonic Antigen	85
Other Peptides	86
LIQUID BIOPSY	86

CONCLUSION	88
CONSENT FOR PUBLICATION	88
CONFLICT OF INTEREST	88
ACKNOWLEDGEMENT	88
REFERENCES	88
CHAPTER 5 DNA METHYLATION BIOMARKERS IN CANCER: CURRENT CLINICAL UTILITY AND FUTURE PERSPECTIVES	95
<i>Sinem Durmus, Remise Gelisgen and Hafize Uzun</i>	
INTRODUCTION	96
DNA METHYLATION AND REGULATION MECHANISM	96
DNA Methylation in Cancer	100
Regional Hypermethylation	101
Global Hypomethylation	102
DNA Methylation Biomarkers in Cancer	104
CONCLUSION	108
CONSENT FOR PUBLICATION	108
CONFLICT OF INTEREST	108
ACKNOWLEDGEMENT	108
REFERENCES	108
CHAPTER 6 CIRCULATING BIOMARKERS IN PREDICTING PATHOLOGICAL RESPONSE TO NEOADJUVANT THERAPY FOR COLORECTAL CANCER	113
<i>Ravindri Jayasinghe, Umesh Jayarajah and Sanjeewa Seneviratne</i>	
INTRODUCTION	113
ESTABLISHED BIOMARKERS	116
Tissue Based Biomarkers	116
DNA Alterations: Polymorphisms	116
Gene Expression	116
MicroRNA (miRNA)	117
Blood Based Biomarkers	118
cfDNA and ctDNA	118
cfmRNA and hTERT	119
cfmiRNA	119
CIRCULATING PROTEINS/PEPTIDES	119
OTHER PREDICTIVE BIOMARKERS	120
Thymidylate Synthase (TS)	120
Epidermal Growth Factor Receptor (EGFR)	121
Cyclooxygenase 2 (COX-2)	121
Bax/bcl-2	121
P21	122
Ki-67	122
CEA	122
ctDNA	123
Circulating Tumour Cells (CTC)	124
CONCLUSION	125
CONSENT FOR PUBLICATION	125
CONFLICT OF INTEREST	125
ACKNOWLEDGEMENT	125
REFERANCES	125

CHAPTER 7 CIRCULATING BIOMARKERS IN THE MANAGEMENT OF BREAST	
CANCER	133
<i>Ravindri Jayasinghe, Umesh Jayarajah and Sanjeewa Seneviratne</i>	
INTRODUCTION	133
ESTABLISHED BIOMARKERS	134
Carcinoembryonic Antigen (CEA)	134
MUC-1	136
HER-2	137
Cytokeratins (CK)	138
Specific Classes of Circulatory Biomarkers	138
<i>Proteins</i>	138
Autoantibodies	139
Circulating Tumour Cells (CTC)	139
Exosomes	140
MicroRNA (miRNA)	140
Circulating Cell-Free DNA (cfDNA)	141
BIOMARKERS FOR DIAGNOSIS AND PROGNOSIS OF BREAST CANCER	142
MONITORING RESPONSE TO THERAPY AND SURVEILLANCE	143
CONCLUSION	143
CONSENT FOR PUBLICATION	143
CONFLICT OF INTEREST	144
ACKNOWLEDGEMENTS	144
REFERENCES	144
CHAPTER 8 CLINICAL APPLICATION OF BIOMARKERS FOR HEMATOLOGIC	
MALIGNANCIES	150
<i>Nurgül Özgür Yurttaş and Ahmet Emre Eşkan</i>	
INTRODUCTION	150
BIOMARKERS IN MYELOID NEOPLASMS	151
Acute Myeloid Leukemia	151
CYTOGENETIC CLASSIFICATION OF AML	152
MRD IN AML	156
Myelodysplastic Syndrome	157
CHROMOSOMAL ABNORMALITIES IN MDS	158
Deletions of Chromosome 5	159
Monosomy 7 and Deletions of Chromosome 7	160
Diagnosis and Classification	160
5q-syndrome/MDS with an Isolated del(5q)	161
Role of Cytogenetics in the Prognosis of MDS	161
GENETIC MUTATIONS IN MDS	162
Myeloproliferative Neoplasms	163
Mutations in PV, ET, and PMF	164
BIOMARKERS IN CHRONIC MYELOID LEUKEMIA	166
Prognostic Factors at the Time of Diagnosis	167
Use of the Mutational Analysis in CML	168
Identification of Molecular Markers of Progression	168
BIOMARKERS IN LYMPHOID NEOPLASMS	169
BIOMARKERS IN ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA	169
CYTOGENETIC AND MOLECULAR ABNORMALITIES IN ACUTE	
LYMPHOBLASTIC LEUKEMIA/LYMPHOMA	171
B-ALL/LBL with Recurrent Genetic Abnormalities	172

T-ALL/LBL	175
Cytogenetic Abnormalities in T-ALL/LBL	175
Molecular Abnormalities in T-ALL/LBL	175
EARLY T-CELL PRECURSOR ALL/LBL	176
MRD IN ALL	176
BIOMARKERS IN LYMPHOMAS	176
Biomarkers of Genetic Changes	177
B-Cell Lymphoma 6 (BCL6)	177
Tumor Protein 53 (TP53)	177
V-Myc Avian Myelocytomatosis Viral Oncogene Homolog (MYC)	177
B-Cell Lymphoma 2 (BCL2)	178
Myeloid Differentiation Primary Response 88 (MYD88)	178
Other Genetic Biomarkers in B-Cell Lymphomas	178
Other Genetic Biomarkers in Peripheral T-Cell Lymphoma (PTCL)	179
Biomarkers Related to Epigenetic Changes	180
Other Epigenetic Gene Features	181
MicroRNA and LncRNA in Diagnosis and Prognosis of Lymphomas	181
Other MicroRNAs and MicroRNA-Based Classifiers	182
Immunophenotypic Biomarkers	183
CD30	183
<i>Bcl-6, Bcl-2, and Myc</i>	184
Cyclin D1 and SOX-11	184
<i>TP53 and MDM2</i>	185
Immunophenotypic Biomarkers	185
Immunohistochemical Biomarkers of Peripheral T-Cell Lymphoma	185
Microenvironment-related Biomarkers for Prognosis and Immunotherapy	186
BIOMARKERS IN MULTIPLE MYELOMA	188
STAGING SYSTEMS	188
GENOMIC BIOMARKERS	190
Gene Expression Profiling	190
NOVEL BIOMARKERS	191
Minimal Residual Disease	191
Next-Generation Biomarkers in MM	191
Immunotherapy-related Biomarkers	192
CONCLUSION	193
CONSENT FOR PUBLICATION	193
CONFLICT OF INTEREST	193
ACKNOWLEDGEMENT	193
REFERENCES	193
CHAPTER 9 APPLICATIONS OF BIOMARKERS IN CANCER SURGERY	213
<i>Berrin Papila Kundaktepe</i>	
INTRODUCTION	213
CIRCULATING TUMOR MARKERS: CLINICAL APPLICATIONS	216
Applications Of Tumor Markers In Colorectal Cancer	216
Applications of Tumor Markers in Hepatocellular Carcinoma (HCC)	217
Applications of Tumor Markers in Pancreatic Adenocarcinoma	217
Applications of Tumor Markers In Breast Cancer	217
Circulating Tumor Cells	219
ENDOCRINE TUMOR MARKERS	220
Immunohistochemical and Circulating Tumor Markers of NETs	224

CONCLUSION	228
CONSENT FOR PUBLICATION	229
CONFLICT OF INTEREST	229
ACKNOWLEDGEMENT	229
REFERENCES	229
CHAPTER 10 A PATHOPHYSIOLOGICAL APPROACH TO CURRENT BIOMARKERS ...	238
<i>Aykut Oruc and Gonul Simsek</i>	
CARDIAC BIOMARKERS	238
Cardiac Troponins	238
<i>Troponin Subunits</i>	239
<i>Regulatory Function of Troponin</i>	240
<i>Cardiac Troponins as a Biomarker for Acute Myocardial Infarction: The Pathophysiology</i>	241
<i>Cardiac Troponins as a Biomarker in Congestive Heart Failure</i>	242
Heart-Type Fatty Acid Binding Protein	242
<i>Heart-Type Fatty Acid Binding Protein in Acute Myocardial Ischemia</i>	243
Glycogen Phosphorylase Isoenzyme BB	243
<i>Myocardial Oxygen Deficiency and GPBB Release: The Pathophysiology</i>	244
Glutathione S-Transferase P1	244
N-Terminal pro-Brain Natriuretic Peptide	245
<i>Pathophysiological Mechanisms in Synthesis and Secretion of BNP and NT-proBNP</i>	246
<i>The Receptors and The Mechanisms of Action</i>	246
CANCER BIOMARKERS	247
Alpha-Fetoprotein	247
<i>Physiological Functions and Oncogenic Roles of Alpha-Fetoprotein</i>	247
MUC1 protein and Related Biomarkers: Cancer Antigens 27.29 and 15-3	248
<i>Physiological Properties of MUC1 and Its Role in Cancer Development</i>	249
<i>MUC1 as a Cancer Biomarker</i>	250
Carcinoembryonic Antigen	251
<i>The Role of CEA in Tumoral Invasion and Metastasis</i>	252
NEURONAL BIOMARKERS	253
Glial Fibrillary Acidic Protein	253
<i>The Physiological Properties and Functions of GFAP</i>	254
<i>Reactive Astrocyte Formation and GFAP</i>	255
Neuron Specific Enolase	257
<i>The Physiological Properties of NSE and Pathophysiology</i>	257
S100B Protein	258
<i>Physiological Properties and Pathophysiology of S100B</i>	258
CONCLUSION	260
CONSENT FOR PUBLICATION	260
CONFLICT OF INTEREST	260
ACKNOWLEDGEMENTS	260
REFERENCES	260
CHAPTER 11 BIOMARKERS IN OTORHINOLARYNGOLOGY	276
<i>Ayşe Pelin Yigider and Ozgur Yigit</i>	
INTRODUCTION	276
Rhinology	277
Sinonasal Inverted Papilloma and Sinonasal Malignancies	280
Head and Neck Cancers	282
Radiosensitivity	286

Chemosensitivity	287
HPV Driven HNSCC	287
Thyroid Pathologies	288
Salivary Glands, Autoimmune Salivary Adenitis	290
Otology	291
Retraction Pockets	291
Cholesteatoma & Chronic Otitis Media	292
CONCLUSION	299
CONSENT FOR PUBLICATION	299
CONFLICT OF INTEREST	299
ACKNOWLEDGEMENT	299
REFERENCES	299
CHAPTER 12 PHARMACOGENOMIC BIOMARKERS	309
<i>Zeynep Gizem Todurga Seven, Deniz Özen and Sibel Özyazgan</i>	
INTRODUCTION	309
AUTONOM AND CARDIOVASCULAR SYSTEM DRUGS	316
Carvedilol	316
Metoprolol	317
Nebivolol	317
Propranolol	318
Propafenone	319
Quinidine	320
Cevimeline	320
Darifenacin	321
Fesoterodine	321
Mirabegron	322
Tamsulosin	323
Tolterodine	323
Formoterol	324
Indacaterol	325
Ivacaftor	325
Umeclidinium	326
Amphetamine	326
Modafinil	326
ENDOCRINE SYSTEM DRUGS	327
Chlorpropamide, Glipizide, Glyburide, Tolazamide	327
Glimepiride	328
Rosuvastatin	328
Drospirenone and Ethinyl Estradiol	328
Elagolix	329
Flibanserin	329
Ospemifene	329
CENTRAL NERVOUS SYSTEM DRUGS	330
Risperidone	330
Aripiprazole	331
Clozapine	331
Iloperidone	332
Pimozide	332
Amitriptyline, Nortriptyline, Desipramine	332
Venlafaxine	333

Duloxetine	333
Vortioxetine	333
Atomoxetine	333
Doxepine	334
Fluoxetine	334
Paroxetine	335
Brivaracetam	335
Phenytoin, Fosphenytoin	336
Oxcarbazepine	336
Carbamazepine	336
Clobazam	337
Diazepam	338
Lacosamide	338
Valproic Acid	338
Articaine and Epinephrine	338
Lidocaine and Tetracaine	339
Mepivacaine	339
Oxymetazoline and Tetracaine	339
Codeine	339
Dextromethorphan and Quinidine	340
Donepezil	341
Galantamine	341
Deutetrabenazine	341
Tetrabenazine	342
Inotersen	342
Patisiran	342
Eteplirsen	343
Nusinersen	343
Amifampridine	343
Amifampridine Phosphate	343
Meclizine	344
Siponimod	344
IMMUNOMODULATION AND CHEMOTHERAPEUTIC DRUGS	344
Abacavir	345
Ceftriaxone	345
Dasabuvir, Ombitasvir, Paritaprevir and Ritonavir	346
Dolutegravir	346
Isoniazid, Pyrazinamide and Rifampin	347
Ledipasvir and Sofosbuvir	347
Raltegravir	348
Sulfamethoxazole and Trimethoprim	348
Voriconazole	349
Abemaciclib	351
Alectinib	352
Anastrozole	352
Capecitabine	353
Cetuximab	353
Crizotinib	354
Erlotinib	355
Everolimus	355
Fluorouracil	357

Imatinib	357
Irinotecan	358
Lapatinib	359
Olaparib	360
Panitumumab	361
Pazopanib	361
Tamoxifen	362
DRUGS WITH IMPORTANT ACTIONS IN BLOOD, INFLAMMATION, AND GOUT ...	362
Clopidogrel	363
Rivaroxaban	363
Warfarin	364
Prasugrel	364
Ticagrelor	364
Azathioprine	364
Carisoprodol	365
Flurbiprofen	365
Lesinurad	365
Pegloticase, Probenecide	366
SPECIAL TOPICS	366
Dapsone	366
Ustekinumab	366
Dronabinol	367
Esomeprazole	367
Lansoprazole	368
Omeprazole	368
Pantoprazole	369
Metoclopramide	369
Ondansetron	370
Sulfasalazine	370
CONCLUSION	370
CONSENT FOR PUBLICATION	370
CONFLICT OF INTEREST	370
ACKNOWLEDGEMENT	370
LIST OF ABBREVIATIONS	371
REFERENCES	372

CHAPTER 13 CLINICAL APPLICATION OF CIRCULATING MICRORNAS AS NOVEL BIOMARKERS FOR DIFFERENT DISEASES 378

Volkan Sozer, Pinar Atukeren and Hafize Uzun

INTRODUCTION	378
The Purpose of Biomarkers	379
MicroRNAs (miRNAs)	379
MiRNAs, Signaling Pathways and Related Diseases	381
<i>Immune System and miRNAs</i>	381
Immunological Originated Diseases and miRNAs	382
<i>Cancer</i>	382
MiRNAs in Infectious Diseases	385
<i>MiRNAs and Viral Infections</i>	385
<i>MiRNAs and SARS-CoV-2</i>	386
miRNAs in Noninfectious Diseases	387
<i>miRNAs and Coronary Artery Disease (CAD)</i>	387

miRNAs and Gynecological Diseases	388
miRNAs and Autoimmune Diseases	388
miRNAs and the Nervous System Diseases	389
CONCLUSION	390
CONSENT FOR PUBLICATION	391
CONFLICT OF INTEREST	391
ACKNOWLEDGEMENT	391
REFERENCES	391
CHAPTER 14 ADVANCEMENTS IN GASTROINTESTINAL SYSTEM BIOMARKERS	407
<i>Suleyman Demiryas and Anil Orhan</i>	
INTRODUCTION	407
Diagnostic Biomarkers of Upper Gastrointestinal System Diseases	408
Diagnostic Biomarkers of Benign Upper Gastrointestinal System Diseases	408
<i>Pepsinogen I & II</i>	408
<i>Gastrin 17</i>	409
<i>Helicobacter pylori IgA - IgG and Stool Antigen Tests</i>	410
<i>Urea Breath Test – Rapid Test</i>	410
<i>Citrulline</i>	411
Biomarkers for Malignant Upper Gastrointestinal System Diseases	412
<i>Carbohydrate Antigens (CA 19-9 & CA 72-4)</i>	412
<i>Circular RNA (circRNA) - Use in Gastric Cancer</i>	413
<i>Diagnostic Biomarkers of Lower Gastrointestinal System Diseases</i>	413
Biomarkers for Benign Lower Gastrointestinal Disorders	414
<i>Calprotectin</i>	414
<i>Lactoferrin</i>	415
<i>Fatty Acid Binding Proteins (FABP)</i>	415
<i>Anti-gliadine, Anti-endomysial and Tissue Transglutaminase Autoantibodies</i>	416
Biomarkers for Malign Lower Gastrointestinal Disorders	417
<i>Carbohydrate Antigen (CA 19-9) and Carcinoembryonic Antigen (CEA)</i>	417
<i>Circular RNA – Use in Colorectal Cancer</i>	418
CONCLUSION	419
CONSENT FOR PUBLICATION	419
CONFLICT OF INTEREST	419
ACKNOWLEDGEMENT	419
REFERENCES	419
CHAPTER 15 NOVEL APPLICATIONS OF BIOMARKERS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE	425
<i>Pelin Uysal</i>	
INTRODUCTION	425
CONCLUSION	431
CONSENT FOR PUBLICATION	431
CONFLICT OF INTEREST	431
ACKNOWLEDGEMENT	431
REFERENCES	431
CHAPTER 16 BIOMARKERS IN DIABETES MELLITUS	440
<i>Fatih Orkun Kundaktepe</i>	
INTRODUCTION	440
GLYCATED ALBUMIN (GA)	441
NETRIN	443

SALIVARY GLUCOSE	444
MicroRNAs (miRNAs)	445
3-Carboxy-4-Methyl-5-Propyl-2-Furanopropanoic Acid (CMPF)	446
OTHER POTENTIAL BIOMARKERS	446
CONCLUSION	447
CONSENT FOR PUBLICATION	447
CONFLICT OF INTEREST	447
ACKNOWLEDGEMENT	447
REFERENCES	447
CHAPTER 17 BIOMARKERS AND THEIR CLINICAL APPLICATIONS IN PEDIATRICS	450
<i>Yusuf Elgormus</i>	
INTRODUCTION	450
CHILDHOOD NONCOMMUNICABLE DISEASES	452
Biomarkers in Patients with NCDs in Childhood	452
<i>Allergy, Asthma, Atopic Dermatitis (AD)</i>	452
<i>Allergic Rhinitis</i>	456
Pediatric Autoimmune Diseases	457
<i>Anti-Nuclear Antibodies (ANA)</i>	458
<i>Rheumatoid Factor (RF)</i>	460
<i>Anticyclic Citrullinated Peptide Antibodies (Anti-CCP)</i>	461
<i>Autoantibodies in Sjögren Syndrome</i>	461
<i>Type 1 Diabetes Mellitus (T1DM)</i>	462
<i>Hemoglobin A1c (HbA1c, Glycolyzed Hemoglobin) Test</i>	463
Pediatric Malignancies	463
Biomarkers in Vasculitis	465
INFECTIOUS DISEASES	467
Biomarkers in Inflammatory Diseases	467
<i>C-reactive Protein (CRP)</i>	468
<i>Serum Amyloid P (SAP) Component</i>	471
<i>Pentraxin 3 (PTX-3)</i>	471
<i>Erythrocyte Sedimentation Rate (ESR)</i>	472
<i>Procalcitonin (PCT)</i>	473
White Blood Cell Count (WBC), Absolute Neutrophil Count (ANC)	473
<i>Coronavirus Disease 2019</i>	474
CONCLUSION	474
CONSENT FOR PUBLICATION	475
CONFLICT OF INTEREST	475
ACKNOWLEDGEMENT	475
REFERENCES	475
CHAPTER 18 BIOMARKERS IN LIVER DISEASE	490
<i>Abdullah Sonsuz and Oguz Kagan Bakkaloglu</i>	
INTRODUCTION	490
Tests Used for the Detection of Liver Injury	493
Aspartate Aminotransferase (AST)	494
Alanine Aminotransferase (ALT)	494
Approach to Patients With Aminotransferase Elevation	495
Enzymes for Detection of Cholestasis	497
Alkaline Phosphatase	498
Approach to a Patient with Elevated Serum Alkaline Phosphatase	500
Gamma Glutamyl Transferase	500

5'- Nucleotidase	502
Tissue Distribution of Cholestasis Biomarkers	502
Test of Liver Synthetic Function	503
Serum Albumin	504
Prothrombin Time	504
Fibrosis Biomarkers	505
<i>Direct Biomarkers</i>	505
<i>Indirect Biomarkers</i>	506
Tumor Markers in Liver Disease	507
Old Biomarkers for HCC [116]	508
New biomarkers for HCC [117]	508
<i>AFP (Alpha-fetoprotein)</i>	509
<i>CA 19-9 and HCC</i>	510
<i>CA 19-9 and Cholangiocarcinoma (CCA)</i>	510
<i>CEA and HCC</i>	511
Liver Scores and Biomarkers for Staging and Prognostic Evaluation	511
LIMITATIONS AND FUTURE DIRECTIONS	512
CONSENT FOR PUBLICATION	512
CONFLICT OF INTEREST	512
ACKNOWLEDGEMENT	512
REFERENCES	512
CHAPTER 19 APPLICATION OF NEW ACUTE KIDNEY INJURY BIOMARKERS	522
<i>Nurhan Seyahi and Seyda Gul Ozcan</i>	
INTRODUCTION	522
Acute Kidney Injury, Biomarkers, And Definitions	522
Classification of AKI Biomarkers	523
Biomarkers of Glomerular Health	524
Biomarkers of Tubular Health	524
Biomarkers of Inflammation	526
Biomarkers of Repair	526
Other Biomarkers	527
Clinical Application of Biomarkers	528
Differentiating between Prerenal Azotemia and Acute Tubular Injury	528
Early Detection and Prognostic Stratification of AKI in Cardiac Surgery Patients	529
Differential Diagnosis of AKI in Patients with Cardiorenal and Hepatorenal Syndromes	529
Defining Prognosis of AKI in Deceased Donor Kidney Transplantation	531
Drug-induced AKI	531
Sepsis-induced AKI	532
Prognostication of AKI Outcomes	533
Biomarkers of Recovery Following AKI	534
LIMITATIONS AND FUTURE DIRECTIONS	535
CONSENT FOR PUBLICATION	536
CONFLICT OF INTEREST	536
ACKNOWLEDGEMENT	536
REFERENCES	536
CHAPTER 20 BIOMARKERS TO PREDICT SUDDEN CARDIAC DEATH	544
<i>Ali Uğur Soysal and Kivanc Yalin</i>	
INTRODUCTION	544
SCD in the Setting of an Acute Coronary Syndrome, Ischemic Cardiomyopathy	545
SCD in the Setting of Nonischemic Cardiomyopathy	548

FUTURE DIRECTIONS	551
CONSENT FOR PUBLICATION	552
CONFLICT OF INTEREST	552
ACKNOWLEDGEMENT	552
REFERENCES	552
CHAPTER 21 OXIDATIVE STRESS BIOMARKERS IN THE DIAGNOSIS AND PROGNOSIS	555
<i>Pınar Atukeren</i>	
INTRODUCTION	555
Oxidative Stress	555
Antioxidants	557
Oxidative Stress Biomarkers	557
Lipid Oxidation Products	558
Protein Oxidation Products	559
Oxidative DNA Damage	559
Glutathione and Protein Thiols	560
Nuclear Factor (erythroid-derived2)-like2 (Nrf2) and the Antioxidant Response as a Biomarker	560
MiRNA Biomarkers	560
CONCLUSION	561
CONSENT FOR PUBLICATION	561
CONFLICT OF INTEREST	561
ACKNOWLEDGEMENT	561
REFERENCES	561
CHAPTER 22 CURRENT BIOMARKERS FOR ENDOMETRIAL RECEPTIVITY	565
<i>Ozlem Erten, Aysun Tekeli Taskomur and Mustafa Albayrak</i>	
INTRODUCTION	565
Endometrial Receptivity	565
Markers Brought by New Technology	566
Genomic Study of the Endometrium	567
Proteomics Study of the Endometrium	568
Lipidomic Analysis of the Endometrium	568
Potential Markers of Endometrial Receptivity	569
Molecules with Determined Functions in Endometrial Receptivity	571
Omics and why is the Measurement of Endometrial Receptivity Important	573
CONCLUSION	574
CONSENT FOR PUBLICATION	574
CONFLICT OF INTEREST	574
ACKNOWLEDGMENT	574
REFERENCES	574
CHAPTER 23 BIOMARKERS FOR PRETERM DELIVERY	581
<i>Ismail BIYIK and Mustafa ALBAYRAK</i>	
INTRODUCTION	582
Preterm Delivery	582
Prediction in Symptomatic Pregnant Women Applying to the Hospital with Threatened Preterm Labour	583
a). <i>Fetal Fibronectin</i>	583
b). <i>IGFBPs</i>	583
c). <i>Inflammatory Markers</i>	584

Preterm Labour Prediction with Markers Checked in First and Second Trimesters	585
<i>Fetal Fibronectin</i>	585
<i>IGFBPs</i>	586
<i>Micro RNAs</i>	586
<i>Progesterone</i>	587
<i>Circulating Microparticles</i>	587
<i>Inflammatory Markers</i>	587
<i>Matrix Metalloproteinases</i>	588
<i>Aneuploidy Syndrome Screening Test Parameters</i>	589
<i>Other Hormones</i>	590
CONCLUSION	590
CONSENT FOR PUBLICATION	590
CONFLICT OF INTEREST	590
ACKNOWLEDGEMENTS	590
REFERENCES	590
CHAPTER 24 BIOMARKERS IN OBESITY AND CLINICAL APPLICATIONS TO SURGICAL PRACTICE: FROM PHARMACOGENOMICS TO SURGIGENOMICS	600
<i>Halit Eren Taskin</i>	
INTRODUCTION	600
Importance of Personalized Medicine	601
The Impact of Genes on Obesity Treatment	602
Proteomics and Lipidomic Profiling	603
Novel Biomarkers Associated with Bariatric Surgery and Eating Control	603
Novel Biomarkers for Inflammation and Endothelial Dysfunction Associated to Bariatric Surgery	604
THE FUTURE OF PERSONALIZED MEDICINE IN THE BARIATRIC-METABOLIC SURGICAL PRACTICE AND CONCLUSION	608
CONSENT FOR PUBLICATION	608
CONFLICT OF INTEREST	608
ACKNOWLEDGEMENT	608
REFERENCES	608
CHAPTER 25 CLINICAL APPLICATION OF NEW POSSIBLE BIOMARKERS IN THE ASSESSMENT AND MONITORING OF NUTRITIONAL STATUS	611
<i>Burcu Yesilkaya</i>	
INTRODUCTION	611
Nutrition and Health	611
Assessment of Nutritional Status and Methods	612
Anthropometric	613
Biochemical	614
Clinical	618
Dietary	618
Biomarkers of Dietary Patterns	618
The General Classification of Biomarkers	619
Omics	620
CONCLUSION	620
CONSENT FOR PUBLICATION	621
CONFLICT OF INTEREST	621
ACKNOWLEDGEMENTS	621
REFERENCES	621

CHAPTER 26 A PHYSIOLOGICAL APPROACH TO INFLAMMATORY MARKERS IN OBESITY	626
<i>Sila H. Bozdogan Polat and Nuran Dariyerli</i>	
INTRODUCTION	626
Macrophages	627
Neutrophils	627
B Cells	628
CD8+T Cells	628
CD4+ T Cells: T-Helper and T-regulatory Cell Subsets	628
Natural Killer T Cells	628
Eosinophils	628
Mast Cells	628
Proinflammatory Cytokines	629
Tumor Necrosis Factor-alpha	629
TNF-Like Weak Inducer of Apoptosis	629
Interleukin-1	629
Interleukin-6	630
Fetuin-A (FetA)	631
Ceramide	631
ER Stress	632
Hypoxia-Inducible Factor (HIF)	632
C-reactive Protein (CRP)	633
GlycA	633
Cell-free DNA (cfDNA)	634
Galectin-3	634
Adiponectin	635
Monocyte Chemotactic Protein-1	636
Toll-Like Receptor-4	637
Leptin	637
Visfatin	638
Vaspin	639
Omentin-1	639
Apelin	640
Cardiotrophin-1	641
Fatty Acid Esters of Hydroxy Fatty Acids	641
Micro RNA (MiRNA)- Containing Exosomes	642
CONCLUSION	642
CONSENT FOR PUBLICATION	643
CONFLICT OF INTEREST	643
ACKNOWLEDGEMENT	643
REFERENCES	643
CHAPTER 27 APPLICATION OF BIOMARKERS IN THE DIAGNOSTIC DISTINCTION OF BACTERIAL AND VIRAL INFECTIONS	655
<i>Fatma Köksal Çakırlar</i>	
INTRODUCTION	655
STANDARD BIOMARKERS	657
White Blood Cell Counts	657
POTENTIAL DIAGNOSTIC BIOMARKERS	658
ACUTE PHASE PROTEINS	658
C-Reactive Protein	658

Procalcitonin	659
Pentraxin-3	660
Hepcidin	660
Lipopolysaccharide Binding Protein (LBP)	660
CYTOKINES AND CHEMOKINES	661
High Mobility Group Box 1 (HMGB1)	662
VASODILATOR BIOMARKERS	662
Proadrenomedullin	662
BIOMARKERS RELATED TO ORGAN DYSFUNCTION	663
Endothelin-1	663
BIOMARKERS RELATED TO VASCULAR ENDOTHELIAL DAMAGE	663
Angiopoietins	664
CELL SURFACE BIOMARKERS	664
CD64	664
Presepsin	665
RECEPTOR BIOMARKERS	665
TREM-1 (Trigger Receptor Released from Myeloid Cells)	665
Soluble Urokinase Plasminogen Activator Receptor (suPAR)	666
NEW BIOMARKERS	666
Lactate	666
TRAIL AND IP-10	667
Human Neutrophil Lipocalin (HNL)	667
Calprotectin	668
Adenosin Deaminaz (ADA)	669
miRNA	669
Myxoma Resistance Protein (MxA1)	670
Lipocalin 2 (Lcn2)	671
FUTURE BIOMARKERS	671
Genome-Based Sepsis Biomarkers	671
Proteomics and Sepsis Markers	671
Intestinal Microbiota	671
Mitochondrial Markers	672
CONCLUSION	672
CONSENT FOR PUBLICATION	673
CONFLICT OF INTEREST	673
ACKNOWLEDGEMENT	673
REFERENCES	673

SUBJECT INDEX	89;
----------------------------	-----

PREFACE

“Basically, there are two things in life, science and personal thoughts. The first leads to knowledge, the second to ignorance (Hippocrates).”

This detailed book will provide a vital guide to further understanding the current and future biomarkers, one of the most important trends in healthcare today. This book will facilitate the combination of therapeutics with diagnostics and will consequently feature the key correlations between diseases and classifications of biomarkers. The book has chapters on topics such as cancer, neuroscience, cardiology, immunology/immunotherapy, metabolism, pharmacology, haematology, obstetrics and gynecology, hepatology, aging, obesity, urology, nephrology, microbiology, gastroenterology, pediatrics, surgery, pulmonary diseases, pathology and also emphasizes on the preclinical and clinical manifestation of the injury and disease process. This book will supply the unique insight of an expert with extensive experience in diagnostics and clinical laboratory, offering case studies and practical examples from different classes of biomarkers on different platforms, including new data for biomarkers in different therapeutic indications. Clinicians managing patients or clinical trials, clinical researchers, clinical laboratories, diagnostic companies, regulatory agencies, medical school graduate students, academic students, and the general public will all benefit from this book. We would like to thank all my colleagues, Bentham publishing house, and the staff for their support in the preparation of this book. A good book is a real treasure.

Pınar Atukeren

Department of Biochemistry
Cerrahpasa Faculty of Medicine
Istanbul University-Cerrahpasa
Istanbul, Turkey
Faculty of Pharmacy
Istanbul University-Cerrahpasa
Istanbul, Turkey

&

Hafize Uzun

Department of Biochemistry
Faculty of Medicine, Istanbul Atlas University
Istanbul, Turkey

List of Contributors

Abdullah Sonsuz	Department of Internal Medicine-Gastroenterology, Cerrahpasa Medical Faculty, Istanbul University – Cerrahpasa, Istanbul, Turkey
Abdurrahman Yigit	Department of Internal Medicine and Medical Oncology, Canakkale 18 Mart University Medical Faculty, Canakkale, Turkey
Ahmet Gurbuz	Department of Urology, Istanbul University- Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
Ahmet Emre Eşkazan	Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
Ali Kirik	Department of Internal Medicine, Balikesir University Medical Faculty, Balikesir, Turkey
Ali Uğur Soysal	Department of Cardiology, Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Istanbul, Turkey
Anıl Orhan	Department of General Surgery, University of Health Sciences, Haseki Training and Research Hospital, Istanbul, Turkey
Aykut Oruc	Department of Physiology, Istanbul University-Cerrahpaşa, Cerrahpasa Faculty of Medicine Istanbul, Istanbul, Turkey
Ayse Pelin Yigider	Istanbul Research and Training Hospital Otorhinolaryngology, Istanbul, Turkey
Aysun Tekeli Taskomur	Department of Obstetrics and Gynecology, Amasya University, Faculty of Medicine, Amasya, Turkey
Berin Selcuk	Department of Urology, Istanbul University- Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
Berrin Papila Kundaktepe	Department of General Surgery, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, Turkey
Bulent Onal	Department of Urology, Istanbul University- Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
Burcu Yesilkaya	Departments of Nutrition and Dietetics, İstanbul Okan University, İstanbul, Turkey
Cigdem Usul Afsar	Department of Internal Medicine and Medical Oncology, İstinye University Medical Faculty,, İstinye Üniversitesi Topkapı Kampüsü, Maltepe Mah., Teyyareci Sami Sk., No. 3 Zeytinburnu, Istanbul 34010, Turkey
Deniz Özen	Department of Medical Pharmacology, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, Turkey
Fatih Orkun Kundaktepe	Department of Internal Medicine, Istanbul Taksim Research and Training Hospital, Istanbul, Turkey
Fatma Köksal Çakırlar	Department of Medical Microbiology, Faculty of Cerrahpaşa Medicine, University of İstanbul-Cerrahpaşa, Istanbul, Turkey
Gonul Simsek	Department of Physiology, Istanbul University-Cerrahpaşa, Cerrahpasa Faculty of Medicine Istanbul, Istanbul, Turkey
Hafize Uzun	Department of Biochemistry, Faculty of Medicine, Istanbul Atlas University, Istanbul, Turkey

Halit Eren Taskin	Department of General Surgery, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey
Ismail BIYIK	Department of Obstetrics and Gynecology, Kutahya Health Sciences University, Kutahya, Turkey
Kivanc Yalin	Department of Cardiology, Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Istanbul, Turkey
Lebriz Uslu-Beşli	Department of Nuclear Medicine, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, Turkey
Mehmet Hamza Gultekin	Department of Urology, Istanbul University- Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
Muhammed Fatih Simsekoglu	Department of Urology, Istanbul University- Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey
Mustafa Albayrak	Department of Obstetrics and Gynecology, Sisli Florence Nightingale Hospital, Istanbul, Turkey
Nuran Dariyerli	Faculty of Medicine, Istanbul University-Cerrahpaşa, Cerrahpaşa, Istanbul, Turkey
Nurhan Seyahi	Department of Nephrology, Cerrahpasa Medical Faculty, Istanbul University, Cerrahpasa, Turkey
Nurgül Özgür Yurttaş	Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
Oguz Kagan Bakkaloglu	Department of Internal Medicine-Gastroenterology, Cerrahpasa Medical Faculty, Istanbul University – Cerrahpasa, Istanbul, Turkey
Ozgur Yigit	Istanbul Research and Training Hospital Otorhinolaryngology, Istanbul, Turkey
Ozlem Erten	Department of Obstetrics and Gynecology, Kutahya Health Sciences University, School of Medicine, Kutahya, Turkey
Pelin Uysal	Department of Chest Diseases, Faculty of Medicine, Mehmet Ali Aydınlar University, Atakent Hospital, Istanbul, Turkey
Pınar Atukeren	Department of Medical Biochemistry, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey Faculty of Pharmacy, Istanbul University-Cerrahpasa, Istanbul, Turkey
Ravindri Jayasinghe	Department of Surgery, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka
Remise Gelisgen	Department of Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
Ruhsen Ozcaglayan	Department of Internal Medicine, Balıkesir University Medical Faculty, Balıkesir, Turkey
Sanjeewa Seneviratne	Department of Surgery, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka
Selim Afsar	Department of Obstetrics and Gynecology, Balıkesir University Medical Faculty, Balıkesir, Turkey
Seyda Gul Ozcan	Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University, Cerrahpasa, Turkey

iv

- Sibel Özyazgan** Department of Medical Pharmacology, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, Turkey
- Sila H. Bozdogan Polat** Faculty of Medicine, Istanbul University-Cerrahpaşa, Cerrahpaşa, Istanbul, Turkey
- Sinem Durmus** Department of Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
- Suleyman Demiryas** Department of General Surgery, Istanbul University – Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey
- Umesh Jayarajah** Department of Surgery, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka
- Yusuf Elgormus** Department of Pediatric Health and Diseases, Medicine Hospital, Istanbul, Turkey
- Zeynep Gizem Todurga Seven** Department of Medical Pharmacology, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, Turkey

CHAPTER 1**New Biomarkers and Immunotherapy Decision****Abdurrahman Yigit¹, Berkay Kuscu², Ali Kirik², Ruhsen Ozcaglayan² and Cigdem Usul Afsar^{3,*}**¹ *Department of Internal Medicine and Medical Oncology, Canakkale 18 Mart University Medical Faculty, Canakkale, Turkey*² *Department of Internal Medicine, Balikesir University Medical Faculty, Balikesir, Turkey*³ *Department of Internal Medicine and Medical Oncology, Istinye University Medical Faculty, Istinye Üniversitesi Topkapı Kampüsü, Maltepe Mah., Teyyareci Sami Sk., No.3 Zeytinburnu, Istanbul 34010, Turkey*

Abstract: As immune checkpoint blockade and other immune-based therapy approaches lead to broad treatment advances among patients with advanced cancer, an important consideration is how to best select patients whose tumors will respond to these therapies. As a consequence predictive and prognostic markers are needed. There are genomic features, such as tumour mutation burden (TMB), microsatellite instability (MSI), and immune phenotype features, such as programmed death-ligand 1 (PD-L1), CTLA-4 and tumour infiltrating lymphocytes (TILs), to predict response to immunotherapies (ITs). Several studies show the correlation between TMB and predicted neoantigen load across multiple cancer types. Response to immune checkpoint inhibitors is higher in tumours with high TMB. The candidate biomarker that has been studied mostly other than TMB is PD-L1 expression in trials utilizing programmed cell death-1 (PD-1) blockade. PD-L1 and PD-1 expression are dynamic markers that change in relation to local cytokines and other factors, and the thresholds that separate “positive” and “negative” PD-L1 expressions remain under debate. PD-L1 expression is now a routine diagnostic marker for patients with newly diagnosed NSCLC. The potential applicability of PD-L1 in other disease settings is still uncertain. Microsatellite instability is characterised by high rates of alterations to repetitive DNA sequences caused by impaired mismatch repair (MMR); MSI was the biomarker was approved according to tumor's initial location. Combining TMB with specific genomic alterations is crucial. Moreover, new biomarkers are being investigated.

Keywords: Checkpoint inhibitor, Immunotherapy, MSI, PD-L1, PD1, Predictive , Prognostic , TIL, TMB.

* **Corresponding author Cigdem Usul Afsar:** Department of Internal Medicine and Medical Oncology, Istinye University Medical Faculty, Istinye Üniversitesi Topkapı Kampüsü, Maltepe Mah., Teyyareci Sami Sk., No.3 Zeytinburnu, Istanbul 34010, Turkey; Tel: +90 (530) 016 42 58; E-mails: cigdemusul@yahoo.com, cigdem.afsar@istinye.edu.tr

NEW BIOMARKERS AND IMMUNOTHERAPY DECISION

Principles of Cancer Immunotherapy

Immunotherapy (IT) is a type of biological therapy. Biological therapy is a type of treatment that uses cytokines made from living organisms to treat cancer. What is expected is that the immune system detects and destroys the abnormal cells and likely inhibits the growth of many cancers. For example, immune cells are sometimes found in and around tumors. These cells, called tumor-infiltrating lymphocytes or TILs, are a sign that the immune system is responding to the tumor. People whose tumors contain TIL generally do better than people who do not have tumors [1].

Even though the immune system can prevent or slow cancer growth, cancer cells have ways to avoid destruction mediated by the immune system. Cancer cells may have genetic changes that make them less visible to the immune system; they also have proteins on their surface that turn off immune cells and change the normal cells around the tumor, thus interfering with how the immune system responds to the cancer cells [2]. Immunotherapy helps the immune system to act better against cancer.

Tumor Immunology

Cell types involved in tumor recognition and rejection — An effective and specific cytotoxic immune response against a tumor requires a complex, serially evolving interaction between various immune cell types in the adaptive and innate immune systems. The Th1/Th2 subclasses of CD8+ lymphocytes and CD4+ T lymphocytes are conventionally referred to as cytotoxic T cells and helper T cells. CD8+ and CD4+ lymphocytes initiate the distinction between self and non-self antigens through recognition at the “immune synapse.” Natural killer (NK) cells do not require antigen presentation by the major histocompatibility complex (MHC) for cytotoxic activity. In fact, NK cells target cells with low MHC class 1 expression for degradation. Like T cells, NK cells express numerous inhibitory molecules, notably the very different lethal immunoglobulin-like receptor (KIR) subtypes [3].

Additional cell types, such as FoxP3+, CD25+, CD4+, T regulatory (Treg), and myeloid-derived suppressor cells (MDSCs), largely inhibit cytotoxic T lymphocyte activity [4, 5]. Th17 cells, subsets of CD4+ T cells that secrete interleukin (IL)-17, are implicated in autoimmunity and cancer [6]. Macrophages differentiate into at least two different phenotypes: M1 macrophages, which release interferon (IFN) gamma and are responsible for phagocytosis, and M2

macrophages, which release cytokines, such as IL-4, IL-10, transforming growth factor-beta (TGF-beta), and dampen inflammatory responses and foster tolerance [7]. The “immune synapse,” the most widely studied phenomenon in immunologic surveillance, is the ability of T lymphocytes to distinguish self *versus* non-self antigens, which are presented by antigen-presenting cells (APCs) such as dendritic cells. Overall, the cytotoxic activity of a CD8+ T cell is regulated by the presence and spatial orientation of a set of stimulatory and inhibitory receptors whose expression is regulated by a myriad of cytokines. Together, this configuration is often referred to as the “immune synapse.”

Therapeutic Approaches

A number of therapeutic approaches are being studied to unleash the immune system and control malignancy. These approaches include cytokines, T cells (checkpoint inhibitors, agonism of costimulatory receptors), manipulation of T cells, oncolytic viruses, therapies directed at other cell types, and vaccines.

Cytokines — Early approaches to immunotherapy exploited the numerous diverse effects of cytokines and other substances that affect immune cell activity. Examples include Interleukin (IL)-2, which was originally discovered as a T cell growth factor. IL-2 has pleiotropic effects on both cytotoxic T cell function and T-regulatory (Treg) cell maintenance. Effects vary in part with the dose and timing of IL-2 administration [8]. Although IL-2 use has been largely supplanted by the use of checkpoint inhibitors, bolus high-dose IL-2 achieved durable objective responses in a minority of patients with melanoma and renal cell carcinoma (RCC), serving as proof of principle that the immune system could eliminate cancer cells [9, 10].

Immune Checkpoint Inhibitors (ICI)

1) PD-1 and PD Ligand 1/2: Programmed cell death 1 (PD-1) is a transmembrane protein expressed on T cells, B cells, and NK cells. It is an inhibitory molecule that binds to the PD-1 ligand (PD-L1; also known as B7-H1) and PD-L2 (B7-H2). PD-L1 is expressed on the surface of multiple tissue types, including many tumor cells, as well as hematopoietic cells; PD-L2 is more restricted to hematopoietic cells. The PD-1:PD-L1/2 interaction directly inhibits apoptosis of the tumor cell, promotes peripheral T effector cell exhaustion, and promotes the conversion of T effector cells to Treg cells [11, 12]. Based upon prolonged overall survival in phase III trials and durable responses in phase II studies, antibodies inhibiting PD-1 (pembrolizumab, nivolumab) and PD-L1 (atezolizumab, avelumab, durvalumab) have been approved for a number of clinical indications and are being evaluated in multiple other malignancies; these are discussed in specific disease-related topics.

Biomarkers in Gynecologic Tumors

Selim Afsar^{1,*}

¹ Department of Obstetrics and Gynecology, Balıkesir University Medical Faculty, Balıkesir, Turkey

Abstract: Gynecologic malignancies are one of the most frequent cancers amongst women. Biomarkers are crucial for the differential diagnosis of adnexal masses; however, their potential for diagnosis is limited. In the era of difficulty in ovarian cancer screening, novel biomarkers are defined, but CA125 still remains the most valuable one. Circulating tumor DNAs, DNA hypermethylation, metabolites, microRNAs, and kallikreins have recently turned out as ovarian cancer biomarkers and are being applied to clinical practice. For uterine cancer, genomic classification has now been described, it will be used as a prognostic tool. In this chapter, we describe ovarian, endometrial, and cervical cancer biomarkers in detail.

Keywords: Biomarker, CA125, Cervical cancer, cfDNA, HE4, High-copy number, miRNA, MSI, MSS, Ovarian cancer, POLE-mutated, ROMA, SCC-Ag, Uterine cancer.

INTRODUCTION

The lifetime risk of developing ovarian cancer (OC) is approximately 1.3% in women, and OC is the most common cause of gynecological cancer deaths [1]. OC is a generalized term for tumors that involve the ovary, and it can be classified into three different subgroups: epithelial, germ cell, and specialized stromal cell tumors. The most common form of ovarian cancer is epithelial ovarian cancer (EOC), which consists of four main histologic subtypes: serous, endometrioid, clear cell, and mucinous cancer. Serous ovarian carcinoma is the most common form [2].

Ovarian and Fallopian Tube Cancers

Carbohydrate Antigen 125 (CA125)

CA125 is a mucin-type glycoprotein that is associated with the cell membrane,

* Corresponding author Selim Afsar: Department of Obstetrics and Gynecology, Balıkesir University Medical Faculty, Balıkesir, Turkey; Tel: +90 (266) 460 40 00; E-mail: selimafsar@yahoo.com

and it is recognized by the OC125 murine monoclonal antibody. CA125 is not only expressed in the tubal, endometrial, and endocervical epithelium but also mesothelial cells of the pleura, pericardium, and peritoneum [3 - 5]. Hence, CA125 is not a specific biomarker for OC.

The cutoff value of 35 U/mL is used in routine clinical practice in premenopausal women, but levels of CA125 tend to be lower in postmenopausal women, so a cutoff value of 26 U/mL has been suggested [4, 6]. Elevated serum levels of CA125 can be detected in approximately 85% of patients with EOC, especially in serous type, but also in benign and physiological states such as fibroids, endometriosis, menstruation, and pregnancy as well as in other malignancies such as pancreas, liver, colorectal and breast cancer (Table 1) [7 - 9].

Screening

Screening modalities for OC are primarily focused on CA125 and the use of transvaginal ultrasonography (TVU). Early detection of OC that requires a screening test with high sensitivity (>75%) and ultrahigh specificity (99.7%) could improve overall survival [10]. False positivity for CA125 has been shown approximately in 1% of the healthy population and 5% of patients with benign disease that limits its use as a stand-alone test [4, 11].

Table 1. CA125 elevations in gynecologic diseases and non-gynecologic malignancies.

Disease Category	Type of Disease	CA125 > 35 u/ML (%)
Benign gynecologic	Ovarian Cysts ^a	14
	Abscess/Hydrosalpinx/PID ^a	37
	Endometriosis/Endometriomas ^a	67
	Fibroid (Leiomyomas) ^a	26
	Cystadenoma, Adenofibroma, Cystadenofibroma ^a	20
	Serous Epithelial Tumors ^a	20
	Mucinous Epithelial Tumors ^a	18
	Germ Cell Tumors (Mature Teratoma) ^a	21
	Sex Cord Stromal Tumors (Thecoma, Fibrothecoma) ^a	52
Ovarian cancer ^b	Serous ^b	80
	Mucinous ^b	69
	Endometriod ^b	75
	Clear cell ^b	78

(Table 1) cont....

Disease Category	Type of Disease	CA125 > 35 u/ML (%)
Gynecologic cancers ^{b,c}	Endometrial ^b	25
	Cervical ^c	39
Non-gynecologic cancers ^d	Pancreas ^d	52.6
	Liver ^d	49.0
	Biliary Tract ^d	45.8
	Colorectal ^d	15.1
	Breast ^d	17.6

^aMoore RG, Miller MC, Steinhoff MM, *et al.* Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. *Am J Obstet Gynecol* 2012; 206(4):351. ^bJacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. *Hum Reprod* 1989; 4:1-12. ^cMuyldermans M, Cornillie FJ, Koninckx PR. CA125 and endometriosis. *Hum Reprod Update* 1999; 1(2):173-87. ^dBast RC Jr, Klug TL, St John E, *et al.* A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. *N Engl J Med* 1983; 309:883-7.

The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial enrolled 78,216 women aged 55-74 years, with 39,105 women randomized annual screening. Women were screened annually with CA-125 for 6 years and TVU for 4 years. Neither at a median follow-up of 12.4 years nor at an extended follow-up of 14,7 years, the PLCO trial reported reduction in mortality rates [12, 13]. On the contrary, the false positivity in the PLCO trial was approximately 5%, resulting in complicated surgeries [12].

In the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), 202,638 postmenopausal women aged 50-74 were randomized to either control or annually multimodal screening group (MMS) or ultrasonography screening (USS) group in a 2:1:1 ratio [14]. Although the trial reported an insignificant mortality reduction on primary analysis (15% in the MMS group, 11% in the USS group), further analysis revealed that a declined mortality was seen after seven years of follow-up (23% in the MMS group, 21% in the USS group) [14].

Hereditary breast-ovarian cancer (HBOC) syndrome, which is related to mutations in BRCA1 and BRCA2 genes, accounts for 14% of EOC. Other identified genes (Lynch syndrome, RAD51C, RAD51D, and BRIP1) account for a minor percentage of EOC [15]. The average risk of developing OC is around 44-45% for BRCA1-mutated women and 12-17% for BRCA2-mutated women [16, 17]. Serous ovarian cancer is the most common histologic subtype for both BRCA mutation carriers [18].

The lifetime risk of endometrial cancer in Lynch syndrome (LS) carriers is 40% due to mutations in mismatch repair genes (MLH1, MSH2, MSH6, and PMS2)

CHAPTER 3**Biomarkers in Urological Cancers****Bulent Onal^{1,*}, Mehmet Hamza Gultekin¹, Muhammed Fatih Simsekoglu¹, Berin Selcuk¹ and Ahmet Gurbuz¹**¹ *Department of Urology, Cerrahpasa School of Medicine, Istanbul University - Cerrahpasa, Istanbul, Turkey*

Abstract: Urological tumours have become one of the most common cancers in the last decade. It is important to apply an approach that evaluates many factors related to the patient and the disease carefully to minimize cancer-associated morbidity and mortality. The clinical use of cancer biomarkers is a valuable part of the clinical management of urological cancers. These biomarkers may lead to optimized detection, treatment, and follow-up of urological cancers. With the development of molecular research, newly developed biomarkers and next-generation sequencing have also contributed to patient management. In this chapter, we will present biomarkers in the most common urological cancers under subheadings of bladder cancer, prostate cancer, kidney cancer, and testicular cancer. Additionally, due to the development that occurred in the next-generation sequencing (NGS), all the above-mentioned malignancies are evaluated with regard to NGS.

Keywords: Biomarkers, Clinical management, Molecular research, Next-generation sequencing, Patient management, Urological cancers.

BIOMARKERS IN BLADDER CANCER

Bladder cancer (BC) is the 11th most commonly diagnosed cancer worldwide [1]. The most common symptom of BC is hematuria. Eighty-five percent of patients newly diagnosed with BC have painless macroscopic hematuria, and almost all present microscopic hematuria [2].

The gold standard test in the diagnosis of BC is cystoscopy. Currently, white light cystoscopy is the standard of care for the diagnosis of BC, and it is considered to be highly sensitive and specific for this type of cancer. However, it remains costly and somewhat invasive. As a result of the search for less invasive methods in the diagnosis and follow-up of bladder tumors, tissue-, blood- and urine-based biomarkers have also been developed.

* **Corresponding author Bulent Onal:** Department of Urology, Cerrahpasa School of Medicine, Istanbul University - Cerrahpasa, Istanbul, Turkey; Tel: +90212 2304300; E-mail: bulent.onal@istanbul.edu.tr

Today, only urine-based biomarkers are used in clinical practice, and although many studies have been conducted on tissue- and blood-based biomarkers, none have found a place in clinical use. In this article, biomarkers are briefly discussed under separate sub-headings, and examples are given.

Blood-based Biomarkers

Tumor Cells

The presence of tumor cells in the blood has been associated with advanced-stage disease in solid organ malignancies. In a study investigating the prognostic effects of circulating tumor cells captured with the CellSerch system, the rates of recurrence, cancer-specific mortality, and overall survival (OS) were significantly lower in those with circulating tumor cells [3].

CD8 Count and Immune Cells

The CD8 count is a measure of the presence of cytotoxic T cells that may be involved in the immune response against tumor cells. One study reported that a low CD8 count was associated with recurrence-free survival after the transurethral resection of bladder tumor (TUR) [4]. However, the literature on the neutrophil-to-lymphocyte ratio (NLR), a marker of acute phase inflammation, is controversial. In a meta-analysis of 21 studies analyzing the prognostic role of NLR in BC, the authors correlated elevated pre-treatment NLR with OS, recurrence-free survival, and disease-free survival in BC [5]. In contrast, a secondary analysis of the SWOG 8710 trial reported that NLR was not a prognostic or predictive biomarker for OS in muscle-invasive bladder cancer, and it was not able to demonstrate OS benefit from neoadjuvant chemotherapy [6].

Matrix Metalloproteinase

Matrix metalloproteinases (MMPs) are calcium-dependent zinc-containing endopeptidases that are capable of degrading all types of extracellular matrix proteins. In the literature, several MMP isoforms have been simultaneously evaluated, but only MMP-7 levels have been associated with cancer-specific mortality [7].

Epigenetic Markers

Epigenetics investigate molecular DNA changes, including methylation and

histone alterations. These DNA changes are dynamic processes that determine which parts of DNA are more frequently transcribed and which regions are silenced. In one study, the promoter methylation of 17 genes was investigated, and that of five gene loci (RASSF1, E-cadherin, TNFSR25, EDNRB, and APC) was defined as a marker for tumor progression [8]. In another study, methylation at the RASSF1A and DAPK loci was identified as an independent predictor for tumor progression [9].

Tissue-based Biomarkers

Cell Cycle-based Markers

These biomarkers consist of p53, pRB, Ki67, cyclins, p21, and p27. Cell cycle regulators are among the most common mutated markers in BC and have been shown to be predictors of aggression, metastases, and cancer-specific mortality in many studies [10].

In a retrospective study with a large sample size, the authors examined four cell-cycle regulators (p53, pRB, p21, and p27) and found that a combination of the four markers was able to significantly improve the prediction of recurrence and cancer-specific mortality [11]. Prospective studies have also revealed that cell cycle-based markers can predict the upstage condition after TURP and the risk of recurrence after cystectomy [12, 13].

Transmembrane- and Signaling-based Markers

PDL/PDL1

In recent years, the programmed-death ligand (PDL) system has become an attractive alternative to treat urothelial carcinoma. PDL is a transmembrane protein pair that helps keep CD8 (cytotoxic) T cells from attacking normal cells. High levels of PD-L1 expression have been shown to be associated with advanced BC and poorer survival outcomes [14].

mTOR

The mammalian target of the rapamycin pathway regulates cell growth, proliferation, motility, and survival. These processes are dysregulated in the presence of multiple malignancies and generally downregulated in muscle-invasive bladder cancer [15].

Circulating Biomarkers in Thyroid Cancer

Lebriz Uslu-Beşli^{1,*}

¹ Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey

Abstract: Thyroid cancer is the most important endocrine cancer with increasing incidence. While thyroid cancers, especially papillary thyroid cancers, are known to exhibit generally a favorable outcome with excellent survival rates, some thyroid cancers are more aggressive with a poor prognosis. Several different biomarkers have been introduced for the diagnosis of disease, identification of tumor load, assessment of therapy response, and the detection of recurrence during follow-up of the thyroid cancer patients. This chapter gives a brief overview of the circulating biomarkers used in thyroid cancer patients.

Keywords: Biomarkers, Calcitonin, Carcinoembryonic antigen, Liquid biopsy, Thyroglobulin, Thyroid cancer.

INTRODUCTION

Thyroid cancer incidence has increased significantly over the last few decades, although the mortality rates have stayed relatively constant [1]. The demographics of thyroid cancer have also changed, with decreasing proportion of anaplastic thyroid cancers (ATC) and an increasing proportion of papillary thyroid cancers (PTC). Relatively stable mortality rates despite an increasing incidence have been attributed to the over-diagnosis of thyroid cancer as a result of better diagnostic tests, as well as to advancements in the treatment strategies of thyroid cancer.

Thyroid cancers are a heterogeneous group of tumors with cell types of different origin, developing from thyroid nodules and exhibiting different genetic alterations, biological behavior, and clinical course. Therefore, different biomarkers exist, each reflecting the unique biology of the selected tumor type. To date, there is not a single circulating biomarker that can be used to diagnose thyroid cancer has been found; rather, the diagnosis relies mainly on ultrasonography and fine-needle aspiration biopsy.

* Corresponding author Lebriz Uslu-Beşli. Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey; Tel: +90 (532) 494 05 96; E-mail: lebriz.uslu@istanbul.edu.tr

Thyroglobulin (Tg) is the most important biomarker for differentiated thyroid cancer (DTC), which originates from follicular epithelium, and calcitonin is the primary biomarker for medullary thyroid cancer (MTC), which stems from parafollicular cells of the thyroid gland. Basal serum calcitonin is a useful biomarker to determine the extent and presence of lymph node metastases in MTC patients.

Thyroid cancer is a malignant disease with generally a favorable prognosis, and relatively low rates of disease-related mortality compared to other cancers, and several studies have been conducted regarding biomarkers for diagnosis, therapy response assessment, and the follow-up of thyroid cancer patients. This chapter gives a brief overview on the histology of the thyroid gland, histopathology of thyroid cancers, their medical management and reviews the most important serum biomarkers that are used in the clinical management of thyroid cancer patients, as well as the liquid biopsy technique, which is a promising tool for the diagnosis and follow-up of thyroid cancer patients.

THYROID GLAND

The thyroid gland is located anterior to the larynx and consists of two lobes and a connecting isthmus in between. It is mainly composed of follicles, which consist of cuboidal-columnar epithelium filled with Tg-rich colloid. The major function of the thyroid follicles is to synthesize thyroid hormones, mainly thyroxine (T_4) and to a lesser extent triiodothyronine (T_3), both of which function in the regulation of metabolic rate and are required throughout human life. During fetal development and childhood, thyroid hormones are crucial for normal brain development, and they are required as regulators of intermediary metabolism in adults [2]. T_4 and T_3 are stored in great quantity in the extracellular colloid within Tg to avoid deleterious effects of thyroid hormone deficiency [2, 3].

Thyroid hormone synthesis and storage involve a unique process where iodide is necessary. Synthesis of thyroid hormones mainly comprises four stages: iodide trapping, which involves uptake of the circulating iodide by a membrane transport protein called sodium/iodide symporter (NIS) located in the basolateral membrane of follicular cells; synthesis of Tg within follicular cells; oxidation of iodide to form oxidized form of iodine by the enzyme thyroid peroxidase (TPO) located in the apical cell membrane and transport of iodine into the follicle cavity by pendrin; finally organification of Tg, which involves iodination of tyrosine residues of Tg within the colloid. Tyrosine is first iodized to monoiodotyrosine (MIT) and then to diiodotyrosine (DIT) by the enzyme TPO. The coupling of two DITs forms T_4 , whereas the coupling of one MIT and one DIT forms T_3 .

Thyroid follicle function is regulated by pituitary thyroid-stimulating hormone (TSH), also called thyrotropin, which stimulates both synthesis of thyroid hormones and their release into the systemic circulation. Upon TSH stimulation, the colloid is taken into the follicular cells and digested in lysosomes to liberate T_4 and T_3 , and finally, T_4 and T_3 are released into the systemic circulation. MIT and DIT, which are freed from Tg during digestion, are not released into the blood; instead, they are recycled for new hormone synthesis.

Apart from thyroid follicles, the thyroid gland also has another cell type, namely parafollicular cells, or C cells, which are located as part of the follicular epithelium or as isolated clusters between thyroid follicles. Parafollicular cells are neuroendocrine cells that synthesize mainly calcitonin, which is a hormone responsible for calcium metabolism. When the serum calcium level is elevated, calcitonin is secreted, which in turn decreases bone resorption and increases calcium absorption by the skeletal system to normalize serum calcium levels. Carcinoembryonic antigen (CEA), adrenocorticotrophic hormone (ACTH), B-melanocyte stimulating hormone, chromogranin, histaminase, neurotensin, and somatostatin are the other hormones or biological amines secreted by parafollicular cells.

CLASSIFICATION OF THYROID CANCER

Major subtypes of thyroid carcinomas are PTC (75-85%), follicular thyroid carcinoma (FTC) (10-20%), MTC (5%), and ATC (<5%) [4].

DTCs, including PTC and FTC, are derived from the follicular epithelium, and they preserve some of the normal thyrocyte functions, such as Tg synthesis and response to TSH stimulation. PTC is the most common thyroid cancer subtype in populations with sufficient iodine intake, whereas the incidence of FTC is higher in areas with iodine deficiency. Most patients with PTCs have favorable outcomes after appropriate disease management, whereas FTCs have a higher risk for recurrence and distant metastasis and lower survival rates compared to PTCs [5, 6]. Mutations in RET, RAS, or BRAF proto-oncogenes, all of which trigger the activation of mitogen-activated protein kinase (MAPK) cascade, are present in nearly 70% of PTC patients, and RAS mutated PTCs are typically follicular variant subtype of PTC [7 - 9]. RAS mutations and PAX8-PPAR γ 1 fusion are seen frequently in FTC patients [10, 11]. While cervical lymph nodes are the most common site of metastasis for PTC, hematogenous metastases to lungs and bones are more frequent in FTC [5].

MTCs are derived from parafollicular cells, therefore, unlike DTCs, they do not produce Tg; instead, they produce calcitonin, and they do not respond to TSH stimulation. Most MTCs are seen sporadically (70-80%), but familial autosomal

DNA Methylation Biomarkers in Cancer: Current Clinical Utility and Future Perspectives

Sinem Durmus^{1,*}, Remise Gelisgen¹ and Hafize Uzun²

¹ Department of Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey

² Department of Biochemistry, Faculty of Medicine, Istanbul Atlas University, Istanbul, Turkey

Abstract: Epigenetic alterations are related to inherited but reversible changes in modifications that regulate gene activity beyond the DNA sequence. DNA methylation is the best characterized epigenetic modification, controlling DNA stability, DNA structure, transcription, and regulation, contributing to normal development and differentiation. In this section, we first discuss the cellular functions of DNA methylation and focus on how this fundamental biological process is impaired in cancer. Changes in DNA methylation status in cancer have been heralded as promising targets for the development of diagnostic, prognostic, and predictive biomarkers due to their noninvasive accessibility in bodily fluids (such as blood, urine, stool), reversibility, stability, and frequency. The absence of markers for definitive diagnosis of most types of cancer and, in some cases, DNA methylation biomarkers being more specific and sensitive than commonly used protein biomarkers indicate a strong need for continued research to expand DNA methylation markers. Although the information on changes in DNA methylation status in cancer and research on its clinical relevance is rapidly increasing, the number of DNA methylation biomarkers currently available as commercial tests is very small. Here, we focus on the importance of DNA methylation location and target genes likely to be developed in the future for the development of biomarkers in addition to existing commercial tests. Following a detailed study of possible target genes, we summarize the current clinical application status of the most studied and validated DNA methylation biomarkers, including *SEPT9*, *SDC2*, *BMP3*, *NDRG4*, *SFRP2*, *TFPI2*, *VIM* and *MGMT*.

Keywords: Biomarkers, Cancer, Carcinogenesis, CpG islands, DNA Damage, DNA Methylation, Genes, Gene Expression, Gene Silencing, Hypomethylation, Hypermethylation, Methyltransferases, Neoplasms, Oncogenes, Tumor, Tumor Suppressor.

* Corresponding author Sinem Durmus: Department of Medical Biochemistry, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpasa Istanbul, Turkey; Tel: +90 (538) 729 79 29; E-mail: durmus.sinem@gmail.com

INTRODUCTION

Although cancer has been defined as a disease caused by mutations in driver genes for a long time, it is now accepted that epigenetic modifications also play a role in both the development and progression of the tumor [1]. Epigenetics is the field of science that studies gene activation or genetic changes in its function through processes, such as histone modification, DNA methylation, and acetylation without changing the DNA sequence. Although all cells in an organism contain the same genetic material, the changes that lead to the emergence of a wide variety of cell types are due to these epigenetic mechanisms [2]. In other words, epigenetic mechanisms are very important regulators for normal development and differentiation [3]. However, as can be predicted, the defects in this regulatory mechanism also lead to the emergence of various diseases such as cancer. If the cancer is to be mentioned, which has a complicated etiology, it should be noted that epigenome dysregulation, especially DNA methylation, is quite common in cancer and is associated with tumorigenesis and cancer phenotype [4]. Identifying epigenetic changes, such as DNA methylation and determining parameters that can be used as biomarkers, are extremely important, especially in determining the focal points of promising personalized treatment approaches. The main point of importance for these therapies is that, unlike genetic changes, such as mutations, epigenetic changes are inherited but reversible. In addition, DNA methylation markers are very important in terms of detecting diseases, such as cancer at an early stage.

DNA METHYLATION AND REGULATION MECHANISM

The best-known type of DNA methylation is defined as the formation of 5-methylcytosine (5mC) by attaching the methyl group (-CH₃) to the 5'-position of the pyrimidine ring of the cytosine (Fig. 1). This methylation can occur in cytosines in the context of CpG, CHG, and CHH (where H refers to either A, C or T nucleotides), but in humans, it usually occurs in palindromic CG (or CpG) dinucleotides, and more rarely in non-CpG sequences [5, 6]. In recent years, it has been shown that *N*⁶-methyladenine (*N*⁶-mA) exists in the mammalian genome. Although it has been stated that this methylation may play a role in epigenetic regulation, its function has not been clearly clarified yet [7, 8]. 5-methylcytosine tends to spontaneously deaminate and undergo C-T transition. Because of this high mutagenicity, the distribution of CpG dinucleotides in the genome is thought to be unevenly distributed throughout the evolutionary process (also called CpG suppression) and is observed less frequently in the genome than expected. However, there are clusters of CpG sites, and such clusters are referred to as CpG islands (CGIs). CGIs are found in the promoter regions of 50% of the genes in the genome and are not methylated in normal cells, thereby transcription occurs.

Approximately 70-80% of the CpG sites are methylated; however, only 10% of the CpGs are methylated in the CGIs and active regulatory regions. These are CGIs in the promoter region of repressed genes such as X chromosome inactivated genes, imprinted genes and some tissue specific genes [6, 9 - 11]. Methylated cytosines do not occur randomly in the genome, they are largely found in transposable elements and repetitive DNA sequences, including centromeric and pericentric satellite DNA [12].




Fig. (1). DNA methylation. Formation of 5-methylcytosine (5mC) by attaching the methyl group from the methyl carrier, S-adenosyl-L-methionine (SAM), to the 5'-position of the pyrimidine ring of the cytosine.

DNA methylation is catalyzed by the DNA methyltransferase (DNMT) family that mediate the covalent addition of a methyl group from the methyl carrier, S-

Circulating Biomarkers in Predicting Pathological Response to Neoadjuvant Therapy for Colorectal Cancer

Ravindri Jayasinghe¹, Umesh Jayarajah^{1*} and Sanjeewa Seneviratne¹

¹ Department of Surgery, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka

Abstract: Circulating biomarkers show promise in the management of many cancers. They have become the novel non-invasive approach to complement the current strategies in colorectal cancer (CRC) management. Their ability in guiding diagnosis, evaluating response to treatment, screening and prognosis is phenomenal, especially when it comes to their minimally invasive nature. These “liquid biopsies,” which show potential for replacing invasive surgical biopsies, provide useful information on the primary and metastatic disease by providing an insight into cancer biology. Analysis of blood and body fluids for circulating tumour DNA (ctDNA), carcinoembryonic antigen (CEA), circulating tumour cells (CTC), or circulating micro RNA (miRNA) shows potential for improving CRC management. Recognizing a predictive model to assess response to neoadjuvant chemotherapy would help in better patient selection. This review was conducted with the aim of outlining the use of circulatory biomarkers in current practice and their effectiveness in the management of patients having CRC with a focus on response to neoadjuvant therapy.

Keywords: Biomarkers, Colon cancer, Neoadjuvant therapy.

INTRODUCTION

Colorectal cancer (CRC) is the second commonest cancer diagnosed in females (approximately 820,000 cases in 2018) and the third commonest cancer in males (approximately 1,020,000 cases in 2018) [1]. It is the second most commonest cause of cancer-related death globally, with approximately 900,000 deaths occurring annually [1]. There is a rising incidence of CRC in both developing and developed countries [2, 3]. The pathogenesis includes a series of genetic and epigenetic mutations causing alterations in cell growth, differentiation, and apoptosis, transforming the normal colonic epithelium into an adenocarcinoma. Loss of oncosuppressor genes, such as *APC*, *TP53*, and a series of molecular alte-

* Corresponding author Umesh Jayarajah: Department of Surgery, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka; Tel: +94 76 680 86 25; E-mail: umeshe.jaya@gmail.com

rations in proto-oncogenes, such as *KRAS*, lead to progression of an adenomatous polyp to invasive carcinoma in a stepwise fashion, which is known as the adenoma-carcinoma sequence [4].

The prognosis of CRC largely depends on the stage of the disease at diagnosis, and therefore, early detection is known to improve morbidity and mortality. Conventional means of disease assessment such as radiological imaging and histopathological analysis have minimum sensitivity in terms of early detection of systemic spread. Therefore, in recent years, the concept of liquid biopsy, which includes the analysis of circulatory biomarkers in blood and body fluids, has emerged as a promising diagnostic tool [5]. The diagnosis and management of CRC have been generally based on biopsy-based techniques for decades. However, determining the individualised response to treatment and the prognosis is often difficult based solely on the histological assessment [6]. This has led to the discovery of biomarkers for early detection of relapse and treatment resistance leading to the improved overall quality of life and patient survival [7]. There is ample evidence to suggest that biomarkers such as CTC in peripheral blood are associated with a negative impact on patient survival [8]. In contrast to the conventional tissue biopsies, liquid biopsies are associated with considerable benefits such as minimal invasiveness, less pain and lower procedural risks. The term “liquid biopsy” reflects a much broader perspective which refers to the utility of all circulating tumour traits, including CTC, ctDNA, circulating miRNA, exosomes, proteins, and mRNAs in the peripheral blood and body fluids [9]. An ideal biomarker should have properties including the ability to quantify, high specificity, reliability, measurability, predictability, and sensitivity [10].

Neoadjuvant chemotherapy revolutionised the management of CRC by substantially reducing the risk of local recurrence and improving outcomes, especially in locally advanced cancers. However, the response to neoadjuvant chemotherapy varies ranging from pathological complete response (pCR) to no response. Pre-operative chemotherapy has its own associated disadvantages, including significant adverse effects which may interfere with timely surgery. The use of circulatory biomarkers in predicting response to neoadjuvant therapy would help select patients who are more likely to respond to such therapy.

CRC restaging after neoadjuvant chemotherapy is equally important, as it will determine the presence of nodal metastasis, involvement of the circumferential resection margin, and the depth of invasion in rectal carcinoma [11]. Conventional imaging modalities, namely computed tomography (CT), magnetic resonance imaging (MRI), endoscopic ultrasonography (EUS), and positron emission tomography (PET) are used in the process of restaging. However, the overall accuracy of these investigations is reduced in restaging after neoadjuvant therapy

in comparison to the initial staging. This is mainly due to failure of differentiating tumour infiltration and residual tumour from radiation-induced fibrosis. Radiation related complications, including proctitis, may also be misinterpreted as local invasion [11, 12].

Among patients receiving neoadjuvant CRT for rectal carcinoma, a significant proportion (15-40%) has been shown to achieve a pCR. Such patients tend to have an excellent prognosis with an almost non-existent risk of local recurrence and more than 95% five-year overall survival [13, 14]. There is an ongoing debate regarding the possibility of managing these patients without surgery, sparing the postoperative and long-term morbidity associated with radical surgical resections [15]. However, classification as pCR mandates a histological examination of the entire specimen which is not possible without surgical resection. Therefore, a complete clinical response (cCR) which is the absence of clinically detectable tumour after neoadjuvant CRT is used as a surrogate for pCR. Assessing for cCR would depend on clinical examination findings correlated with endoscopy radiological investigations and may also include histological examination of biopsies from the previous tumour site [16]. Surgery is usually timed within 10 to 12 weeks following completion of CRT, which allows adequate time for tumour regression. Management of patients who have achieved cCR to neoadjuvant therapy still remains a controversial topic, where non-operative management is becoming a popular alternative in this group, especially among patients who are at high risk for surgery. Although controversial, a combination of frequent clinical, endoscopic and radiographic evaluation have been shown to be helpful in ensuring local tumour control and detecting early recurrences [17]. Patients after completion of 10-12 weeks of neoadjuvant CRT with evidence of residual tumour, should undergo surgery. The rest with a cCR may be given the option for surgical resection or watch and wait strategy. Those who opt for non-operative management should be monitored closely for 1-year after neoadjuvant CRT followed by a long-term follow up protocol [13, 18]. As cCR is only a surrogate of pCR, the utility of circulatory biomarkers in this scenario is a matter of great interest.

The objective of this comprehensive review is to outline the use of circulatory biomarkers in current practice and their effectiveness in the management of patients with colorectal cancer. This review summarises tissue-based biomarkers in blood, blood-based biomarkers, circulating peptides, and other novel biomarkers in CRC with a special emphasis on predicting response to neoadjuvant therapy in CRC.

CHAPTER 7

Circulating Biomarkers in the Management of Breast Cancer

Ravindri Jayasinghe¹, Umesh Jayarajah^{1,*} and Sanjeewa Seneviratne¹

¹ Department of Surgery, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka

Abstract: Circulating biomarkers have become a promising modality in the management of many cancers. Similarly, in breast cancer, circulatory biomarkers are useful, non-invasive methods in the diagnosis, prognostication, and evaluation of response to treatment. Invasive surgical biopsies can be potentially replaced by “liquid biopsy,” which involves analysing circulatory biomarkers that may reveal features of primary and metastatic disease. Therefore, providing an insight into the cancer biology can be utilised to monitor treatment response, treatment-induced adaptation and tumour and disease progression through non-invasive means. The objective of this review is to provide an overview of the current status of the circulating biomarkers highlighting their promising impact on the management of patients with breast cancer.

Keywords: Biomarkers, Breast cancer, Circulatory biomarkers, Diagnosis, Prognostication, Liquid biopsy.

INTRODUCTION

Breast cancer is the most frequently diagnosed cancer worldwide, being a leading cause of cancer death among women in both developing and developed countries [1, 2]. However, the survival rates are improving due to the advances in screening, diagnosis, understanding of tumour biology and targeted systemic therapy [3]. Furthermore, the role of surgery and invasive approaches in the management of breast cancer has evolved substantially over the past century, where radical approaches have gradually been replaced by more conservative approaches [4]. The triple assessment is used as the ‘gold standard’ in the assessment of symptomatic breast lumps, which comprises a clinical examination, radiological investigations and histopathological analyses [5]. Circulating biomarkers are promising non-invasive surrogates for tissue diagnosis. They are defined as soluble molecules released to the bloodstream by tumour cells or cells in the

* Corresponding author Umesh Jayarajah: Department of Surgery, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka; E-mail: umeshe.jaya@gmail.com

tumour microenvironment or response to the tumour [6]. Analysis of these biomarkers would provide useful insight into the molecular makeup of cancer.

The study of circulatory biomarkers in the form of circulating tumour cells (CTC) dates back to the late 1800s although, they were studied extensively after the mid-20th century. Their presence was generally considered to be associated with a poorer prognosis [7]. Similar to other solid malignancies, breast cancer is associated with changes in immune [8], glycoproteomic [9], proteomics [10], and nucleic acid [11] biomarkers in the blood, which arise directly from the tumour cells. A measure of these indicators can be acquired by simply drawing peripheral blood, which is less invasive and more feasible compared with tissue biopsy. With the advancements of molecular diagnostics, this method of “liquid biopsy” for biomarkers helps immensely in clinical management [12].

Although many potential biomarkers have been identified, only a few are used in clinical practice which include carcinoembryonic antigen (CEA), MUC-1 protein, human epidermal growth factor receptor-2 (HER-2), and cytokeratins [7]. Recently the interest has shifted towards other markers, including cell-free plasma DNA (cfDNA), circulating tumour cells (CTCs) and microRNAs (miRNAs) [13]. However, there is still an ongoing debate concerning their usefulness in patient monitoring, follow-up and assessment of response to therapy. These biomarkers lack reliability when considered singularly due to their intrinsic lack of specificity and sensitivity. However, certain biomarkers such as circulating tumour cells likely will have a predictive value in specific situations including diagnosis of metastatic carcinoma [14]. With the advancing interest in these markers, it is evident that they provide valuable information on the status of malignancy both qualitatively and quantitatively [14]. These biomarkers are useful in analysing the molecular characteristics of cancer cells in instances where tissue samples cannot be obtained or are not available and as a valuable tool in monitoring the therapeutic response of the tumour and to assess residual disease after treatment [13]. The purpose of this review is to objectively summarize the current recommendations on different types of circulating biomarkers in breast cancer, their usefulness in the diagnosis, prognosis, and monitoring of response to treatment.

ESTABLISHED BIOMARKERS

Carcinoembryonic Antigen (CEA)

CEA is a serum-based glycosylated oncofoetal glycoprotein expressed in normal mucosal cells and overexpressed by adenocarcinomas of the colon, rectum, breast, pancreas, and lungs [15, 16]. CEA is useful in the monitoring metastatic breast cancer during treatment [15, 16]. Immunobiological studies have revealed that the

domain structure of CEA proteins belonging to a large family of glycoproteins closely resembles the gamma heavy chain of the immunoglobulin IgG [6]. Being a member of the immunoglobulin superfamily, CEA attaches on to cell membranes by a glycosyl phosphatidylinositol (GPI) anchor [17]. The exact mechanism on how it is released to the extracellular matrix still remains unclear. However, experiments have revealed that similar to other GPI anchored proteins, CEA could be released through a GPI anchor cleavage catalysis, mediated by an endogenous enzyme called glycosylphosphatidylinositol-specific phospholipase D [18].

Although the exact function of CEA has not been identified yet, recent studies portray an involvement in cancer growth, invasion and metastasis by playing a role in cell migration [19]. Elevated CEA levels are observed in approximately 50-60% of patients with metastatic breast cancer [20]. However, this marker can only be accurately interpreted in combination with normal levels of CA15-3 and CA 27.29 [20]. Increased levels of CEA and CA 15-3 have been shown to be independent prognostic factors of metastatic breast cancer. CA 15-3 elevation is more marked in younger patients while CEA is a good prognostic marker in the context of older patients with estrogen receptor (ER) negative disease. The two biomarkers were also shown to provide information on recurrence and overall survival in metastatic breast cancer [21].

Elevated levels of CEA in the preoperative context generally devise a poorer prognosis when interpreted in combination with CA 15-3 [22]. Ebeling et al studied a sample of 1046 women on the association of CEA and CA 15-3 with disease free survival and death from breast cancer [23]. In that study, the postoperative decrease of CEA was an independent prognostic factor for both these study outcomes. Furthermore, multivariate comparison of preoperative and post-operative CEA levels showed a decrease in postoperative levels by more than 33% to be associated with a higher risk of relapse and death [23]. This finding was further confirmed by a similar study which also showed that raised preoperative values of CEA was associated with overall unfavourable cancer status with regards to tumour burden, lymph-node metastasis and tumour stage leading to poorer clinical outcomes [21]. Furthermore, this study also showed that reduced CEA and CA 15-3 levels predicted an overall better outcome [21]. It is quite noteworthy that the reliability and the prognostic values improved when the two biomarkers are used in combination rather than in singular where both the sensitivity and the specificity dropped substantially [21]. Although these classic biomarkers were found to be of considerable clinical importance, they may not be objectively representative of a reliable panel in the context of a liquid biopsy.

Clinical Application of Biomarkers for Hematologic Malignancies

Nurgül Özgür Yurttaş¹ and Ahmet Emre Eşkazan^{1,*}

¹ Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey

Abstract: Over the last decade, significant advancements have been made in the molecular mechanisms, diagnostic methods, prognostication, and treatment options in hematologic malignancies. As the treatment landscape continues to expand, personalized treatment is much more important.

With the development of new technologies, more sensitive evaluation of residual disease using flow cytometry and next generation sequencing is possible nowadays. Although some conventional biomarkers preserve their significance, novel potential biomarkers accurately detect the mutational landscape of different cancers, and also, serve as prognostic and predictive biomarkers, which can be used in evaluating therapy responses and relapses. It is likely that we will be able to offer a more targeted and risk-adapted therapeutic approach to patients with hematologic malignancies guided by these potential biomarkers. This chapter summarizes the biomarkers used (or proposed to be used) in the diagnosis and/or monitoring of hematologic neoplasms.

Keywords: Chromosomal, Classification, Cytogenetic, Epigenetic, Genomic biomarkers, Hematologic neoplasm, Immunohistochemistry, lncRNA, Microenvironment, MicroRNA, Minimal residual disease, Molecular, Mutations, Scoring system.

INTRODUCTION

There are many markers (both traditional and novel) described for hematologic malignancies that might play a role in the pathogenesis, diagnosis, and prognosis. These biomarkers may also act as targets that might have the potential for providing new therapeutic approaches.

* Corresponding author Ahmet Emre Eşkazan: Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey; Tel: 905337227376; Fax: 902125897934; E-mail: emre.eskazan@iuc.edu.tr

Hematologic malignancies can be categorized as lymphoid and myeloid. The most recent World Health Organization (WHO) classification of these malignancies includes many subgroups [1, 2]. In this chapter, we try to summarize the biomarkers used (or proposed to be used) in the diagnosis and/or monitoring of these neoplasms.

BIOMARKERS IN MYELOID NEOPLASMS

This part of the chapter mainly focuses on the biomarkers for the myeloid neoplasms such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPNs), including chronic myeloid leukemia (CML).

Acute Myeloid Leukemia

AML arises from the clonal expansion of malignant hematopoietic precursor cells in the bone marrow. AML is the second most common leukemia in adults and the most common type of acute leukemia. The median age at diagnosis is approximately 65 years, and the incidence increases with age. There is a slight predominance in men and a higher incidence in non-Hispanic whites than other racial and ethnic groups.

AML has been associated with environmental factors like exposure to chemicals, radiation, tobacco, chemotherapy, and retroviruses. In some cases, AML precedes other clonal hematopoietic disorders such as MDS, MPNs, paroxysmal nocturnal hemoglobinuria, and aplastic anemia.

Initial genetic analyses are not practical in AML because of the genetic heterogeneity of the disease. This makes the diagnosis difficult and as a result, influences therapeutic strategy negatively [3]. AML is lethal if untreated, and with intensive treatment, 60-80% of younger adults achieve a complete remission (CR), and almost one-third are finally cured. However, a 5-year relative survival rate of AML is approximately 25%. Outcomes are heterogeneous and overall survival (OS) rates range between 5-70% [4, 5]. Therefore, prognostic markers to guide therapy and predict outcome are still needed. Prognostic markers can be clinical, disease-related, and molecular. However, the strongest prognostic factor for predicting therapeutic response and survival is cytogenetics.

Multiparameter flow cytometry (MFC) immunophenotyping gives information for AML diagnosis, classification, and monitoring. MFC allows identification, quantification, and lineage assessment of blasts and disease classification according to the maturation stage. AML confers very heterogeneous immunophenotypic features, mainly due to the genetic diversity of the disease [3].

Performing precise risk stratification due to immunophenotypic profiles can be difficult. There are not any exact recommendations and/or any reliable approaches for the use of new biomarkers in the immunophenotypic panels for AML as well as for the markers that might have an effect on prognosis and survival in clinical practice [3].

CYTOGENETIC CLASSIFICATION OF AML

The WHO criteria for the diagnosis and classification of AML are based on morphologic, immunophenotypic, cytogenetic, and molecular features [2, 6]. This categorization provides information for prognosis and may be useful for the selection of the best therapy [7]. The WHO classification has replaced the former French-American-British (FAB) classification system, which mainly depended on morphology and cytogenetic features [2, 8] (Tables 1 and 2).

Table 1. WHO classification of AML and related malignancies (adapted from reference [2]).

AML with Recurrent Genetic Abnormalities	AML, NOS
AML with t(8;21) (q22;q22.1); <i>RUNX1-RUNX1T1</i>	AML with minimal differentiation
AML with inv(16) (p13.1q22) or t(16;16) (p13.1;q22); <i>CBFB-MYH11</i>	AML without maturation
APL with <i>PML-RARA</i>	AML with maturation
AML with t(9;11) (p21.3;q23.3); <i>MLLT3-KMT2A</i>	Acute myelomonocytic leukemia
AML with t(6;9) (p23;q34.1); <i>DEK-NUP214</i>	Acute monoblastic/monocytic leukemia
AML with inv(3) (q21.3q26.2) or t(3;3) (q21.3;q26.2); <i>GATA2, MECOM</i>	Pure erythroid leukemia
AML (megakaryoblastic) with t(1;22) (p13.3;q13.3); <i>RBM15-MKL1</i>	Acute megakaryoblastic leukemia
AML with <i>BCR-ABL1</i>	Acute basophilic leukemia
AML with mutated <i>NPM1</i>	Acute panmyelosis with myelofibrosis
AML with biallelic mutations of <i>CEBPA</i>	Myeloid sarcoma
AML with mutated <i>RUNX1</i>	Myeloid proliferations related to Down syndrome
AML with myelodysplasia-related changes	Transient abnormal myelopoiesis (TAM)
Therapy-related myeloid neoplasms	Myeloid leukemia associated with Down syndrome

Applications of Biomarkers in Cancer Surgery

Berrin Papila Kundaktepe^{1,*}

¹ Department of General Surgery, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey

Abstract: The most problematic and difficult cases of general surgery applications are cancers. Cancer can be diagnosed in many ways, including the presence of some symptoms and signs, screening tests, and imaging methods. The diagnosis of cancer is confirmed anatomically by microscopic examination of tissue samples. Biomarker research has become increasingly interesting for many medical fields today. Biomarkers are indicators of the biological process that can show changes in disease and health status and reveal pathological conditions. The sensitivity of markers used for early and painless diagnosis is weak in all types of cancer, including thyroid, breast, stomach, pancreatic, and colorectal cancers. Biochemical and molecular markers have been found to be of great importance in cancer research in recent years in the formation mechanisms and treatment steps of cancer. Several biomarkers have been studied in the circulating body fluids and tissue of preoperative, intraoperative, and postoperative patients. The main use of tumor markers is the follow-up of the response to treatment and early detection of recurrences in patients diagnosed with cancer. Tumor markers correctly selected will guide the patient's monitoring and treatment planning. But, still, the field of cancer surgery needs new biomarkers.

Keywords: Biomarkers, Breast cancers, Colorectal cancers, Pancreatic cancers, Stomach cancers, Surgery, Thyroid cancers.

INTRODUCTION

Biomarkers are molecules that can evaluate biological and pathological processes and are present in measurable amounts in blood, body fluids, or tissues. Biomarkers used in surgery may play a role in early diagnosis, risk stratification, evaluation, and metastasis and prognosis prediction [1]. An ideal biomarker should be determined easily in body fluids as plasma and urine samples, predict relevant clinical outcomes and reflect prognosis and treatment efficacy. These evaluations are essential (essential/indispensable/ crucial) to establish an appropriate treatment and recruit the patient. The properties sought in an ideal biomarker are as follows: it is biochemically stable, it can be studied with low

* Corresponding author Berrin Papila Kundaktepe: Department of General Surgery, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey; Tel: +90 (532) 493 34 74; E-mail: papilaberrin@yahoo.com

blood amounts or body fluids, its sampling time is wide, it can be detected with a fast, cheap, simple, and automated system, its sensitivity is 100%, and its specificity is > 85%, it can distinguish bacterial and viral pathogens, and it is associated with inflammatory response [2].

Clinical use of circulating tumor markers include neoplasia screening, risk identification, cancer diagnosis, clinical classification of cancer, treatment selection, monitoring response to treatment, determination of the prognosis, recurrence detection, and metastasis tracking. Tumor markers are rather used after the initial treatment is completed to define the disease state and to evaluate the treatment options. Detection of cancer recurrence allows re-initiation of treatment or changes in treatment [3].

Although high levels of tumor markers are seen in malignancies, many hormonal and metabolic changes can be encountered in benign diseases. Sometimes a tumor may not produce the substance it is associated with until the advanced stage. A substance may not be specific to a single tumor type. In other words, these items are not sensitive and specific enough. However, they are useful in monitoring a malignancy with a tissue diagnosis, treatment selection, and survival prediction [4 - 6]. Tumor markers are often used in combination with immunohistochemical tests to diagnose cancer.

The most known and used tumor markers are shown in Tables 1, 2 and 3.

Table 1. The most known and used enzyme tumor markers in routine clinical use.

ENZYME TUMOR MARKERS			
-	Malignancy	Non-neoplastic Causes	Clinical Utility
Prostate specific antigen (PSA)	Prostate cancer	Prostatitis, prostate hypertrophy	Screening, therapy monitoring, and recurrence
Lactate dehydrogenase (LDH)	Hematologic malignancies, lymphoma, Ewing sarcoma, Germ cell	Hepatitis, hemolytic anemia	Prognostic indicator and elevated nonspecifically in numerous cancers.
Alkaline phosphatase (ALP)	Metastatic carcinoma of bone, hepatocellular carcinoma, osteosarcoma, lymphoma, leukemia.	Growth-development, pregnancy, bone diseases, liver diseases	Determination of liver and bone involvement; nonspecific elevation in many bone-related and liver cancers.
Neuron-specific enolase (NSE)	Neuroendocrine tumors, Small cell lung cancer, neuroblastoma	Septic shock, pneumonia, and nervous system trauma	Prognostic indicator and monitoring disease progression for neuroendocrine tumors.

Table 2. The most known and used endocrine tumor markers in routine clinical use.

h-CG	Gestational trophoblastic diseases, germ cell tumors	Pregnancy, renal failure, heterophile antibody	Diagnosis of choriocarcinoma, testicular cancer
Adrenocorticotrophic hormone (ACTH)	Pituitary adenoma, ectopic ACTH-producing tumor	Cushing syndrome	Diagnosis of ectopic ACTH-producing tumor
Calcitonin	MTC and neuroendocrine tumors	Chronic renal failure, Zollinger-Ellison syndrome, pernicious anemia	Screening, response to therapy, and monitoring recurrence of MTC
Growth hormone (GH)	Pituitary adenoma, ectopic GH-secreting tumors	Acromegaly, dwarfism, gigantism	Diagnosis and post monitoring of acromegaly
Prolactin	Pituitary adenoma	Irregular or no periods, infertility, breast milk discharge in non-pregnant, tenderness in the breast	Diagnosis and postsurgical monitoring of prolactinoma
Antidiuretic hormone (ADH)	Posterior pituitary tumors	Guillain-Barré syndrome, multiple sclerosis, epilepsy, and acute intermittent porphyria	Diagnosis of SIADH
Cortisol	Adrenal tumors	Cushing syndrome, excess cortisol, adrenal insufficiency or Addison disease, deficient cortisol.	Diagnosis of Cushing's syndrome, adrenal adenoma

Table 3. The most known and used tumor markers as oncofetal proteins in routine clinical. use.

α-fetoprotein (AFP)	Hepatocellular carcinoma, Hepatoblastoma, Non-semitomatous germ cell tumours	Hepatitis, cirrhosis, biliary obstruction,	Hepatocellular carcinoma (screening, diagnosis, treatment monitoring), hepatoblastoma (diagnosis), non-semitomatous germ cell tumours (prognosis, treatment monitoring)
Carcinoembryonic antigen (CEA)	Colorectal carcinoma (main), Other gastrointestinal malignancies, breast and ovarian carcinoma.	Cigarette smoking, bronchitis, hepatitis, alcoholic liver disease, ulcerative colitis, Crohn's disease and pancreatitis.	Prognosis, treatment monitoring and recurrence of colorectal carcinoma.

A Pathophysiological Approach To Current Biomarkers

Aykut Oruc^{1,*} and Gonul Simsek¹

¹ Department of Physiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey

Abstract: Biomarkers are necessary for screening and diagnosing numerous diseases, predicting the prognosis of patients, and following-up treatment and the course of the patient. Everyday new biomarkers are being used in clinics for these purposes. This section will discuss the physiological roles of the various current biomarkers in a healthy person and the pathophysiological mechanisms underlying the release of these biomarkers. This chapter aims to gain a new perspective for evaluating and interpreting the most current biomarkers.

Keywords: AFP, Alpha-fetoprotein, CA15-3, CA27.29, Carcinoembryonic antigen, CEA, GFAP, GPBB, GSTP-1, H-FABP, MUC1, NSE, NT-proBNP, Pathophysiological mechanisms, Physiology, S100B, Troponin.

CARDIAC BIOMARKERS

Cardiac biomarkers are widely used to detect functional heart problems and predict possible heart disease that may clinically show up later. The most common use of cardiac biomarkers is for acute myocardial infarction and congestive heart diseases, but they can also be used for a wide variety of diseases [1].

Cardiac biomarkers are, in general, intracellular components of myocytes or enzymes, formally. This title will discuss the pathophysiological mechanisms of typical and recent cardiac biomarkers, and the intracellular pathways of the release of these biomarkers will be explained in detail.

Cardiac Troponins

Troponin functions as a Ca⁺² receptor and regulates Ca⁺² levels during myosin and actin's interaction for contraction in skeletal and cardiac muscles. It is shown that

* **Corresponding author Aykut ORUC:** Department of Physiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey; Tel: +90 212 414 30 56; Fax: +90 212 633 29 87; E-mail: aykutoruc86@istanbul.edu.tr

troponin spreads through the thin filaments of a muscle with a length of 38 nm. Troponin that runs along the thin filament and attaches to active sites of tropomyosin settles on the grooves of actin. When intracellular Ca^{+2} levels decrease, troponin suppresses the contractile interaction between actin and myosin with the help of tropomyosin. On the contrary, this suppression is removed when intracellular Ca^{+2} levels increase as Ca^{+2} ions bind to troponin [2].

Troponin complex consists of three different subunits: troponin I, C, and T. They all have different functions such as removing of interaction between actin and myosin (troponin I), binding to Ca^{+2} (troponin C), and binding to tropomyosin (troponin T). Also, studies have shown that several mutations in genes that encode cardiac troponin subtypes are associated with inherited cardiomyopathies [2].

Cardiac troponin subtypes are widely used for myocardial ischemia. Before the discovery of troponin, different biomarkers were used to identify myocardial ischemia, such as aspartate transaminase (AST), lactate dehydrogenase (LDH), and creatinine kinase (CK). These biomarkers are still in use, but none show specificity for cardiac muscle. The later found biomarkers showed more specificity to cardiac muscle, such as CK-MB and LDH, but they still had a high false positivity rate. Troponins were first found in 1965, but the routine laboratory usage as a marker started in the 1990s. Troponin measurements have up to 100% sensitivity when observed 6 – 12 hours after the start of chest pain, and they also have high specificity for damaged cardiac muscle. Because of these benefits, high troponin levels were added as a criterion of myocardial infarction in “Third Universal Definition of Myocardial Infarction”, which is the current definition used by the American College of Cardiology [3 - 5].

Troponin Subunits

Troponin consists of three different subunits: troponin I, C, and T. The primary function of the troponin is inhibiting the interaction between actin and myosin, which is directly related to intracellular Ca^{+2} levels.

Troponin I: Troponin I directly inhibits the contractile interaction between myosin and actin. This inhibition occurs with the absence of Ca^{+2} and is also very strong in the presence of tropomyosin. After discovering troponin I, studies with synthetic troponins showed a region composed of residues 105–114 (minimum inhibitory peptide), called the 'inhibitory region.' It is believed that this region is essential for showing the inhibitory activity with the help of a secondary region of residues 140–148 (second actin-binding region). The presence of this secondary region is also necessary for total inhibition. The N-terminus of troponin I, which is close to the inhibitory site, attaches to troponin C and together with troponin T, they all build a helix-coil structure.

On the other hand, the C-terminus attaches to the tropomyosin and actin complex. The N-terminal region that binds to troponin C- Ca^{+2} dependent troponin – is called the ‘switch region.’ This switch region is constantly phosphorylated and dephosphorylated *via* protein kinase A (PKA). When PKA phosphorylates the switch region, the affinity of troponin C with Ca^{+2} decreases, which inhibits the contraction of muscle as well. This mechanism is essential for the sympathetic nervous system to decrease diastole duration with increasing intracellular cyclic adenosine monophosphate (cAMP) levels and cAMP-related PKA activity *via* β_2 receptors [6].

Troponin C: Troponin C is the main subunit that reacts with Ca and forms a complex structure with troponin I and troponin T. The primary function of troponin C is suppressing the inhibition of the interaction between actin and myosin formed mainly by tropomyosin. Troponin C can bind calcium *via* four active sites located in the N terminus. Sites 1 and 2 are formally low-affinity Ca^{+2} receptors, while sites 3 and 4 are both high-affinity Ca^{+2} and Mg^{+2} receptors. This explains the necessity of magnesium in striated muscle contraction as well as in cardiac contraction. The binding of Ca^{+2} to these sites induces a conformational change resulting from a hydrophobic site that connects to troponin I to open (open conformation). After binding to troponin I, they form a helical structure and inhibit the suppression of troponin I-troponin T-tropomyosin complex on actin [6].

Troponin T: Troponin T is the subunit that binds to tropomyosin and also attracts other troponins. Troponin T is a tropomyosin-binding subunit of troponin. Troponin T is the largest of the three troponins and interacts with both troponins I and troponin C. Troponin T consists of two subunits: TnT1 and TnT2, which bind to N-terminus and C-terminus of tropomyosin, respectively. The role of troponin T is not directly regulating contractile interaction, but it works as an indirect factor. Troponin T adjusts the sensitivity of troponin C to Ca^{+2} with its subunit TnT2. The N-terminal part of cardiac troponin T (cTnT) contains 30 more residues than troponin T in striated muscle. These residues contain mainly exons, and by alternative splicing of these exons, four different isoforms can be produced in the human heart, and all these variants show different sensitivity to Ca^{+2} . Also, aberrant splicing of these exons due to genetic and epigenetic changes may alter the ventricular pumping function [7].

Regulatory Function of Troponin

The primary function of the troponin complex is to regulate Ca^{+2} with two related mechanisms: inhibiting actin-tropomyosin complex *via* troponin T and interacting between troponin C and troponin I, depending on intracellular Ca^{+2} levels. The

Biomarkers in Otorhinolaryngology

Ayşe Pelin Yigider^{1,*} and Ozgur Yigit¹

¹ Istanbul Research and Training Hospital Otorhinolaryngology, Istanbul, Turkey

Abstract: Biomarkers of otorhinolaryngologic diseases with higher insult over a person's him/herself and overall health services are summarized in brief. In order to define, diagnose, treat and monitor any disease markers are needed. Otorhinolaryngology (ORL) is interested in special disease entities of the region besides otorhinolaryngologic involvements of the systemic diseases and unique forms of pathologies such as cholesteatoma, Meniere's disease and otosclerosis. Neoplasia is another heading to deal with. In the following chapter, one will find an overview of molecules that have been used as a biomarker as well as the end points of the present research on the issue relevant with ORL. Day by day, new molecules are being named however, the pathways of action are rather the same. Readers will find the headings related to the most common diseases of the field, informing them about where to look for defining new strategies of understanding of each disease.

Keywords: Biomarkers, laryngology, Biomarkers, otology, Biomarkers, rhinology, Biomarkers, thyroid.

INTRODUCTION

Biomarkers are used to diagnose, define the pathophysiology, determine therapeutic alternatives and monitor the outcome by means of both curative attempts and natural history of the disease, which may overall be named as prognosis. In the present chapter, biomarkers of otorhinolaryngologic diseases that have more insult over a person's him/herself and overall health services are summarized in brief. Protein can be monitored *via* their code/decode patterns in the course of a specific disease, namely fragmented RNA particles, mRNA, or DNA's. Owing to the higher cost of the genetic laboratory, it seems more feasible to define biochemical reflections of protein synthesis. It is not rational to list any diseases, but rather frequent diseases are tried to be given with their future-lightening markers by means of diagnosis, disease monitoring and prognosis.

* Corresponding author Ayşe Pelin Yigider: Istanbul Research and Training Hospital, Department of Otorhinolaryngology Head and Neck Surgery, İstanbul. Turkey; Tel: +90 (532) 410 90 25; E-mail: pelin.gor@gmail.com

Rhinology

In rhinology practice, infections, namely sinusitis acute or chronic, space occupying benign masses of sino-nasal tract polyps or papilloma, are frequent. Main underlying pathology emerges as allergy. Immune reactions of any type can be monitored *via* re-popularized hematological parameters such as PMN/Lymphocyte ratio, Platelet number or platelet volume, however most of those are far from being specific for an illness. They can be monitored as an adjunctive measure but cannot discriminate a confounding simultaneous inflammatory process from the primary disease of concern.

Sinusitis is basically divided into two as acute or chronic. While acute sinusitis is an infection caused by mainly bacteria, chronic sinusitis is a complex disease entity related to various inflammatory pathways. CRS is classified into CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP). CRS, especially CRSwNP, is further subdivided into eosinophilic CRS (E CRS) and non-eosinophilic CRS. According to the diagnostic criteria established by a multicenter study called the Japan Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis Study (JESREC Study) in 2015, JESREC score and mucosal eosinophil count have been used to diagnose eosinophilic chronic rhinosinusitis (E CRS) [1].

TH2 inflammation was formerly reported to predominate which is associated with elevated levels of eosinophils and cytokines, including Interleukin (IL)-4, IL-5, and IL-13 [2].

The testing mediums to obtain CRS biomarkers are peripheral blood, nasal secretions and nasal lavage, tissue biopsies from the sinuses, and nasally exhaled breath. CRSwNP is an eosinophilic process and CRSsNP is noneosinophilic. In different parts of the world, eosinophilia may be absent in the pathogenesis of CRSwNP, yet if present is generally associated with higher disease severity. Additionally, eosinophilic polyps are generally more glucocorticoid responsive in comparison to non-eosinophilic counterparts.

IgE, as an inducer of eosinophilia, is utilized as a biomarker for CRS phenotyping. Patients with CRS frequently express high levels of IgE in both serum and local secretions. Allergic sensitization to bacterial antigens is believed to be an important part of the process. Staphylococcus aureus enterotoxins can serve to activate basophil degranulation in those with CRSwNP. Increased local IgE is predictive of recurrence requiring repetitive surgical intervention. The omalizumab, an anti-IgE therapeutic, was also tested and provided benefit up to some extent in patients with CRSwNP. Cytokine profile of CRS w/s NP differs dramatically. In CRSsNP, neutrophilia dominates with the expression of

Transforming Growth Factor β (TGF- β), type I interferons, and IL-6, IL-8, or IL-17. CRSwNP has a TH2 leading microenvironment with marked expression of thymic stromal lymphoprotein (TSLP) and type 2 inflammatory cells. Type 2 Innate Lymphoid (ILC-2) cells, which produce IL-4, IL-5, IL-13, IL-25, and/or IL-33, activate T and B cells that overall result in increased leaking of the epithelial barrier. Evidence nonetheless points to elevated IL-4 playing a role in the overexpression of cysteinyl leukotriene [13]. CD45⁺ CD4⁻ IL-4 producing cells were found to be elevated in patients with AERD (asprin exacerbating resp disease) [3].

There can be an overlap of cytokine expressions of both TH 1 and 2 pathways. The presence of IL-5 may be defined for a specific endotype of CRSwNP individuals with more severe disease. IL-25 expression is upregulated in CRSwNP tissue is associated with increased severity in CT scores. Anti IL-4,5,13, 25 are used in several trials and provided unneglectable outcomes. Eotaxin-3 as a plasma biomarker for mucosal eosinophil infiltration is closely related to IL-33 and TSLP levels which indicate respiratory diseases [4]. Eotaxin-3 and total IgE in the nasal secretions of patients receiving dupilumab, a monoclonal IgG4 antibody against the alpha subunit of the IL-4 receptor, decreased in comparison to the placebo group, while eosinophilic cationic protein (ECP) did not decrease significantly. Tissue analysis of nasal polyp revealed that while total IgE, ECP, eotaxin-2, eotaxin-3, IL-13 and PARC are significantly lowered in the dupilumab group; IL-6, IL-1 β , IL-4, eotaxin-1, IL-5, IL-10, IL-17, IL-33, TNF- α or TARC are not significantly different.

Longitudinal tracking of biomarkers is important to objectively measure therapeutic efficacy. Cytokines have local and indirect systemic effects of long term. IL 4 and IL-13 has a direct effect on Periostin, that is an extracellular protein taking place in subepithelial fibrosis in airway tract through interacting with integrins. and working with VEGF, resulting in angiogenesis. It was shown that Periostin levels are treatment responsive as the protein works with tissue remodeling factors. IL-16 is an eosinophilic chemotaxis that promotes persistent eosinophil activation with increased levels of serum IL-16 is significantly elevated in eosinophilic CRS [5].

An ATP-dependent transmembrane efflux pump, P-glycoprotein is upregulated in TH2 disease that is thought to take place in CRS-related inflammation through promotion of cytokine secretion. Verapamil is an antagonist of p- glycoprotein, and preliminary trials show that low dose verapamil therapy is safe and effective for CRSwNP treatment [6]. Autoimmunity seems to play a greater role. CXCL-12 and CXCL-13 molecules are present with increased levels, which enhance B-cell chemotaxis. Anti-dsDNA IgG antibody is correlated with a worse clinic. The

Pharmacogenomic Biomarkers

Zeynep Gizem Todurga Seven^{1*}, Deniz Özen¹ and Sibel Özyazgan¹

¹ Department of Medical Pharmacology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey

Abstract: Why does the usual dose of medication work for a person while another individual cannot give the expected response to the same drug? On the other hand, how come half of the usual dose of an analgesic relieves an individual's pain immediately, as another man continue to suffer even after taking double dose? Although a treatment method has been successfully used in majority of the population for many years, why does the same therapy cause serious side effects in another region of the world? Most presently approved therapies are not effective in all patients. For example, 20-40% of patients with depression respond poorly or not at all to antidepressant drug therapy. Many patients are resistant to the effects of antiasthmatics and antiulcer drugs or drug treatment of hyperlipidemia and many other diseases. The reason for all those is basically interindividual differences in genomic structures of people, which are explained in this chapter in terms of the systems and the most frequently used drugs in clinical treatment.

Keywords: Adverse reactions, Carriers, Clinical pharmacology, Cytochrome P-450 enzyme family, Drug response, Enzyme activity, Extensive metabolizer, Intermediate metabolizer, Metabolism, Optimal dosage, Personalized medicine, Pharmacodynamics, Pharmacogenetics, Pharmacogenomic biomarkers, Pharmacokinetics, Polymorphism, Poor metabolizer, Targeted treatment, Transporter molecules, Ultra-rapid metabolizer.

INTRODUCTION

Personalized medicine has been an outstanding subject for overcoming this challenge and providing each individual with a tailored treatment rather than the traditional method of “trial-and-error” dosing. The primary goals of personalized medicine are to minimize the potential adverse drug reactions and obtain the optimal efficacy from the medication.

* Corresponding author Zeynep Gizem Todurga Seven: Department of Medical Pharmacology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey; Tel: +90 (212) 414 30 00; E-mail: zeyneptodurga90@gmail.com

Many drugs were withdrawn from the market because they caused severe adverse effects, so targeted drug administration or dosing based on an individual's genetics has become important to avoid withdrawals. Moreover, the optimum efficacy can be reached when the drug is administered in the right dosage for each individual. For instance, 40-50% of patients with asthma, migraine, or diabetes cannot benefit from their medications, while the response rate of patients to cancer chemotherapy is only 25%.

The individual risk for drug inefficacy or drug toxicity is a product of the interaction between genes and the environment. The environmental variables can be nutritional factors, lifestyle influences such as smoking, barbecued meat or alcohol consumption, and also diseases or concomitantly administered drugs [1]. These factors act in concert with an individual's genes that code for pharmacokinetic and pharmacodynamic determinants of a drug, such as receptors, ion channels, drug-metabolizing enzymes, and drug transporters. In brief, the aim of personalized medicine is to give the right drug in the right dose at the right time to the right patient, having the right symptom for optimum efficacy while avoiding adverse effects [2].

Pharmacogenetics deals with the effect of individual gene variants on drug action. It investigates the simple relation between hereditary factors and the diversity of drug response. Simple mutations, which play important roles in the response of an individual to a specific drug, are determined by combining genetics and pharmacological methods. On the other hand, genomics involves the systematic identification of all human genes and gene products. It is the study of human genetic variations in health and disease, as well as changes in gene and protein expression over time. Pharmacogenetics has been evolved into pharmacogenomics to study the entire genomic structure that determines drug response, including the diversity of the human genome sequence and its clinical consequences. According to the definition of Food and Drug Administration (FDA), "Pharmacogenomics is the discipline for the estimation of drug response of an individual based on the genetic structure." Genetic information is being used to guide both drug and dosage selection for individual patients in clinical practice.

Pharmacogenomic biomarkers are variations, leading to person-to-person differences in the metabolism of drugs and thus, in drug kinetics and response. Single nucleotide polymorphisms (SNPs) are single-base differences that exist between individuals with a frequency of more than 1%, and they are the most common types of variations among pharmacogenomic biomarkers. An SNP may cause an amino acid substitution during transcription (non-synonymous/missense), which affects protein activity; on the other hand, it may not result in the amino acid change (synonymous), but still, it may alter the gene expression

and the amount of the product. Other types of variations include insertion, deletion, inversion of the gene, encoding the protein of interest, and also copy number variation, tandem duplication, dispersed duplication, mobile element insertion, or translocation (Fig. 1).




Fig. (1). Different types of genetic variations.

Polymorphisms and other genetic variations commonly occur for genes encoding proteins that function in drug metabolism, drug transporters, and drug target proteins. Drug metabolism and drug transporter genotypes can alter drug availability at the target site. In addition, drug target genotypes can affect a patient's sensitivity to a drug. If a large number of variations and their frequencies in different populations are known, they can be used to generate an individual's genetic fingerprint, indicating the individual's potential drug response to any given drug. Thus, those biomarkers can be used to provide a drug response profile, which is the resulting phenotype after all of the known affecting variations are contributed.

There are two main concepts, which are pharmacokinetics and pharmacodynamics, investigating the relationship between a drug and the human body after administration; there are specific proteins working in the process. If there is one of any aforementioned variations on the encoding gene of a protein, its function may be changed, which constitutes differences in the individual's drug response profile.

Clinical Application of Circulating MicroRNAs as Novel Biomarkers for Different Diseases

Volkan Sozer¹, Rıfca Atukeren^{2,3} and Hafize Uzun^{4,*}

¹ Department of Biochemistry, Yildiz Technical University, Istanbul, Turkey

² Department of Medical Biochemistry, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey

³ Faculty of Pharmacy, Istanbul University-Cerrahpaşa, Istanbul, Turkey

⁴ Department of Biochemistry, Faculty of Medicine, Istanbul Atlas University, Istanbul, Turkey

Abstract: Biomarker research has become increasingly interesting in many areas nowadays. Biomarkers are indicators of the biological process that can show changes in disease and health status and reveal pathological conditions. There is always a need for markers that divide patients into risk categories that can help in early diagnosis, detect complications ahead of time, guide treatment, and predict adverse outcomes in a chronic complex and certain diseases such as cancer. microRNAs (miRNAs) are ~ 22 nt long npcRNAs involved in post-transcriptional arrangements. miRNAs regulate messenger RNAs (mRNA), especially through negative regulation of gene expression. The fact that miRNAs have come to the fore in many disease mechanisms brings up their use as biomarkers in the early stage. The purpose of this review is to gather the latest information on this subject by bringing together recent articles and reviews to contribute to understanding the role of miRNAs, which act as biomarkers in different ways in vital processes, in the formation, early diagnosis, and treatment of diseases. miRNAs have an important potential to become a next-generation biomarker and therapeutic. But, each miRNA molecule can bind to a large number of different mRNAs, and different miRNAs in each mRNA. Therefore, new findings are needed to determine the expression activities and targets of miRNAs.

Keywords: Autoimmune Diseases, Biomarkers, Cancer, Coronary Artery Disease, Genital Diseases, Female, MicroRNAs, Nervous System Diseases, SARS-CoV-2.

INTRODUCTION

A feature that can be objectively measured and evaluated, which can be an indicator of pharmacological response to normal biological processes, patho-

* Corresponding author Hafize Uzun: Department of Biochemistry, Faculty of Medicine, Istanbul Atlas University, Istanbul, Turkey; Tel: +90 (535) 542 11 47; E-mail: huzun59@hotmail.com

logical processes, or a therapeutic process, is called a “biomarker.” This definition was developed in 2001 by the “Biomarkers Definitions Working Group” [1].

Biomarkers are biological signals originating from the human body. In this case, virtually any biological sign, if measurable, *e.g.*, biological material analysis, electrocardiography (ECG), blood pressure, etc., are all biomarkers.

The Purpose of Biomarkers

1. Diagnosis
2. Disease staging
3. Risk identification
4. Disease prognosis
5. Treatment evaluation
6. Treatment follow-up
7. Population screening

An ideal biomarker [1] should be biochemically stable and able to be studied in a small blood volume [2]; sampling time should be wide (> 48 hours); It should be detected by fast, cheap, simple, and automated analysis method [3]; results should be comparable between laboratories, and the threshold value should be well established [4]; sensitivity/negative predictive value should be 100%, and specificity/positive predictive value > 85% [5]; should be able to predict a complicated course in determining prognosis, and [6] should have features that can demonstrate the efficacy of treatment.

MicroRNAs (miRNAs)

miRNAs are a class of endogenous small RNAs and are functional RNA molecules that are transcribed from the intron or exon regions encoding protein on the genome and RNA genes in regions that do not encode a protein and are not translated into protein [2]. miRNAs consist of an average of 20-22 nucleotides. They regulate post-transcriptional gene expression by targeting messenger RNA (mRNA). Suppression of translation or fragmentation of the target mRNA with the relationship between miRNA and mRNA are possible consequences that may occur. But what if miRNAs are more than gene regulation? Many studies have shown that the miRNA profile in the blood of patients changes compared to

healthy people. These discoveries have been of great interest in the use of the level of extracellular (extracellular) miRNAs as a novel biomarker in various diseases [3, 4].

miRNAs have the ability to leave the cell. Extracellular miRNAs were first discovered in a cell culture medium. Extracellular miRNAs encapsulated in exosomes and secreted from donor cells could be transferred to other recipient cells. The presence of extracellular miRNAs in human body fluids has been mentioned in several studies. Extracellular miRNAs have been discovered in various macromolecules in blood and other body fluids. As a result of disease or other necrotic events, cells die, and miRNAs are released passively from the cytoplasm, which can be detected in the blood. Exosomal miRNAs from miRNAs released outside the cell are transported in the vesicle covered with a lipid bilayer membrane. These are more stable than free circulating miRNAs [5].

A biomarker based on miRNA levels has several advantages over biomarkers currently used at the levels of specific proteins in the blood [5, 6].

1. The strongest advantage is that the global miRNA level can be measured quickly and accurately.
2. Because of the high precision and efficiency of transcriptome profiling techniques, it is much easier to profile global miRNA levels than proteins or metabolites.
3. The miRNA population consisting of different sequences in humans can be rapidly measured with high-throughput sequencing technology because many miRNAs are expressed differently in different tissues and cellular situations. It can help more with the combination of miRNA levels.
4. The origin of cancer tissues can be classified at the miRNA level.
5. If we compare it with protein or other types of molecules where no amplification method can be applied, polymerase chain reaction (PCR) based amplification enables measurement of the low amount of miRNA in body fluids, even in small volumes.

The fact that miRNAs have come to the fore in many disease mechanisms brings to the agenda their use as biomarkers in the early stage. Much research has been done to find extracellular miRNAs that can be used as diagnostic or prognostic markers for specific diseases. After the first promising results of the studies, it turned out that the exact quantification of circulating miRNAs is more complex than expected. One of the uncertainties it brings is why the expression profiles of

CHAPTER 14

Advancements in Gastrointestinal System Biomarkers

Suleyman Demiryas^{1,*} and Anil Orhan²

¹ Department of General Surgery, Cerrahpaşa School of Medicine, Istanbul University – Cerrahpaşa, Istanbul, Turkey

² Department of General Surgery, Haseki Training and Research Hospital, University of Health Sciences, Istanbul, Turkey

Abstract: The requirement for diagnostic surgical operations of gastrointestinal system diseases significantly decreases with the help of proper diagnostic tools. These modalities are also beneficial for identifying postoperative complications, allowing us to diagnose them in earlier stages, and increasing the postoperative survival rates. Biomarkers are considered an integral part of diagnostic examinations. Developments of biomarkers used for diagnosing and treating abdominal diseases are essential for improving our capabilities in non-invasive monitoring. In this chapter, we review both the novel and the routine biomarkers in the diagnosis and follow-up of gastrointestinal system diseases.

Keywords: Benign Gastrointestinal System Diseases, Biomarker, Diagnostic biomarkers, Malignant Gastrointestinal System Diseases, Surgery.

INTRODUCTION

In the last century, great advancements have been made in the preoperative preparation, intraoperative technique, postoperative follow-up, and treatment stages in surgery. While these advancements facilitate our routine surgical procedures, they also increase disease-free survival rates after surgery. Especially in the last thirty years, surgery has enormously evolved in an attempt to ensure minimally invasive operations.

With the advancements in surgery, the routine practices we use in the screening and diagnosis of diseases have also advanced. These advances reached their pinnacle in biochemical and radiological examinations. Thus, differential diagnosis of acute abdominal diseases can be performed much easily, and the

* Corresponding author Suleyman Demiryas: Department of General Surgery, Cerrahpaşa School of Medicine, Istanbul University – Cerrahpaşa, Istanbul, Turkey; Tel: +90 (542) 366 72 32; E-mail: suleyman.demiryas@iuc.edu.tr

need for diagnostic laparotomy has decreased significantly. Brilliant advances in endoscopic methods have paved the way for minimally invasive interventions, especially in the screening, diagnosis, and treatment of gastrointestinal diseases.

These advancements allowed surgeons to perform cost-effective, easily accessible procedures which cause the least trauma for the patient. Although previous studies have focused on the structure and functions of these biomarkers, recent studies have also focused on their clinical usage. Therefore, the clinical usage of biochemical markers as diagnostic tests and patient follow-ups has gradually increased. This chapter focuses on biomarkers that we are now using or incorporating into our clinical practice, which do not require excessive surgical procedures or post-operative pathological evaluation.

Diagnostic Biomarkers of Upper Gastrointestinal System Diseases

Upper gastrointestinal system diseases are one of the most common causes of global hospital admissions. More than 10 million applications for upper gastrointestinal system complaints were made in the United States in 2018 [1]. According to 2019 clinical data, out of 1,806,590 cancer cases in the United States, 333,680 were diagnosed in the gastrointestinal system and approximately 46,000 in the upper gastrointestinal tract (stomach and esophagus) [2]. Many methods have been developed for the diagnosis and treatment of these disorders, and undoubtedly endoscopic interventions and radiological examinations account for a large percentage. According to the clinical data of 2013, 6.1 million upper gastrointestinal system endoscopies were performed in the United States [3]. However, the fact that endoscopic interventions are considered invasive, which may also require anesthesia for the procedure, and their occasional inappropriate usage, researchers are looking for easier methods for diagnosing these disorders.

Diagnostic Biomarkers of Benign Upper Gastrointestinal System Diseases

Pepsinogen I & II

Pepsinogen (PG) is the zymogenic form of pepsin and it is classified as an endoproteinase with two different isoforms. While Pepsinogen I is released from the chief cells and neck cells in the stomach fundus and corpus, Pepsinogen II is secreted from Brunner glands in cardia, antrum, pylorus, and duodenum [1, 4]. It turns into its activated form pepsin in acidic conditions and takes part in the hydrolysis of nutritional proteins. Pepsinogens I & II are useful markers that can reveal gastritis. Especially in *Helicobacter pylori*-associated gastritis, both PG values elevate in serum, predominantly PG II [5, 6]. A rapid decrease in PG II

after the treatment of *H. pylori* infection makes serum PGs useful in the control after eradication treatment [5]. Furthermore, PG tests can be used as a confirmation test for other non-invasive tests, as a high false positivity rate can be seen in other non-invasive tests such as urea breath test and *H. pylori* stool antigen test, especially in acute cases with a low prevalence of *H. pylori* [6].

PG values can also be used to diagnose atrophic gastritis. In chronic atrophic gastritis cases in which the corpus is affected, a decrease in PG values is observed. It has been reported that serum PG I - PG II values and PG I / II ratio may be useful for the early diagnosis of gastric atrophy [7, 8].

The use of serum PGs in gastric cancer screening is also increasing day by day. Recent studies have shown that there is a possible link between low serum PG I value and the risk of stomach cancer due to atrophic gastritis [9, 10]. In the study conducted in asymptomatic patient groups, higher rates of gastric cancer and intestinal-type intramucosal cancer were observed in upper GIS endoscopy in patients with low PG values (PG test positive) compared to the patients with normal PG values (PG test negative) [11]. Thus, it is thought that serum PG values may be a useful biomarker in terms of screening for gastric cancer in the patient population with high risk.

Gastrin 17

Gastrin 17 (G-17) is a peptide hormone consisting of 17 amino acids produced by antral G cells, and it provides the control of gastric acid secretion with the help of a negative feedback mechanism. G-17 release is directly related to intragastric acidity, so it is a significant indicator of gastric acidity [12].

Gastroesophageal reflux (GERD) and reflux-related diseases are conditions in which gastric acidity increases significantly. Thus, G-17 values are found to be decreased in GERD and reflux-related diseases. A study in which patients with retrosternal burning complaints were evaluated showed a correlation between different reflux patterns and G - 17 values, and no additional invasive procedures were required [13]. Barrett's esophagitis (BE) is another reflux-related disorder that occurs due to high gastric acidity. BE patients have lower G - 17 levels compared to normal patients, suggesting that it may help the diagnosis for early detection of esophageal cancer [12].

Another condition which both gastric acidity and G - 17 affected is atrophic gastritis. The stomach can be evaluated in two different segments from the corpus-antrum junction; the proximal segment mainly produces exocrine secretion, and the distal segment is widely responsible for the endocrine secretion

Novel Applications of Biomarkers in Chronic Obstructive Pulmonary Disease

Pelin Uysal^{1,*}

¹ Department of Chest Diseases, Faculty of Medicine, Mehmet Ali Aydınlar University, Atakent Hospital, Istanbul, Turkey

Abstract: Chronic obstructive pulmonary disease (COPD) is an important health problem and an increasing cause of morbidity and mortality worldwide. Currently, COPD is considered a multisystem disease. Although it primarily affects the lungs, structural and functional changes occur in other organs due to systemic inflammation. It is stated that in patients with COPD, airway and systemic inflammatory markers are increased and that these markers are high are associated with a faster decline in lung functions. In recent years, numerous articles have been published on the discovery and evaluation of biomarkers in COPD. Many markers have also been studied to accurately assess COPD exacerbations and provide effective treatment. However, based on the evidence from published studies, a single molecule has not been adequately validated for broad clinical use.

Keywords: Chronic obstructive pulmonary disease, Biomarkers, Exacerbation, Therapy.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) was previously defined only by the presence of airflow limitation, is now defined as an inflammatory disease. It is also stated that COPD is a systemic disease, and comorbid and common comorbidities contribute to the severity and mortality of COPD. In COPD, the musculoskeletal system (muscle dysfunction and osteoporosis), cardiovascular system (atherosclerosis), endocrine, and nervous system are mainly affected [1]. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), interleukin-8 (IL-8), IL-6, tumor necrosis factor-alpha (TNF- α), and leukotriene B4 (LTB4) are the major inflammatory markers that may cause COPD. The importance of changes in these markers during exacerbation and after treatment has been emphasized in various studies [2].

* Corresponding author Pelin Uysal: Department of Chest Diseases, Faculty of Medicine, Mehmet Ali Aydınlar University, Atakent Hospital, Istanbul, Turkey; Tel:+90 505 453 56 23; E-mail: pelinuysal@gmail.com

With the demonstration that many inflammatory cells, cytokines and enzymes are involved in different stages of COPD, the place and importance of inflammation in the pathophysiology of the disease has been better understood in recent years. Many inflammatory cells and markers are involved in the pathogenesis of COPD and this inflammation has been demonstrated by different methods. Developments in this area will also help develop new approaches to the treatment of the disease [3].

Biomarkers are measurable indicator molecules that show biological developments, pathological changes, and responses to pharmacological treatment. A good biomarker should be disease-related, sensitive, reliable, consistent, reproducible, practically applicable, and should also be generalizable and cost-effective; these can be cells, cytokines, proteins, genes, and products, *etc* [4].

To show inflammation in COPD and other respiratory system diseases, samples of bronchial biopsy, induced sputum, bronchoalveolar lavage (BAL) fluid, and expiratory air can be taken. Many inflammatory markers can be measured in BAL fluid. Eosinophil cationic protein (ECP), myeloperoxidase and IL-8 levels were found to be higher in COPD and smokers than in healthy non-smokers. Protease and antiproteases can be detected in BAL fluid. In COPD, there is an increase in total elastase activity and a decrease in anti-elastase activity, which reveals the protease-antiprotease imbalance compared to normal smokers. It has been reported that the ratio of neutrophils and macrophages is increased in BAL fluid and sputum in patients with COPD. Neutrophils increase the release of proteases, such as neutrophil elastase and matrix metalloproteinase (MMP), and toxic peptides, such as oxidants and defensins in COPD. While neutrophil ratios in bronchial biopsies and induced sputum correlate with the severity of the disease, they also show parallelism with the rate of decline in pulmonary function tests. Macrophages are significantly increased in the airways, lung parenchyma, BAL fluid, and sputum. Macrophages increase the release of TNF- α and chemokines sensitive to some monocytes, especially with the effect of smoking in COPD. Macrophages also cause the release of many MMPs such as MMP-1, MMP-9, and MMP-12. In stable COPD patients, activated T-lymphocytes such as macrophages and especially CD-8 T-lymphocytes, interferon (IFN) - γ , CXCL10 (IFN--induced protein [IP-10]), IL-4 and IL-9 oscillate. CD-8 T-cells cause a variety of inflammatory changes. CD-8 T-cells have been demonstrated to increase the airways of patients with COPD, and it is known that the CD-4/CD-8 ratio reverses in COPD. Natural killer (NK) cells increase numerically at a low rate in terms of phagocytosis ability in patients with COPD. However, more pronounced increases in NK cell counts were found in the sputum of COPD patients, especially during acute attack periods [5 - 8].

Increases in the number of neutrophils, CD-8 T cells, and sometimes eosinophils are observed in the induced sputum of patients with COPD. The increase in eosinophils helps identify coexisting asthma or higher bronchodilator response and subgroups of patients who will benefit from corticosteroids [3, 6, 9]. Increased levels of IL-8 in the sputum of patients with COPD correlate with bacterial load in the airways and myeloperoxidase released from activated neutrophils. IL-6, IL-1 β , TNF- α , and IL-8 were increased in induced sputum; monocyte chemoattractant factor-1 (MCAF-1) increases, causing IL-8 release in the bronchial epithelium. Cytokines are proteins that are generally smaller than 80 kilodaltons and enable communication between cells. Cytokines have important roles in inflammation, and they function with surface receptors with high affinity for them. TNF- α increases ICAM-1 level in patients with COPD. The activation of macrophages results in the formation of MMP. In bronchial epithelial cells, extracellular TNF- α plays an important role in the production of tenascin, a matrix glycoprotein. Increased serum TNF- α concentration has been shown to be associated with weight loss in COPD. TNF- α and receptors in COPD are higher than non-smokers. IL-8 is a neutrophil-specific chemotactic factor and a CXC chemokine that activates LTB₄ and neutrophil 5-lipoxygenase. LTB₄ is known to provide chemotactic activity in the sputum of patients with COPD. IL-8 also functions as a chemotactic for T-cells. IL-8 was found to be higher in induced sputum in COPD patients compared to smokers without COPD and the control group. The value of IL-8 increases even more with the severity of the decrease in FEV₁ values, and this becomes more pronounced in attacks. Leptin, another important cytokine, is detected in the induced sputum of patients with COPD and correlated with TNF- α and other inflammatory markers such as CRP [10].

Measurement of markers in exhaled air is preferred due to its noninvasiveness and easy reproducibility. Nitric oxide (NO) in the expiratory air (eNO, FeNO) has been extensively studied in asthma. However, the clinical benefit of measuring eNO in COPD is limited and normal or slight elevations can be seen. The increase in eNO in COPD correlates with the increase in bronchodilator and corticosteroid response, just like the increase in eosinophils [11, 12]. It is not useful for practical use as it is highly variable due to environmental CO levels and the effects of passive smoking. Concentrated exhaled breath condensate (EBC) is easy to make. It has been preferred frequently in recent years due to its nature and non-invasiveness, protein biomarkers in exhaled air could not be measured reliably by conventional methods [13, 14]. Hydrogen peroxide (H₂O₂) and 8-isoprostane, which are among oxidative stress markers, are found to be high in the EBCs of patients with COPD. pH is lower. While pro-inflammatory cytokines, including IL-1, IL-6, and TNF- α , are detected higher in exhalation air during COPD exacerbation, some important markers are fully observed in EBCs [6, 14].

Biomarkers in Diabetes Mellitus

Fatih Orkun Kundaktepe^{1,*}

¹ Department of Internal Medicine, Istanbul Taksim Research and Training Hospital, Istanbul, Turkey

Abstract: Diabetes mellitus (DM) is a chronic metabolic disease characterized by hyperglycemia that occurs as a result of impaired insulin secretion and/or insulin effect, or both of these factors. The fact that the disease has both individual and social dimensions makes it important to detect as early as possible and make the necessary lifestyle changes. For this purpose, it becomes necessary to develop fast, effortless, cheap, and reliable methods for diagnosis. We discussed which biochemical markers should enter routine use according to their sensitivity and specificity among the biochemical markers that have been used and are still being studied. In this chapter, we explored some methods that may be used as biomarkers and discussed advantages and pitfalls for each.

Keywords: Advanced glycation end-products, Biomarkers, Diabetes mellitus, Glycated albumin, HbA1c, microRNAs, Netrin, Salivary glucose.

INTRODUCTION

Diabetes mellitus (DM) is a chronic metabolic disease presents with hyperglycemia caused by impaired insulin secretion or insulin resistance and/or destruction of pancreatic β cells. By 2019, IDF declared that approximately 463 million adults were suffering from DM, and by 2045, this number is projected as 700 M. DM also caused 4.2 M deaths in the aforementioned year [1].

DM is classified into three major subgroups; Type I (5-10%), Type II (most common, 90-95%), gestational DM, and some other specific types. Type I diabetes mostly occurring in juveniles is immune-mediated and insulin-dependent diabetes. Patients with Type I DM have to use subcutaneous insulin injections several times a day to survive. Type II diabetes, also known as insulin-independent diabetes, is a result of impaired cellular insulin response, which may be called insulin resistance. In patients with type II DM, there is also a phase called pre-diabetes, which presents insulin resistance and impaired fasting plasma

* Corresponding author **Fatih Orkun Kundaktepe**: Department of Internal Medicine, Istanbul Taksim Research and Training Hospital, Istanbul, Turkey; Tel: +90 (530) 826 00 99; E-mail: doktorkun@gmail.com

glucose (FPG) levels. Insulin resistance and Type II DM are associated with obesity, age, and family history [1].

With novel approaches in DM treatment, it is possible to prevent DM progression before causing microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (coronary artery disease, peripheral arterial disease, and stroke) complications. In this context, detecting DM at the pre-diabetes phase provides better control of this disease. Thus, new diagnostic techniques and tools will help us to detect DM as earlier as possible so we can start treatment in an early phase of diabetes.

Currently, FPG and hemoglobin A1c (glycated hemoglobin, HbA1c) measurements are in use as a biomarker at DM diagnosis. There is also an oral glucose tolerance test (OGTT) for detecting pre-diabetes and gestational diabetes. DM is diagnosed with;

- An FPG level of 126 mg/dL (7.0 mmol/L) or higher, *or*
- A 2-hour plasma glucose level of 200 mg/dL (11.1 mmol/L) or higher during a 75-g OGTT, *or*
- Random plasma glucose of 200 mg/dL (11.1 mmol/L) or higher in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, *or*
- An HbA1c level of 6.5% (48 mmol/mol) or higher [2].

HbA1c is currently a reference test being used for diagnosis, screening, and follow-up in patients with DM. HbA1c reflects blood glucose levels over a 2-3 months period and is insufficient with rapid glycemic changes. Furthermore, it is not recommended in patients with uremia, hemoglobinopathy, anemia, and pregnancy. Patients with those situations are very common in daily clinical practice. Thus, alternative biomarkers would help clinicians for better diagnosis and follow-up in patients with DM.

In this chapter, we will explore some other methods may be used as biomarkers.

GLYCATED ALBUMIN (GA)

Albumin is the most abundant protein in plasma. With a molecular weight of 66.7 kDa, it contains a single polypeptide chain with 585 amino acids and 17 disulfide chains. Albumin makes up approximately 60% of total serum protein with concentrations in a range of 30-50 g/L and a half-life of 14 to 20 days [3].

Glycation is defined as a non-enzymatic spontaneous reaction that occurs in situations with high plasma glucose, initiated with the addition of reducing sugars and/or their metabolites to amine groups (typically lysine and arginine) within

proteins. With forming a Schiff base, an intermediate product can undergo a rearrangement to create a more stable Amadori product. After dehydration and oxidation, reactive dicarbonyl compounds transform into precursors of advanced glycation end-products (AGEs). This incident is known as the Maillard reaction [3].

Albumin glycation is affected by glucose concentration and the time of exposure between glucose and protein [4]. Compared to hemoglobin, albumin glycation rates are about 9 to 10 times greater [5]. Ueda and Matsumoto conducted an *in vitro* experiment, and they showed that GA production was 4.5 times greater than HbA1c production after adding the same glucose concentrations. That showed GA production is faster in the same *in vitro* conditions [6].

There are several ways to measure GA like ion-exchange high-performance liquid chromatography (HPLC), boronate affinity chromatography, immunoassays, and colorimetric method with thiobarbituric acid and enzymatic methods using proteinase and ketamine oxidase [7]. Enzymatic methods result in a shorter time and are easy to perform compared to other methods [8]. In all methods, GA levels increase 2 to 5 fold in patients with DM compared to healthy individuals [3].

GA is being considered as a biomarker for DM diagnosis since Tomigana and colleagues conducted a study to determine a reference interval for GA in 2006, which resulted in a range of 12.3% to 16.9% in 699 patients [8]. In 2011, a study with a larger patient number (N=1575) reported a similar interval with a cut-off point for DM diagnosis as 15.5% shows 83.3% sensitivity and specificity by using fasting glucose (≥ 126 mg/dL) and HbA1c ($\geq 6.5\%$) as reference tests [9]. In years following, studies showed similar cut-off points with similar sensitivity and specificity rates.

After diagnosis, GA has also been considered as a consistent follow-up biomarker. As mentioned before, GA has a half-life of 14-20 days, making it suitable for detecting rapid glucose changes in a shorter time than HbA1c with a mean life of 120 days. GA can show the efficacy of drug therapy [10] and insulin treatment with a better correlation with fasting glucose than HbA1c [11]. Thus, GA is more useful for managing the medication or dosage of oral antidiabetics and titration of insulin therapy.

Long-term complications of DM are another challenge to predict by biomarkers. A study showed GA and HbA1c had a similar association with microvascular complications like retinopathy and nephropathy. Same study showed cardiovascular complications were predicted by only HbA1c [12].

Biomarkers and their Clinical Applications in Pediatrics

Yusuf Elgormus^{1,*}

¹ Department of Pediatric Health and Diseases, Medicine Hospital, Istanbul, Turkey

Abstract: Biomarker studies are becoming increasingly interesting for many fields of medicine. The use of biomarkers in medicine is involved in detecting diseases and supporting diagnosis and treatment decisions. New research and new discoveries on the molecular basis of the disease show that there may be a number of promising new biomarkers for use in daily clinical practice. Clinical trials in children lag behind adult research both in quality and quantity. The number of biomarkers validated to optimize pediatric patient management is limited. In the pathogenesis of many diseases, it should not be extrapolated to the pediatric clinical setting, taking into account that biomarkers that are effective in adults are clearly different in children and that ontogeny directly affects disease development and therapeutic response in children. The search for ideal biomarkers or markers that can make an early and definitive diagnosis in neonatal sepsis is still ongoing. The ideal biomarker for pediatric diseases should be cost-effective, noninvasive, applicable to pediatric specific diseases, and its results should correspond to age-related physiological changes. Lactate, troponin and B-type natriuretic peptide are valuable biomarkers in the evaluation and management of critically ill children with cardiac disease. Tumor markers in children are biochemical substances used in the clinical treatment of pediatric tumors and to detect the presence of cancer (regression or progression). In this chapter, current and brief information about biomarkers and their clinical applications used in the diagnosis and monitoring of pediatric diseases is presented.

Keywords: Biomarker, Early predictor, Management, Monitoring, Premature, Tumor markers.

INTRODUCTION

Biomarker research has become increasingly interesting for many areas of medicine today. Biomarkers (biological markers) are indicators of the biological process that can show changes in disease and health status and pathological conditions. Biomarkers may include biofluids (urine, blood, saliva, stool, amniotic

* Corresponding author Yusuf Elgormus: Department of Pediatric Health and Diseases, Medicine Hospital, Istanbul, Turkey; Tel:+905322939282; E-mail: yusuf.elgormus@medicinehospital.com.tr

fluid, bronchoalveolar lavage, cerebral spinal fluid), other tissue (including skin, hair or nails), radiographic, genetic, or any other physiologic testing. While biomarker provides important information in the diagnosis of a disease, they may be ineffective in showing the course of the disease. However, even if a biomarker may not be a good diagnostic biomarker, there are numerous other types of potential applications for newly discovered markers. For example, prostate-specific antigen (PSA) used in prostate cancer is an important parameter for diagnosis, but it is not a suitable marker for monitoring the disease. Similarly, carcinoembryonic antigen (CEA) used in ovarian carcinomas is not an important indicator for diagnosis, but it is a good biomarker in the follow-up of the disease [1, 2]. The most important characteristics of an ideal biomarker are summarized in Table 1.

Table 1. The most important characteristics of an ideal biomarker.

<ul style="list-style-type: none"> • It should be specific for the tumor type identified. <ul style="list-style-type: none"> • Analysis should not require an expensive tool. • The results of the biomarker should be easily interpreted. <ul style="list-style-type: none"> • It must have analytical and clinical validity. • Its quantity should not show a wide variation in the general population. • It must be precise, sensitive and specific for the condition of the disease. • Its measurement is practical and easy; its levels should be compatible with the stages of the disease. <ul style="list-style-type: none"> • Adequate and reliable amounts of body tissues and fluids should be obtained.
--

Despite the lack of knowledge on child-specific biomarkers, their use is beneficial as it is integrated into the pediatrician's daily practice. When a complete blood count (leukocyte) and C-reactive protein (CRP) are measured for the initial evaluation of bacterial infection in a febrile child or HbA1c to assess glycemic control in a diabetic patient, biological surrogates are used to assess pediatric disease processes and direct the care plan. There are many approaches when considering pediatric biomarkers. A more traditional approach uses well-established adult biomarkers and applies data directly to children. This approach is similar to the drug development process where a drug is developed for adult disease, studied in adult patients, and then investigated for potential use in children [3]. This chapter reviews and summarizes the different types of biomarkers and their clinical applications in many childhood diseases. Although many diseases have overlapping biological system involvement, they were broadly categorized as noncommunicable diseases, metabolic diseases, inflammatory diseases, liver diseases, urological diseases, autoimmune diseases, genetic diseases, and rare diseases.

CHILDHOOD NONCOMMUNICABLE DISEASES

Noncommunicable diseases (NCDs), such as cardiovascular diseases, cancer, diabetes and chronic respiratory diseases, are the leading global cause of death and are responsible for just over 70% of deaths worldwide [4].

Biomarkers in Patients with NCDs in Childhood

Allergy, Asthma, Atopic Dermatitis (AD)

Allergy is not one disease but a collection of a number of allergic conditions. The frequency of allergic diseases is increasing day by day. Asthma, atopic dermatitis (AD), hay fever, food allergy, eosinophilic esophagitis (EoE), and allergic rhinitis are among the most prevalent chronic NCDs in children from 0-18 years of age [5, 6]. If food allergy accompanies AD in young children, asthma and allergic rhinitis (AR) may develop in these children at later ages. This clinical course is known as the “**atopic march**”. Epidemiologic studies indicate that asthma begins in the preschool years even when chronic symptoms do not appear until early adulthood [7, 8]. The lack of definitive diagnostic criteria in differentiating children with recurrent bronchiolitis/bronchitis patients who have progressed to asthma and those who have had one or two non-recurring bronchiolitis/bronchitis attacks prevents predicting the progression of these children. The genes containing differential methylation robustly associated with asthma and allergy are likely to play a role in allergic disease pathogenesis, and understanding the biological implications of these epigenetic signatures may help elucidate mechanistic pathways and define disease endotypes [9].

The diagnosis of allergic disorders is most often made on clinical history, supported by the results of skin tests and diagnostic markers *e.g.* immunoglobulin E (IgE). Although skin testing has advantages of relative sensitivity and specificity, rapid results, and good tolerability, it is subject to some operator, observer and interpretation variability. IgE is also known to be elevated in non-allergic conditions and many allergic patients have IgE levels within the normal range [10]. Schools *et al.* [11] demonstrated that there is a substantial disagreement between skin prick test (SPT) and specific IgE (sIgE) for diagnosing allergic sensitization in young children, which increases with age for food sensitization. sIgE and SPT cannot be used interchangeably as the choice of method significantly influences the diagnosis of IgE - mediated allergy in young children. The lack of agreement between tests and a poor correlation to clinical disease underscores that allergy testing should not be used as a screening tool in children [11].

Biomarkers in Liver Disease

Abdullah Sonsuz^{1,*} and Oguz Kagan Bakkaloglu¹

¹ Department of Internal Medicine-Gastroenterology, Cerrahpasa Medical Faculty, Istanbul University – Cerrahpasa, Istanbul, Turkey

Abstract: Symptoms and signs of liver diseases are highly variable depending on the etiology, disease stage, and type of liver involvement. There are different types of liver diseases; causes of liver diseases may be viral, toxic, metabolic, or autoimmune. However, in some cases, liver disease can develop as a result of diseases of other organs or systems. It is almost impossible to differentiate all of these solely on the basis of clinical symptoms and findings. Furthermore, the early stages of liver disease may be completely asymptomatic, or in some cases, the disease may progress with only subtle and non-specific symptoms. Therefore, biomarkers have a critical role in screening, diagnosis, staging, and evaluation of therapeutic response to treatment in liver diseases.

Keywords: 5'-Nucleotidase, Alanine aminotransferase, Albumin, Alkaline phosphatase, Alpha-fetoprotein, Aspartate aminotransferase, AST isoenzymes, Biomarkers, CA 19-9, Cholangiocarcinoma, Cholestasis, Fibrosis, Gamma-glutamyl transferase, Hepatocellular carcinoma, Hepatocellular injury, Liver disease, MELD-Na score, Prognosis, Prothrombin time, Staging of liver disease.

INTRODUCTION

Biomarkers are important tools for screening, diagnosis, assessment of treatment response, and evaluating the prognosis of diseases or other medical conditions. There are various definitions for biomarkers in the medical literature, and a more broadened definition of biomarkers may as well include the measurable clinical signs, radiologic or histopathologic findings [1].

National Institutes of Health Biomarkers Definitions Working Group defines a biomarker as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to therapeutic interventions” [2].

* **Corresponding author Abdullah Sonsuz:** Istanbul University – Department of Internal Medicine-Gastroenterology, Cerrahpasa Medical Faculty, Istanbul University – Cerrahpasa, Istanbul, Turkey; Tel: +90 (532) 255 6 991; E-mail: abdullahsonsuz@yahoo.com

The burden of liver diseases has been underestimated for many years. Recent data show that liver diseases account for approximately 2 million deaths per year worldwide [3]. Although WHO aims to reduce the incidence of HBV and HCV infections and the associated mortality substantially by 2030, changes in the epidemiology and etiology of liver diseases indicate that nonalcoholic fatty liver disease and related other diseases will be much more important public health problems in the future [4, 5]. Rational usage of biomarkers is not important only for the diagnosis of liver diseases but also for the prediction and prevention of life-threatening complications and other clinical consequences. Unfortunately, most of the biomarkers used for liver diseases in daily clinical practice have some limitations.

The liver may be affected directly and specifically by viral, toxic, or hereditary disease, but also some systemic diseases may cause liver dysfunction or even overt liver disease that is indistinguishable from the liver-specific diseases. Clinical symptoms such as nausea, vomiting, right upper quadrant abdominal pain, fatigue, weakness, weight loss, and jaundice are not specific to liver diseases and may also be seen in many other diseases or medical conditions. Furthermore, these symptoms may not occur until late-stage liver disease. Diagnosis of liver diseases is more difficult than the diagnosis of many other systems' diseases and requires not only a high level of knowledge about liver diseases but also advanced clinical experience.

The intervals between the beginning of the disease, the appearance of the clinical signs and symptoms, and detectable laboratory findings of the liver disease are highly variable; thus, there may be different timeline models for the course of the liver disease (Fig. 1).

One typical example for model-A is Bud-Chiari syndrome. Immediately after the occlusion of the hepatic veins with thrombus (cause of the liver disease), radiological findings of the venous obstruction can be demonstrated at the early phase of the disease; painful hepatomegaly and ascites (clinical findings) occur within a short time period, followed by other laboratory and clinical findings (Fig. 1A).

The clinical course of some genetic liver diseases may be described as model-B. Although some of the laboratory findings are present from the beginning or earlier in the course of the disease, clinical findings may be delayed for a long time (Fig. 1B). Wilson's disease is caused by a mutation in the ATP7B gene; low levels of serum ceruloplasmin and increased urinary copper excretion may be demonstrated many years before overt clinical signs and symptoms.




Fig. (1). Different timeline models depicting the manifestation sequence of “The cause”, “The biomarker positivity” and “Clinically apparent signs and symptoms” in liver diseases.

Clinical models of some other liver diseases may have a long-time-interval between laboratory and clinical signs of the disease; the cause of the liver disease may persist for many years without any significant alteration of laboratory tests and before clinical symptoms or signs are evident (Fig. 1C). The course of the immune tolerant phase of chronic hepatitis B virus infection is typical for this model. Despite the initial HBsAg positivity and the presence of high levels of HBV DNA, neither the biochemical findings of liver damage nor the clinical signs of liver disease are present. Aminotransferase elevation will manifest in the next phase (immune active phase), but many years later, clinical signs and symptoms of liver disease will be evident in some of these patients.

Biomarkers are of critical importance for the diagnosis and clinical evaluation of most of the liver diseases in any of the three clinical course models.

Biochemical findings used for the diagnosis of liver diseases are classified into four groups traditionally.

1. Tests used to evaluate the hepatocellular injury
2. Enzymes for detection of cholestasis
3. Tests of liver synthetic function
4. Quantitative liver function tests

Application of New Acute Kidney Injury Biomarkers

Nurhan Seyahi^{1*} and Seyda Gul Ozcan²

¹ Department of Nephrology, Cerrahpasa Medical Faculty, Istanbul University - Cerrahpasa, Istanbul, Turkey

² Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University - Cerrahpasa, Istanbul, Turkey

Abstract: Kidney-related biomarkers can provide structural and functional information about different parts of the nephron. These biomarkers can be used to evaluate glomerular, tubular, or interstitial injury, inflammation, or repair, and glomerular or tubular function. Furthermore, biomarkers can improve the acute kidney injury diagnosis in various clinical conditions, including acute interstitial nephritis, acute tubular injury, hepatorenal and cardiorenal syndrome, ischemic and nephrotoxic acute kidney injury, and drug-induced acute kidney injury. Biomarkers might be used as an additional precision medicine tool in managing patients with acute kidney injury; they can help with clinical decision-making and impact patient outcomes. In this chapter, we reviewed the utility of biomarkers used in acute kidney injury.

Keywords: Acute kidney injury, Biomarkers, Nephrotoxicity, Tubular injury.

INTRODUCTION

Acute Kidney Injury, Biomarkers, And Definitions

Acute kidney injury (AKI) is the rapid loss of kidney function and is a serious problem, particularly in patients hospitalized in intensive care units (ICUs) [1, 2]. However, until about two decades ago, the condition lacked a uniform definition. The Acute Dialysis Quality Initiative first introduced the international consensus criteria, which was subsequently modified by the AKI Network and finally by the Kidney Disease Improving Global Outcomes (KDIGO) workgroup [1]. Although a standardization in the definition of AKI has been achieved using the serum creatinine and occasionally urine output, there is still a need for more robust tools to define the etiology, type, and prognosis of AKI [3].

* Corresponding author Nurhan Seyahi: Department of Nephrology, Cerrahpasa Medical Faculty, Istanbul University - Cerrahpasa, Istanbul, Turkey; Tel: +90 (532) 296 32 03; E-mail: nseyahi@yahoo.com

The KDIGO guidelines emphasize early diagnosis and treatment in AKI, and the preferred diagnostic biomarker of the condition remains the measurement of the serum creatinine level because of its convenience and low cost. However, the utility of this marker is limited due to many reasons; for example, renal hypoperfusion may cause prerenal kidney injury, and creatinine levels may increase without any renal parenchymal damage [4]. Additionally, in patients with renal parenchymal injury, especially in chronic kidney disease (CKD) patients, renal compensation may delay the creatinine increase, and creatinine levels might not increase until a GFR loss of more than 50% occurs [5, 6]. Therefore, more sensitive and specific new biomarkers will likely improve the early diagnosis of AKI [7].

Biomarkers in kidney injury are new tools for risk assessment that can help determine which therapy to use. [8]. The Food and Drug Administration (FDA) has defined a “biomarker” as a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to therapeutic interventions [3].

Classification of AKI Biomarkers

Different schemes, usually based on the site of origin or pathophysiological process on the nephron (Table 1) [9, 10], might be used to classify the AKI biomarkers. Biomarkers can help evaluate glomerular or tubular function, glomerular, tubular, or interstitial injury, inflammation, or repair. Selected biomarkers of AKI according to the site of origin on the nephron are shown in Fig. (1).




Fig. (1). Biomarkers and their predictive area of injury in the nephron. The illustration was prepared using the following references [10, 75, 94, 98].

Additionally, tissue inhibitors of metalloproteinases-2 (TIMP-2) and insulin-like growth factor binding protein-7 (IGFBP-7) might be classified as cell cycle arrest biomarkers [11].

Table 1. Acute kidney injury biomarkers classified according to the site of origin and pathophysiological process on the nephron [9, 10, 45].

Biomarkers of glomerular health	Cystatin-C, galectin-3, proenkephalin
Biomarkers of tubular health (function and injury)	KIM-1, L-FABP, IGFBP7, TIMP-2, UMOD, NGAL
Biomarkers of inflammation	TNF-alpha, IL-9, IL-18, IL-6, IL-10, TNFR1, TNFR2
Biomarkers of repair and fibrosis	MCP-1, CHI3L1 (YKL 40), PIIINP, EGF

KIM-1: kidney injury molecule-1, L-FABP: liver-type fatty acid-binding protein, TIMP-2: tissue inhibitor of metalloproteinases 2, IGFBP-7: insulin-like growth factor-binding protein 7, UMOD: uromodulin, NGAL: neutrophil gelatinase-associated lipocalin, TNF-alpha: tumor necrosis factor alpha, IL: interleukin, TNFR1: tumor necrosis factor receptor 1, TNFR2: tumor necrosis factor receptor 2, MCP-1: monocyte chemoattractant protein 1, PIIINP: procollagen type III N-terminal propeptide, EGF: epidermal growth factor.

Biomarkers of Glomerular Health

Cystatin C: Classically, creatinine is used as a biomarker of glomerular health, while cystatin C is a new biomarker that depicts the glomerular function. In contrast to creatinine, serum cystatin C is not correlated with age, sex, and muscle mass, and in certain situations, such as in patients with marginal muscle mass, it might be used as a more appropriate marker of glomerular function [12]. Cystatin C is eliminated entirely by glomerular filtration. Following filtration, the protein is almost completely catabolized in the proximal tubule. Therefore, in physiological conditions, it scarcely appears in the urine. An impairment in the proximal tubular reabsorption causes an increase in the urinary cystatin C levels [13].

Biomarkers of Tubular Health

Alpha-1-Microglobulin (α 1M): Alpha-1-microglobulin is a biomarker of proximal tubular function and is mainly produced by the liver. The protein might be in free form, or it might form a complex with immunoglobulin A (IgA) [14]. Following free glomerular filtration and proximal tubular reabsorption, α 1M is completely catabolized. Increased urinary concentration of this biomarker is associated with proximal tubular injury or dysfunction. Urinary α 1M extraction is increased in patients who have a renal tubular disease [14].

Liver-type Fatty acid-binding Protein (L-FABP): There are several types of FABPs expressed in various organs, including the kidneys and the liver. Following glomerular filtration, the circulating L-FABP is reabsorbed by the

Biomarkers to Predict Sudden Cardiac Death

Ali Uğur Soysal^{1,*} and Kivanc Yalin¹

¹ Department of Cardiology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey

Abstract: Sudden cardiac death (SCD) is a common disorder and an unsolved issue for health care providers. Despite several risk factors for SCD, some cases experience SCD as an initial presentation of cardiovascular disease. Prediction of individuals at increased risk for SCD is important for implementing community-based approaches and individual-based therapies with high costs, such as implantable defibrillators. This chapter discusses the potential role of biomarkers in predicting SCD in different cardiovascular diseases.

Keywords: Biomarkers, Cardiovascular disease, Health care providers, Implantable defibrillators, Risk factors, Sudden cardiac death (SCD).

INTRODUCTION

Sudden cardiac death (SCD) is defined as the unexpected death of a person from the loss of cardiac function either within one hour of medical observation or 24 hours without medical observation. Cardiovascular diseases are responsible for 17 million deaths every year, and 25% of these are SCD. Males are currently at higher risk in terms of cardiovascular disease. SCD affects 6.68 out of every 100,000 males and 1.4 out of every 100,000 females. The highest prevalence of SCD is amongst individuals with a history of cardiac arrest or myocardial infarction, and this SCD risk is at the highest level between the 6th and 18th months after the initial cardiac event. There are also racial differences observed among the SCD cases; the black race is at more risk than the white race. SCD occurs mostly outside of the hospital or in the emergency rooms. There are different mechanisms identified that lead to SCD. Physical fragility of the atherosclerotic plaque, thrombus formation due to this, and unstable electrical conductivity are amongst the reasons for SCD in individuals with coronary atherosclerosis. Arrhythmic events can also be accelerated by hypokalemia and

* Corresponding author Ali Uğur Soysal: Department of Cardiology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey; Tel: +90 (212) 414 30 00; E-mail: aliugursoysal993@gmail.com

certain drugs that can alter QT time. Genetic causes of arrhythmogenic cardiac death, such as channelopathies, are amongst the common reasons behind SCD in relatively young population [1 - 5]. This review aims to discuss possible risk factors, especially biomarkers, among different cardiovascular substrates.

SCD in the Setting of an Acute Coronary Syndrome, Ischemic Cardiomyopathy

Sudden death is mostly due to cardiac causes and is mainly seen in patients with heart disease secondary to ischemia. Sudden death due to cardiac causes constitutes approximately 50% of all cardiovascular deaths. STEMIs that lead to SCD are associated with more proximal acute coronary artery occlusion than STEMIs without SCD. Compared to patients with STEMI, NSTEMI patients who develop SCD have been shown to be elderly patients with diffuse and multiple coronary artery disease and have more cardiovascular risk factors [4].

The risk of SCD is higher, especially in the first 30 days after MI. Although its predictive value for myocardial scar formation is weak, an echocardiogram is one of the imaging methods that can predict SCD due to ventricular tachycardia or ventricular fibrillation. As ejection fraction of the left ventricle is an indirect measure of an LV scar and can be affected by hemodynamic-autonomic factors, direct visualization of the scar and its architecture may increase risk stratification accuracy. Cardiac MR imaging with late gadolinium enhancement is superior to echocardiography in determining total scar tissue [6]. The relationship between certain ECG changes has been identified with SCD, either with or without the coronary syndrome. QRS-T angle between depolarization and repolarization, QRS-T area angle, QRS area, QT prolongation, QT dispersion, QRS fragmentation, QRS amplitude, and T wave elevation are independent predictors of SCD on an ECG reading. The angle of the QRS-T area below 112 degrees was associated with the low rate of SCD in 30-month follow-up cases [7]. The presence of microvolt T-wave alternation in patients with MI was shown to be risky in terms of arrhythmic events [8]. It is also shown that the presence of early repolarization pattern in the ECG, especially in the inferolateral leads, in patients who have no previous history of cardiac disease, who have had the first acute coronary event, creates the environment for fatal arrhythmias due to which the risk of SCD is doubled [9]. QRS wave fragmentation seen on the ECG has been associated with heterogeneous activation of ventricles due to myocardial scar in individuals with known or suspected coronary artery disease. The presence of fragmented QRS waves in patients with acute coronary syndrome triggers arrhythmogenic mechanisms and can shorten the process of fatal events [10].

The autonomic nervous system plays a key role in the development of ventricular arrhythmias, especially in patients with a history of MI. Sympathetic stimulation in cardiac disease may accelerate the development of VT or VF. Therefore, autonomic tonus measurements are included in the risk classification. Heart rate variability may occur as a decrease in spontaneous variation secondary to the loss of vagal tone after MI. The association of decreased heart rate variability with both SCD and non-sudden death has been documented. Heart rate turbulence, on the other hand, measures the short-term change in heart rate after ventricular premature beats and is closely related to baroreceptor sensitivity. Unlike baroreceptor sensitivity, heart rate turbulence can be obtained from ECG recordings alone. In addition, the REFINE study revealed heart rate turbulence association with fatal or non-fatal cardiac arrest. Compared to heart rate variability, heart rate turbulence may be more specific for SCD due to VT or VF. Advances in scintigraphical imaging (SPECT / PET) may allow visualization of the cardiac sympathetic function of the left ventricle using norepinephrine analogs (C-meta-hydroxyepinephrine). This may reveal both arrhythmic and non arrhythmic outcomes [6]. In patients presenting acute coronary syndrome symptoms, several biomarkers have been evaluated for endpoints. In a study conducted with NT-proBNP, GDF-15, CRP, cystatin-C, troponin I, and troponin T values, it was shown that basal levels of NT-proBNP and GDF-15 are associated with arrhythmia and SCD [11]. Natriuretic peptides are associated with an increased risk of SCD in both men and women. There is evidence that effective HF treatments reduce BNP values, as in the MADIT-CRT study, and transform into a better prognosis for ventricular arrhythmias and SCD. Patients with decreased BNP levels by more than a third of baseline have a lower risk of VT/VF [12]. Cardiac troponins play an important role in the evaluation of patients with the acute coronary syndrome. Detectable levels of hs-Tn in the circulation reflect cardiac myocyte damage. Basal hs-Tn levels have been shown to be associated with SCD, and it is postulated that detectable levels of hs-Tn may provide an anatomical substrate for scar-related re-entry into ventricular tachycardia. The fact that troponin levels are specific for cardiac myocytes and can be measured more easily than other lethal rhythm predictive biomarkers provide clear advantages to the clinician [13]. Sst-2 is a member of the interleukin-1 family and is associated with myocardial dysfunction and fibrosis. It plays a role in the pathophysiological processes of different ischemic events, including the progression of coronary atherosclerosis. Although serum levels of Sst-2 increase with ischemic damage, they may remain high even after MI. As a result of the analysis obtained from the MUSIC records, Pascual-Dual *et al.* were able to show that high Sst-2 levels are associated with SCD. The authors suggested that the combination of natriuretic peptide and Sst-2 may be valuable in predicting SCD [12]. Cystatin-c, which is one of the indicators of renal dysfunction and plays a role in measuring the degree

Oxidative Stress Biomarkers in the Diagnosis and Prognosis

Pınar Atukeren^{1,2,*}

¹ Department of Medical Biochemistry, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, Turkey

² Faculty of Pharmacy, Istanbul University-Cerrahpaşa, Istanbul, Turkey

Abstract: Oxidative stress describes the state of a cell where there is an imbalance between free radical formation and antioxidants due to either excess formation of reactive oxygen species (ROS) or inadequate antioxidant defence. It is very well known that oxidative stress plays an important role in the pathophysiology of various diseases through impaired intracellular redox homeostasis. To evaluate and imply the excess production of ROS, various biomarkers are used and suggested, yet it is also known that there is a lack of standardization and validation for these methods. It is almost very difficult to measure ROS directly because of their short half-life, yet it is still possible with a suitable technique. The most frequently used biomarkers are represented by oxidized macromolecules such as lipids, proteins, and nucleic acids, which are modified *via* ROS, and also the amounts or activities of antioxidant molecules and enzymes, respectively. There are also various genetic biomarkers measuring the susceptibility of modification due to oxidative stress. However, the preferred biomarker would be dependent on the aim of the study and the clinical relevance.

Keywords: Antioxidants, Oxidative biomarkers, Oxidative stress, Reactive oxygen species.

INTRODUCTION

Oxidative Stress

In normal cells, there is balanced redox homeostasis which is regulated by free radicals' production and the antioxidant defense systems [1]. Reactive oxygen species (ROS), so-called free radical molecules, are produced not only during normal cellular metabolism but also there are various exogenous sources of ROS (Tables 1 and 2). In both experimental and clinical medicine, oxidative stress,

* **Corresponding author Pınar Atukeren:** Department of Medical Biochemistry, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa Istanbul, Turkey and Faculty of Pharmacy, Istanbul University-Cerrahpaşa, Istanbul, Turkey; Tel: +90 (532) 513 93 10; E-mail: p_atukeren@yahoo.com

which is mediated by ROS due to either an excess of ROS or a reduction in the amount of activity of antioxidant defense mechanisms, is important [2]. ROS are known to have a dual role as they might also have beneficial effects [3]. The intracellular redox imbalance is induced by oxidative stress, which triggers a number of factors such as cancer stimulation, increased metabolic activity, and mitochondrial dysfunction [4, 5]. The cell's redox status includes physiological and pathological effects related to the endogenous antioxidant status, which has a vital role in the prevention against oxidative stress due to the imbalanced defense mechanism of antioxidants, and the healthy living system will be exposed to serious damage [6].

Table 1. Reactive oxygen species.

O_2^- (Superoxide radical) H_2O_2 (Hydrogen peroxide) HO (Hydroxyl radical) $HOCl$ (Hypochlorous acid) Singlet O_2 $R\cdot$ (Alkyl radical) ROO (Peroxyl radical) $RCOO$ (Organic peroxyl radical) HO_2 (Peroxyl radical) RO (Alkoxy radical)
--

Table 2. Sources of reactive oxygen species.

Endogenous sources	Exogenous Sources
Mitochondrial electron transport chain	Radiation (UV lights, X-rays, Gamma-rays)
Autooxidation reactions	Chemotherapeutics, Chemicals, Drugs
Redox cycles	Environmental toxins
Cytochrome p450 reactions	Diet; Charcohalbroiled foods
Xanthine oxidase	Smoke
NADPH oxidase, Lipoxygenase, Prostaglandin synthase	
Inflammation; Oxidative reactions in phagocytic cells (Myeloperoxidase)	
Transition metals	

Indeed biological oxidation is the natural process of aerobic metabolism, but during this process, these destructive reactive molecules are produced constantly and express deleterious effects on human cells and damage [7].

Antioxidants

When the antioxidant system is unable to neutralise the overly generated ROS, oxidative stress develops as a result of the impaired redox balance [8]. There are many antioxidant defense systems in the human body to cope with the oxidative damaging effects of ROS [9]. The antioxidants might be either endogenous or exogenous too. They might be water or lipid-soluble due to their molecular structure. Some antioxidants are vitamins such as vitamin C and vitamin E; some antioxidants are enzymes such as catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx), and glutathione reductase (GR). SOD is the first defending enzyme dismutating O_2^- . Also, there are some endogenous metabolites having antioxidant activities (Table 3).

Table 3. Antioxidants.

Enzymatic Antioxidants	Superoxide dismutase (SOD) Catalase (CAT) Glutathione peroxidase (GPx) Glutathione reductase (GR) Glutathione-S-transferase Thioredoxine system (Trx/TrxR)
Non-enzymatic Antioxidants	Glutathione (GSH), Ubiquinone, Selenium Vitamin A, Vitamin C, Vitamin E, α -Lipoic acid, Flavonoids Albumin, Haptoglobin, Ceruloplasmin, Lactoferrin Uric acid, Bilirubin, Melatonin

Cells have various antioxidant mechanisms that balance the concentrations of ROS. SOD, CAT and GPx are the most effective [10]. There are non-enzymatic antioxidants such as vitamin C, vitamin E, carotenoids and glutathione, thioredoxin, lipoic acid, which are thiol antioxidants [11]. Glutathione (GSH) is a key thiol-containing antioxidant that detoxifies intracellular H_2O_2 to H_2O and O_2 through GPx and recycles through (GR), which is critical for maintaining cellular redox equilibrium [12, 13].

Oxidative Stress Biomarkers

Oxidative stress status is evaluated by investigating the cell's oxidant and antioxidant status as various biomolecules will be damaged. Oxidative stress biomarkers are related to the status of the disease and the effects of antioxidant molecules. The frequently measured oxidative stress related biomarkers and their properties are shown in Table 4. These biomarkers can be measured in biological samples, mostly blood and tissue samples and also in other biological fluids such as urine and saliva.

Current Biomarkers for Endometrial Receptivity

Ozlem Erten^{1*}, Aysun Tekeli Taskomur² and Mustafa Albayrak³

¹ Department of Obstetrics and Gynecology, School of Medicine, Kutahya Health Sciences University, Kutahya, Turkey

² Department of Obstetrics and Gynecology, Faculty of Medicine, Amasya University, Amasya, Turkey

³ Department of Obstetrics and Gynecology, Sisli Florence Nightingale Hospital, Istanbul, Turkey

Abstract: Implantation and the continuation of pregnancy occur through a complicated and sophisticated dialogue, called “cross-talk,” which starts between the embryo and the endometrium in the early stages of oocyte maturation. This dialogue provides synchronization of the journey of the embryo to be implanted with the receptive endometrium. Understanding the activity and function of the hormones and factors involved in this dialogue will provide an understanding of endometrial receptivity, which plays a key role in implantation, and the determination of biomarkers specific for this period. As a result of the development of omics technology, it has become possible to identify biomarkers specific to endometrial receptivity by performing genomic, proteomic, and lipidomic analyses of these hormones and factors. The determination of these biomarkers, their optimization, and making them usable in the clinic will allow increased success in ART.

Keywords: Biomarkers, Endometrial receptivity, Genomic analysis, Implantation, Lipidomic analysis, Omics, Proteomic analysis.

INTRODUCTION

Endometrial Receptivity

A successful pregnancy is achieved only with successful implantation, with two important factors forming the basis of successful implantation. The first is to obtain a good-quality embryo, and our chance to obtain quality embryos has increased with the development of assisted reproduction techniques. The second is the receptive endometrium [1]. The allowance of the endometrium of implantation of the blastocyst. The receptive endometrium has a very important physiological role in implantation and also in the maintenance of pregnancy. However, the

* Corresponding author **Özlem Erten:** Department of Obstetrics and Gynecology, School of Medicine, Kutahya Health Sciences University, Kutahya, Turkey; Tel: +90 530 563 0015; E-mail: ozlem.erten@ksbu.edu.tr

endometrium is not always receptive through the luteal phase of the menstrual cycle, and its time is limited. This short period lasting about 4 days at most in the mid-secretory phase is called the implantation window, which usually corresponds to the 20th-24th day of the cycle [2, 3]. Other than this window, the endometrium is non-receptive. In order to achieve successful implantation, the journey of the embryo and the receptive period of the endometrium must be synchronized with each other [4, 5].

This happens through “cross-talk” between the embryo and the adhesive endometrium by means of endocrine, paracrine, and autocrine factors [6].

The mechanism for the non-receptive endometrium to become receptive is not fully understood. Studies have determined that endometrial receptivity occurs due to the development of changes such as adhesion, invasion, growth, differentiation, decidualization, and immunomodulation. The factors arising during these developing changes play an important role in the preparation process for implantation [7, 8].

Various studies have been conducted to determine these synthesized factors in order to better understand endometrial receptivity. These studies have been conducted with a wide range of endometrial sampling for the use of omics technology [6, 9].

Determining the activity and function of these factors in the dialogue between the embryo and the endometrium allows us to use these factors as endometrial receptivity biomarkers in the clinic. Considering that two-thirds of recurrent implantation failure (RIF, *i.e.*, failure of three IVF cycles in which one or two high-quality embryos are transferred to the patient per cycle) is due to endometrial receptivity; it is very important to determine potential biomarkers and evaluate their significance in order to provide utility in the clinic and increase the success of implantation [1, 10].

Markers Brought by New Technology

The complete sequencing of the human genome has opened a new era of system biology, called omics technologies. The term omics is expressed as a comprehensive analysis of biological systems. The omics technologies driving these new fields of research include DNA and protein microarrays, mass spectrometry, and many other tools that enable high throughput analysis. Due to these developments, it is possible to examine the genome, transcriptome, proteome, and metabolome of cells, tissues, and organisms and to investigate the interactions between them [11, 12].

The histology of the endometrium has been studied since the 1950s to evaluate the developmental cycle and receptivity of the endometrium [9]. When the endometrial surface was examined with electron microscopy, it was determined that new projections were formed on the endometrial surface where the embryo first came into contact. Pinopodes, which were first defined by Psychoyos, were determined by Niklas in a certain period of the cycle, namely in the implantation window, and were named as endometrial receptivity markers [13, 14]. The development of omics technology, genomic, proteomic, and lipidomic studies have enabled the search for new biomarkers that can evaluate endometrial receptivity and provide utility in the clinic. Diagnostic markers of the implantation stage can be found by examining the microarray of many genes expressed in the endometrium at the stages of the menstruation cycle. Many proteins related to reproduction can be discovered by proteomic analysis. Thus, the detection of biomarkers specific to the receptive and non-receptive period of the endometrium could be identified [15].

Genomic Study of the Endometrium

In recent years, many transcriptomic studies in which important information has been obtained in determining the receptive endometrium have been conducted. These studies have found 107-2878 genes that are expressed differently in the endometrium by up and down-regulation during the transformation of the endometrium from the pre-receptive (LH+1/5) period to the receptive period (LH+7/9) [5, 16, 17]. However, the results have not shown a correlation with each other due to the different microarrays used for the analysis and the different sampling methods and conditions in these studies. For this reason, a common consensus could not be reached in the transcript studies. Another issue that causes confusion in these studies is whether the evaluation of the endometrium should be based on the natural cycle of fertile women or the cycle of infertile women. The studies conducted to solve this problem are classified into three groups: 1) the comparison of fertile women with the cycles of infertile women, 2) studies on the natural cycles of fertile women [16, 18 - 20] or fertile donors [21,22], and 3) the comparison of natural cycles with stimulated cycles [21]. Having such a classification in studies will facilitate the determination of biomarkers of the non-receptive endometrial period (proliferative or early secretory) and the receptive endometrium (mid-secretory), and will enable the determination of common biomarkers from the results of the studies on the cycles, increasing the specificity of the biomarkers.

In 2011, Diaz-Gimeno *et al.* identified 238 genes with expression specific to early and mid-secretory phases, 134 of which carry transcriptomic signatures of the

Biomarkers for Preterm Delivery

Ismail BIYIK^{1,*} and Mustafa ALBAYRAK²

¹ Department of Obstetrics and Gynecology, Kutahya Health Sciences University, Kutahya, Turkey

² Department of Gynecologic Oncology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

Abstract: Preterm birth occurring before the thirty-seventh gestational week complicates 4.5%-18% of pregnancies worldwide. The pathogenesis of spontaneous preterm delivery is not fully understood. Among the factors held to be responsible for its pathogenesis, the most emphasized is the inflammatory process. Studies in terms of the prediction of preterm delivery are basically divided into 3 categories: 1) Prediction in pregnant women who are asymptomatic and without risk factors, 2) Prediction in pregnant women who are asymptomatic and have risk factors, 3) Prediction in symptomatic pregnant women who have threatened preterm labour. In this chapter, the topic of biomarkers in relation to preterm delivery is discussed. The most commonly used markers in published studies are fetal fibronectin, cervical pIGFBP-1 and cervical length measurement by transvaginal ultrasound. For prediction in symptomatic pregnant women applying to the hospital with threatened preterm labour, the markers used are fetal fibronectin, insulin-like growth factors (IGFs) and inflammatory markers. Preterm labour prediction with markers checked in the first and second trimesters are fetal fibronectin, insulin-like growth factors (IGFs), micro RNAs, progesterone, circulating microparticles (CMPs), inflammatory markers, matrix metalloproteinases, aneuploidy syndrome screening test parameters and other hormones.

Keywords: Aneuploidy syndrome screening test parameters, Circulating microparticles, Corticotropin-releasing factor, Corticotropin-releasing hormone, C-reactive protein, Fetal fibronectin, Hsa-let-7a-5p, Hsa-miR-15b-5p, Hsa-mi-19b-3p, Hsa-miR-23a-3p, Hsa-miR-93-5p, Hsa-miR-150-5p, Hsa-miR-185-5p, Hsa-miR-191-5p, Hsa-miR-374a-5p, IGFs, IGFBPs, Inflammatory markers, Insulin-like growth factor-binding protein 4, Interleukin 6, Lipopolysaccharide-binding protein, Macrophage inflammatory protein, Matrix metalloproteinases, MicroRNAs, PAPP-A, Placental alpha microglobulin-1, Prediction, Preterm birth, Preterm delivery, Toll-like receptors.

* **Corresponding author Ismail BIYIK:** Department of Obstetrics and Gynecology, Kutahya Health Sciences University, Kutahya, Turkey; Tel: +90 (532) 786 70 31; E-mail: dribiyik@hotmail.com

INTRODUCTION

Preterm Delivery

Preterm birth occurring before the thirty-seventh gestational week complicates 4.5%-18% of pregnancies worldwide [1 - 3]. Preterm birth can occur in three ways: 1) Spontaneous preterm delivery without preterm premature rupture of membranes, 2) preterm delivery after preterm premature rupture of membranes, 3) Preterm labour induced by maternal or fetal indications. This chapter aims to cover spontaneous preterm labour without preterm premature rupture of membranes. Preterm delivery occurs as a result of 40-50% spontaneous preterm labour, 25-30% after preterm prelabour membrane rupture and 30-35% medical or obstetric reasons [4]. Spontaneous preterm delivery is one of the most important causes of neonatal mortality and morbidity [5].

The pathogenesis of spontaneous preterm delivery is not fully understood. Among the factors held to be responsible for its pathogenesis, the most emphasized is the inflammatory process [6 - 8]. Spontaneous preterm delivery occurs as a result of the onset of labour after pathological signal transmission [8]. The onset of labour begins and progresses with similar mechanisms in both term and preterm pregnant women. All mechanisms cause cervical maturation and initiation of uterine contractions [9]. Cervical maturation is associated with an increase in prostaglandins, chemokines and cytokines, and infiltration of inflammatory cells and increased matrix metalloproteinase activity [10]. Spontaneous delivery occurs from proinflammatory cytokines in the myometrium, amniotic membranes and cervix, and through increased uterine contractility and cervical dilatation due to the increase in prostaglandins [11].

The onset of uterine contractions before the 37th gestational week is called threatened preterm labour (TPL). 9% -24% of pregnant women are hospitalized due to TPL [12 - 15]. However, spontaneous preterm delivery occurs in approximately 50% of pregnant women with complaints related to TPL [15].

Prediction of which women in preterm labour will have a preterm delivery would enable us to apply tocolysis and antenatal steroids to the right patients. Also, this would make it possible for us to refer the mother to a tertiary maternity centre, for the mother to give birth and the baby to be born under safer conditions [16]. In addition, pre-determination of women who will have preterm delivery, and referral of risky pregnancies to perinatal centres and corticosteroid therapy may be possible [17]. There are still no markers with high sensitivity and specificity that can be used for this purpose [18 - 20]. Women who had a preterm birth in their previous pregnancy are in the high-risk group in terms of preterm delivery in their next pregnancy. However, most women with preterm birth do not have a history

of preterm birth [21]. Therefore, there is a need for markers to predict preterm birth, except for those with a history of preterm birth.

Studies in terms of the prediction of preterm delivery are basically divided into 3 categories: 1) Prediction for pregnant women who are asymptomatic and without risk factors, 2) Prediction for pregnant women who are asymptomatic and have risk factors, 3) Prediction for symptomatic pregnant women who have threatened preterm labour. These 3 categories will be examined under separate subheadings.

Prediction in Symptomatic Pregnant Women Applying to the Hospital with Threatened Preterm Labour

The most commonly used markers in published studies are fetal fibronectin, cervical pIGFBP-1 and cervical length measurement by transvaginal ultrasound [22].

a). Fetal Fibronectin

Fetal fibronectin (FFN) is found in maternal choroidal tissues, and with the inflammatory process, it is separated from the tissues and mixed with cervicovaginal tissue [23]. The quantitative fetal fibronectin (qFFN) measured in the cervicovaginal fluids of pregnant women who went to the hospital due to preterm labour had a high negative predictive value in predicting preterm labour, but its positive predictive value was lower [24 - 26]. Iams *et al.* reported that fetal fibronectin (in cervicovaginal fluid) may be useful in determining the birth that will develop within 7 days for those who go to the hospital with threatened preterm labour [27]. In their large series prospective study, Esplin *et al.* reported that quantitative vaginal fetal fibronectin and serial transvaginal ultrasound cervical length measurement have low predictive value in predicting spontaneous preterm birth in patients with a nulliparous singleton pregnancy, and therefore cannot be recommended for routine use [28]. In the conducted studies, the sensitivity and positive predictive value of cervicovaginal fetal fibronectin measurement in predicting preterm labour were found to be low [29 - 32].

b). IGFBPs

Insulin-like growth factors (IGFs) play a role in fetal and placental development [33]. In circulation, IGFs bind to IGFBP-3. The clearance of IGFs slows down through this binding [34]. Eroglu *et al.* were able to predict preterm deliveries before 35 weeks of gestation by examining insulin-like growth factor binding protein-1 (pIGFBP-1) in cervicovaginal secretions in 90 pregnant women going

Biomarkers in Obesity and Clinical Applications to Surgical Practice: From Pharmacogenomics to Surgigenomics

Halit Eren Taskin^{1,*}

¹ Department of General Surgery, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey

Abstract: Personalized medicine is an evolving field and helps in detecting putative targets for pharmacological treatment modalities in obesity treatment. Obesity has become a pandemic and major threat, increasing all causes of mortality and bringing a heavy cost burden on health budgets. Although bariatric/metabolic surgery justified its role as the most effective treatment regimen for obesity and related comorbidities in the long-term, some patients require revisional operations, do not respond to this treatment option, or experience a relapse of their co-morbidities. For this reason, detection of possible non-responders and prediction of patients at high risk for developing cardiovascular or metabolic adverse events in long-term follow-up is of utmost importance. Therefore, the individualization of surgical treatment by the use of novel biomarkers has come into prominence recently. Many biomarkers and gene loci had been identified related to adiposity, insulin resistance, and oxidative stress. In this brief chapter, the recent advances and clinical implications of these biomarkers will be elaborated.

Keywords: Bariatric surgery, Biomarkers, Obesity, Oxidative stress, Inflammation, Personalized medicine, Proteomics.

INTRODUCTION

Obesity has become a global health challenge, affecting almost 27.5% of adults and 47.1% of children worldwide [1]. Obesity increases the development of many chronic diseases such as Type II diabetes (T2DM), hypertension, coronary heart disease, and certain types of cancer, decreasing the quality and life span of an individual. Moreover, obesity has shown to be a multifactorial, heritable disease for which no gold-standard treatment or preventive strategy has been developed [2]. World Health Organization defined obesity as an abnormal or excessive

* Corresponding author Halit Eren Taskin: Department of General Surgery, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey; Tel: +90 (505) 669 39 05; E-mail: eren.taskin@istanbul.edu.tr

accumulation of fat that impairs the health status of an individual. Diagnosis of obesity has shown variation methodology, and certain indexes, most commonly body mass index and anthropometric measurements, are currently being used as simple methods for the classification of obesity [3].

Bariatric surgery proved its role to be the most effective treatment modality for the long-term management of overweight, obesity, and related comorbidities. Currently, a variety of operations have been approved by international organizations for the treatment of obesity and metabolic disorders; however, there have been no classification criteria developed on which operation should be used for specific patients. It is unfortunate that even today, the decision-making process for the type of operation for the treatment of obese patients depends on the expertise of the surgeon and the patient's choice. It has been well known that certain types of operations yield better results in patients with T2DM and dyslipidemia. There are many comparative retrospectives and prospective studies in the literature regarding the potency and the long-term results of the bariatric procedures; however, randomized trials with concrete evidence are scarce. Also, hundreds of biomarkers have been defined in literature as a result of animal and human studies, but only a couple of these are used routinely in our daily practice.

Identification of predictors of diabetes remission and the markers that reveal the early start of serious complications such as endothelial injury and oxidative stress resulting from diabetes is immensely important for the decision of treatment strategy in metabolically ill patients. Currently, the ability to do whole genome sequencing allows us to detect major genetic polymorphisms that may leave the patients vulnerable to metabolic disorders. Also detecting putative genetic targets for pharmacological therapy in obese and diabetic patients may help the development of drugs that can show a similar mechanism of highly effective bariatric surgical procedures [4].

Genetic variations among patients treated with bariatric surgery might provide clues for differences in outcomes. Patients with single-gene mutations that lead to early-onset monogenic obesity were recently found to be more resistant to weight loss induced after sleeve gastrectomy. This fact might explain the presence of non-responders after revisional surgical procedures, that who cannot accomplish satisfactory weight loss. Thus, in this chapter, we tried to make a thorough evaluation of the biomarkers that can be used for the decision-making process for the treatment of obesity and co-morbidities [5].

Importance of Personalized Medicine

Up-to-date evidence implies that patients may show variable responses to medical and surgical treatment of obesity and metabolic disorders. Yet every patient has a

unique pharmacogenetic profile. This genetic variability determines the outcomes of both primary and revisional bariatric surgical procedures. It has been evident that pharmacotherapy alone cannot accomplish optimal results compared to surgery. However, it is known that even the most effective methods of bariatric surgical practice may fail in the long-term resulting in weight recidivism and relapse of co-morbid disorders. This is why detecting genetic mutations that may lead to this failure before the operation may help decide on the best procedure tailored for the individual patient [6, 7].

Personalized health risk assessment and a greater understanding of the specific obesity and co-morbid conditions of an individual may help providers to make more rational and specific medical decisions and may prescribe personalized interventions that will best prevent obesity and associated diseases, delay their onset, or reduce their negative impact on the individual. This fact also is amenable to surgical decision-making strategy. This is why we created the word *surgigenomics* which means the use of the genetic makeup of an individual to decide on the optimal surgical treatment method for the optimal care of an illness. Also, studying biomarkers in obesity and bariatric surgical practice may increase the number of drugs that can be used for obesity treatment. The best example of this fact is the novel use of liraglutide, which is a synthetic form of glucagon-like peptide-1 (GLP-1). Thus, both the gastric bypass procedure and the use of liraglutide reduce gastric emptying, increase satiety, and decrease food intake. In long-term follow-up, patients with weight regain on this medication showed promising results; personalized medicine can predict patients who might respond to surgery and/or medical treatment modalities and thus provide cost-effective strategies [8].

The Impact of Genes on Obesity Treatment

The impact of genes on obesity is complex, and since obesity is a multifactorial disease, the predictive ability to genotype in bariatric surgery can only be of value with clinical correlation with outcomes. Swedish Obese Subjects study (SOS) is the most prominent non-randomized, prospective trial studying intentional weight reduction in severely obese health effects. As a continuation of this study on patients in the surgical intervention group during 6 years of follow-up with full genomic and bodyweight data, single nucleotide polymorphisms (SNAP) has been studied on 11 obesity candidate genes. Twelve SNPs in the ADIPOQ, FTO, LEP, LEPR, MC4R, PPARGC1A, and TNF gene loci were found to be nominally associated with maximum weight loss after bariatric surgery. However, the correctional analysis showed that only the FTO SNP rs16945088 remained statistically associated with maximum weight loss. Although more than 20 culprit genes are associated with obesity, less than 5% of obese subjects carry these

Clinical Application of New Possible Biomarkers in the Assessment and Monitoring of Nutritional Status

Burcu Yesilkaya^{1,*}

¹ Departments of Nutrition and Dietetics, İstanbul Okan University, İstanbul, Turkey

Abstract: Nutrition is directly related to human health. It is very critical to determine the nutritional status to prevent or diagnose diseases and create the right treatment plans. The determination of the nutritional status provides an early diagnosis of growth and development retardation such as malnutrition. It also plays a major role in preventing diseases that may be caused by vitamin and mineral deficiencies. It helps in the surveillance of one of the world's most serious health problems, namely "obesity." Different ways can be used to assess nutritional status. One of the best ways to assess the nutritional and health status is to use biomarkers. A biomarker is a substance whose detection indicates a specific disease state or a response to a therapeutic intervention. Biomarkers are used to detect nutrient consumption and deficiencies as early as possible, enabling early intervention for metabolic problems. Biomarkers also allow the visualization of diseases that a person might develop or potentially have with a sample, such as blood, tissue, and urine, from the person. Health interventions such as nutritional advice will preserve health or promote rapid recovery. In this chapter, the topic of biomarkers related to nutrition and nutrient deficiencies is discussed. The existence of new possible biomarkers is also reviewed.

Keywords: Biomarker, Dietary biomarkers, Food Exposure Markers, Macronutrient, Metabolomics, Micronutrient, Nutrient, Nutrigenomics, Nutrition, Nutritional Assessment, Omics technologies.

INTRODUCTION

Nutrition and Health

According to World Health Organization (WHO), health is a state of complete physical, mental, and social well-being [1]. In a healthy life, nutrition is an important key factor. Nutrition is also a part of healthy growth and development.

* Corresponding author Burcu Yesilkaya: Departments of Nutrition and Dietetics, İstanbul Okan University, İstanbul, Turkey; E-mail: Tel: +90(543)5278676; burcuyavunc@hotmail.com

The body, as a living organism, needs nutrients to perform mental and physical activities [2].

Nutrition is a compulsory human behavior for survival. Food consumption and hormonal control mechanisms such as hunger and satiety involve many physiological processes. However, this needs to be a conscious behavior to protect and improve one's health and the quality of life. Healthy nutrition is defined as adequate and balanced nutrient consumption, with macronutrients and micronutrients consumed according to personal requirements. These recommended amounts can change according to age, gender, preferences, and physical activity status [3, 4].

Nutrients provide the required "energy" to the body. This energy comes from carbohydrates, proteins, and fats, which are called macronutrients. Micronutrients such as vitamins and minerals do not provide energy but play major roles in the processes of energy metabolism. These include chemical reactions that maintain tissues, electrical conduction of nerves, mechanical workings of muscles, and heat generation to keep body temperature stable [5]. Healthy nutrition is also based on a variety of nutrients. Daily requirements of energy and nutrients are taken into the body with foods. Foods are divided into five groups according to the similarity of nutrients they contain. These are vegetables, fruits, grains, proteins, and dairy products that need to be consumed daily [3].

The nutritional status is stable when a person's nutrient intake meets the requirements. Determination of the nutritional status may prevent diseases and promote health. Most chronic diseases show up due to poor nutrition. Assessing the nutritional status will help determine the lack of nutrients. Early diagnosis of diseases also prevents severe deficiencies and functional disorders. As an intervention program, nutritional support and counseling help improve insufficient nutrition and poor nutritional status [6]. A sufficient and balanced diet, including macronutrients and micronutrients, is beneficial for complete health and, ultimately, the quality of life, especially for patients with chronic diseases/wounds [7].

Malnutrition, such as undernutrition, overnutrition, or particular nutrient deficiencies, are identified during the nutritional assessment. These problems are usually caused by poor or overnutrition. Lack of essential nutrients causes various diseases. Malnutrition problems such as obesity, malnourishment, or diseases caused by nutrient deficiencies are examples of an unhealthy nutritional status [8].

Assessment of Nutritional Status and Methods

The nutritional statuses of people are evaluated by dietitians who are nutrition

experts. However, it requires a multidisciplinary screening to determine the nutritional status. As a result of the evaluation, the requirements and deficiencies are seen, and the possible risks are revealed [9].

The nutrition care process has 4 steps: 1) assessment of nutritional status, 2) identifying the nutritional diagnosis, 3. interventions such as education, supports, counseling, *etc.* 4. monitoring and evaluation of the effectiveness of the interventions [6]. To determine the nutritional status, many methods may be used. Dietary indicators, anthropometric indicators, laboratory indicators, and clinical indicators help to define health problems.

The most harmful nutritional status is malnutrition. It refers to deficiencies, excesses, or imbalances in energy and/or nutrient intake. Early diagnosis of malnutrition can both prevent the long-term treatment of the person and contribute greatly to the national economy. Nutritional assessment methods (such as anthropometric measurements) can easily identify malnutrition. The early detection of malnutrition can save the infant's life [10, 11].

In addition to continuous and regular follow-up, a good nutrition plan is required in the treatment plan. This plan must be constantly evaluated and its usefulness measured. Generally, the ABCD nutrition assessment method is used. It includes *anthropometric* (A) indices based on body measurements, *biochemical* indicators (B), an examination of *clinical* status (C), and *dietary* assessment (D) [12, 13].

Anthropometric

Anthropometry investigates the measurements of the human body. Anthropometric measurements include measurement methods used to evaluate body components such as bone, muscle, and fat tissue [14, 15]. Anthropometry has an important role in the nutritional evaluation and is used in general nutritional screening, surveillance, and follow-up, as well as clinical use. A single measure may not provide a comprehensive overview of the patients' condition and the other measurements combinations are required for certain assessments [16, 17].

Anthropometric measurement components vary according to the age, gender, ethnicity, status (pregnancy, athletes, *etc.*) of individuals. The basic elements of anthropometry are height (length for newborns), weight, body circumferences (waist, hip, and limbs), and skinfold thickness. The cut-off points and the classifications of these measurements depend on the person's status [15, 18].

Body mass index (BMI), a person's weight (in kilograms) divided by the square of his/her height (in meters). It is kg/m^2 . WHO classification for BMI is generally

A Physiological Approach to Inflammatory Markers in Obesity

Sila H. Bozdogan Polat^{1,*} and Nuran Dariyerli¹

¹ Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey

Abstract: Obesity is one of the most critical health problems all over the world; it is associated with metabolic dysfunction and overnutrition. Changes in the physiological function of adipose tissue, leading to altered secretion of adipocytokines, inflammatory mediators release, and chronic low-grade inflammation, are seen in obesity. Macrophages, neutrophils, CD4+ and CD8+ T cells, B cells, natural killer T (NKT) cells, eosinophils, mast cells, and adipocytes are involved in the inflammatory response that occurs during obesity. Various inflammatory markers are released from these cells. In this chapter, we will mention inflammatory mechanisms and markers of obesity.

Keywords: Adipocytes, Adiponectin, Apelin, Cardiotrophin-1, Ceramide, CfDNA, Fetuin-A, Galectin-3, GlycA, HIF-1 α , Interleukin-1, Interleukin-6, Leptin, MCP-1, Omentin, TNF- α , TWEAK, Vaspin.

INTRODUCTION

Obesity is abnormal or excessive fat accumulation. As a result of the excess of macronutrients in adipose tissues, inflammatory mediators such as leptin, interleukin (IL-6), tumor necrosis factor- α (TNF- α), monocyte chemoattractant protein-1 (MCP-1), resistin are released, and adiponectin production is reduced. In this way, a state sensitive to the inflammatory process occurs [1]. It is unclarified how obesity-induced inflammation in adipose tissue (AT) is triggered. However, potential mechanisms include dysregulation of fatty acids homeostasis, increased adipose cell size and death, local hypoxia, mitochondrial dysfunction, ER stress, and mechanical stress [2]. These are thought to link chronic caloric excess and AT inflammation or factors that may perpetuate chronic tissue inflammation (Fig. 1) [3].

* Corresponding author Sila H. Bozdogan Polat: Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey; Tel: +90 (534) 844 83 94; E-mail: sila.polat@istanbul.edu.tr

Numerous immune cell types are involved in the inflammatory response during obesity. These are macrophages, neutrophils, CD4⁺ and CD8⁺ T cells, B cells, natural killer T (NKT) cells, eosinophils, and mast cells. They can regulate inflammation either positively or negatively [4].




Fig. (1). Pathogenesis of obesity.

Macrophages

Tissue macrophage populations comprise a heterogeneous group of cells, and they have a variety of phenotypes and functions. Mantovani *et al.* defined polarized macrophages in two classes; M1 and M2. M1 macrophages (integrin CD11c⁺), are proinflammatory, whereas M2 macrophages, which do not express CD11c, are anti-inflammatory [5]. In the obese WAT (white adipose tissue), proinflammatory M1 macrophages form crown-like structures around dead adipocytes, contributing to the obesity-induced, low-grade inflammation. The elevated M1 macrophages in the obese WAT are the main sources of TNF α and IL-6 [6].

Neutrophils

Within a week of starting a high-fat diet (HFD), an increase in neutrophil uptake into adipose tissue occurs, suggesting that neutrophils may play a role in initiating the inflammatory cascade in response to excess nutrients and energy [7].

B Cells

Shortly after initiating an HFD, B cells accumulate in adipose tissues [8]. In addition, the transfer of IgG antibodies from obese WT mice to B cell-deficient mice enhances TNF α production and proinflammatory macrophage polarization [9].

CD8⁺T Cells

CD8⁺ T cells are recruited to obese adipose tissue, which begins within two weeks of HFD feeding [10]. Obesity is associated with an increase in the number of CD8⁺ T cells in AT, and these cells promote macrophage differentiation and chemotaxis [11].

CD4⁺ T Cells: T-Helper and T-regulatory Cell Subsets

CD4⁺ T cells can be separated into distinct subsets with diverse phenotypes and functions referred to as T-helper (Th1, Th2, and Th17) cells and T-regulatory (Treg) cells, and each of these subsets is present in AT [12].

Treg and Th2 cells predominate in lean AT, where they prevent the onset of inflammation [13].

Natural Killer T Cells

NKT cells are primarily responsible for target cell killing and cytotoxic activity, but they are also a source of pro-inflammatory cytokines and chemokines. They are present in significant proportions in lean WAT and the liver, although their numbers are depleted after the onset of obesity [14, 15].

Eosinophils

Eosinophils accumulate in adipose tissue by an integrin-dependent process. This promotes M2 macrophage polarization by the secretion of IL-4- or IL-13 [16].

Mast Cells

Mast cells are mainly associated with allergic response [17]. Increased numbers of mast cells are found in obese adipose tissues of mice and humans compared with their lean counterparts, and this is accompanied by increased circulating levels of the mast cell protease tryptase. Genetic depletion of mast cells or pharmacologic inhibition of mast cell function reduces body weight gain, reduces the levels of inflammatory cytokines, chemokines, and proteases in serum and adipose tissue, increases energy expenditure, and improves glucose homeostasis [18].

Application of Biomarkers in the Diagnostic Distinction of Bacterial and Viral Infections

Fatma Köksal Çakırlar^{1,*}

¹ Department of Medical Microbiology, Faculty of Cerrahpaşa Medicine, University of İstanbul-Cerrahpaşa, İstanbul, Turkey

Abstract: Infectious diseases, which pose a great threat worldwide, have a significant impact on public health and the world economy. It contributes to increased healthcare costs, unnecessary drug-related side effects, and increased antimicrobial resistance. It is not always easy to distinguish the etiological differentiation of diseases that can develop with bacteria and viruses. Therefore, one of the biggest challenges in medicine is how to correctly distinguish between the different causes of these infections and how to manage the patient. Because bacterial and viral infections often present similar symptoms. The real decision is whether the infection is caused by bacteria or viruses and whether to treat the patient with antibiotics. There are many different methodological approaches to diagnosing infections. Biomarkers have been used in the diagnosis of diseases and other conditions for many years. Biomarkers are molecules found in blood and body fluids in measurable amounts, which can evaluate biological and pathological processes. These key indicators can provide vital information in determining disease prognosis, predicting response to treatments, adverse events and drug interactions, and identifying key risks. An effective biomarker is extremely important for the early diagnosis of various diseases. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic, and prognostic products in modern medical practice. The purpose of this review is to demonstrate the use and diagnostic potential of current and investigational biomarkers in the distinction between bacterial and viral infections.

Keywords: Current and investigational biomarkers, Bacterial and viral infections.

INTRODUCTION

Infectious diseases are defined as clinical diseases that occur as a result of many inflammatory reactions in the host when an infectious agent such as bacteria, virus, parasite, and fungus enters the body and multiplies. It can be transmitted directly or indirectly from person to person under appropriate conditions, causing epidemics and pandemics [1].

* Corresponding author Fatma Köksal Çakırlar: Department of Medical Microbiology, Faculty of Cerrahpaşa Medicine, University of İstanbul-Cerrahpaşa, İstanbul, Turkey; Tel: +90 (534) 844 83 94; E-mail: fatma.koksal@istanbul.edu.tr

The most of emergency infections are caused by pathogens that are already present in the environment or that gain a selective advantage as conditions change, allowing them to infect new host populations. In rare cases, a new variant may also develop and cause a new disease. Emergency infections are a concern, especially when they are spreading rapidly and death rates are high. Previously unidentified or unknown pathogens may be agents that affect new geographic regions or new populations or re-emergent agents with significantly reduced disease incidence in the past. The world is still struggling with various infectious diseases such as malaria, H1N1, Ebola, dengue Fever, Chagas disease, yellow fever, West Nile, Japanese encephalitis, and chikungunya [1].

Gram-negative bacteria caused by newly evolved organisms such as multidrug-resistant tuberculosis and plasmid-mediated colistin-resistant, newly emerging organisms in the human population, HIV-1 infection, respiratory syndrome (SARS) coronavirus in 2003 and MERS-CoV (Middle East respiratory disease) The current coronavirus disease-2019 (COVID-19) pandemic caused by the eastern respiratory syndrome caused by the syndrome coronavirus, and the new coronavirus SARS-CoV-2, which affects the whole world, is challenging the world [2]. Globally, as of October 17, 2020, the COVID-19 outbreak has spread to more than 200 countries and 39,023,292 confirmed cases of COVID-19, including 1,099,586 deaths, have been reported by WHO [3].

With the ongoing evolution of viral and microbial variants and the choice of drug resistance, it appears that new infections will continue to emerge, possibly increase, and will make human beings very challenging. Infectious diseases contribute to increased healthcare costs, unnecessary drug-related side effects, and increased antimicrobial resistance. These diseases have a significant impact on public health and the world economy. In cases where the focus of infection cannot be effectively eliminated or treated appropriately, sepsis, septic shock, and multi-organ failure may develop. In the presence of infection in any part of the body, the immune system begins to react and sepsis occurs due to the body's exaggerated response to this infection. If early treatment is not initiated, organ failure, shock, and death are inevitable. It is not always easy to distinguish the etiological differentiation of diseases that can develop with both bacteria and viruses. Bacterial and viral infections usually present with similar symptoms. In most cases, the decision is whether the infection is caused by bacteria or viruses and whether to treat the patient with antibiotics. This is primarily a challenge for clinicians and healthcare administrators. In addition, correct separation is important in reducing unnecessary antibiotic use [4].

There are many different methodological approaches to diagnosing infections. It

is based on patient symptoms, laboratory tests, radiological examinations as well as clinical findings. These procedures take a long time and are limited. Therefore, additional tools are needed to increase diagnostic accuracy. Biomarkers have been used for many years in the diagnosis of diseases and other conditions. Biomarkers are structures found in the blood or other body fluids, with little or no normal state, that appear or increase in the disease state. Protein metabolites are often used as biomarkers. Nucleic acids and various analytical targets are also used as biomarkers. A better understanding of disease mechanisms is required to fully utilize biomarkers. Bacteria and viruses activate or block different signaling pathways in the cells they infect. Because biomarkers are molecules that can evaluate biological and pathological processes and can be found in measurable amounts in blood and body fluids, they are considered physical, functional or biochemical markers of disease processes. Biomarkers used in the diagnosis of sepsis may play a role in early diagnosis, risk stratification, evaluation, and prognosis prediction. These key indicators can provide vital information in determining disease prognosis, predicting response to treatments, adverse events and drug interactions, and identifying key risks. An effective biomarker is extremely important for the early diagnosis of various diseases [5]. However, the problem with existing biomarkers; It gives late results, low specificity, complicate clinical decisions, and interact with corticosteroid and immunosuppressive treatments. For this reason, new biomarkers are needed to make early and etiological diagnosis, decide on early, correct and adequate treatment, determine the severity of the infection, and evaluate the response to treatment. The explosion of interest in biomarker research will enable the development of new predictive, diagnostic, and prognostic products in modern medical practice. This could advance the use of personalized medicine in the treatment of infectious disease and will also raise important considerations for validating the use of biomarkers as diagnostic or prognostic markers. Many different classes of molecules have been studied in the search for new diagnostic biomarkers to overcome the problems in currently used methods that could help distinguish between bacterial and viral infections. The purpose of this review is to demonstrate the use and diagnostic potential of current and investigational biomarkers in the distinction between bacterial and viral infections.

STANDARD BIOMARKERS

White Blood Cell Counts

White blood cell counts, especially differences in white blood cell counts or neutrophil counts in the blood, are the most commonly used tests to diagnose acute infections. Counting can easily be done manually under the microscope or with automatic cell counters. However, at least 400 cells must be counted for

SUBJECT INDEX

A

- Abdominal diseases 407
acute 407
Abemaciclib 351, 352
Abnormalities 155, 156, 157, 159, 161, 169,
172, 174, 175, 472
erythrocyte 472
genetic 157, 169
mutational 175
Abnormal 175, 617, 632
karyotype 175
lipid processing 632
thyroid function 617
Absorption 312, 314, 342, 348, 413, 415
intestinal 348
Absorptive cells, intestinal 616
Acanthocytosis 472
Accumulation, reactive astrocyte 254
Acetaminophen 501
Acetylation 96, 347, 370
reaction 370
Acetyl-d-galactosamine 285
Acetyltransferase 299
Achlorhydria 227
Acid(s) 155, 293, 318, 324, 326, 330, 338,
347, 442, 446, 465, 497, 501, 557, 558,
559, 607, 641, 662
anoic 446
bile 497
carboxylic 324
hydroxy fatty 641
hydroxy-stearic 641
lysis theory 293
modafinil 326
naphthyloxylactic 318
retinoic 155
ribosomal ribonucleotide 662
thiobarbituric 442, 558, 559
uric 557, 607
valproic 330, 338, 347, 501
vanillylmandelic 465
Acidity, intragastric 409
Acne vulgaris 366
ACTH-producing tumor 215
Actin 169, 239, 240
and myosin 239, 240, 241
tropomyosin, inhibiting 240
Activates macrophages 429
Activation 8, 102, 103, 176, 178, 185, 250,
251, 287, 289, 294, 298, 354, 427, 428,
469, 545, 588, 637, 638, 668
aberrant pathway 176
heterogeneous 545
integral 178
myometrial 588
neutrophil 668
phenotype 8
signal 354
Activator 169, 219, 382
protein 169
urokinase-type plasminogen 219
Active 99, 318, 368
benign gastric ulcer 368
DNA demethylation 99
duodenal ulcer 368
isomer 318
Active metabolite(s) 321, 322, 336, 337, 340,
341, 342, 352, 362, 363, 364, 365, 367,
368, 369
concentration 337, 363, 369
of abemaciclib 352
of fesoterodine 322
Activity 2, 3, 84, 98, 118, 122, 239, 248, 254,
279, 296, 280, 320, 326, 327, 338, 345,
347, 410, 411, 415, 427, 453, 470, 471,
494, 495, 502, 547, 555, 556, 557, 560,
565, 566, 569, 628, 631, 670
adenylate cyclase 297
antagonize protease 296
antiarrhythmic 320
antimicrobial 415
antioxidant 557, 560
antiviral 345

- aspartic-glutamic transaminase 494
- astrocyte 254
- chemotactic 427
- cytotoxic 2, 3, 628
- endocytotic 248
- endogenous RNAse 670
- immune cell 3
- inducing glucuronyltransferase 338
- inflammatory 547
- inhibiting osteoclastic 84
- inhibitory 239
- isoniazid 347
- lipoprotein lipase 631
- low DNase 118
- lymphocyte 2
- neutrophil 470
- nucleotidase 502
- tumour suppressor 122
- urease 410, 411
- Acute 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 166, 169, 416, 504, 522, 525, 658,
 - basophilic leukemia 152
 - inflammations 658
 - interstitial nephritis 522
 - ischemic injury in humans 525
 - kidney injury diagnosis 522
 - leukemias 151, 156, 158, 169
 - liver failure (ALF) 504
 - megakaryoblastic leukemia 152, 153
 - mesenteric ischemia 416
 - monoblastic leukemia 153
 - myeloid leukemia (AML) 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 166
- Acute myocardial 152, 153, 155, 238, 241, 242, 243, 386, 387, 470, 522, 528, 530
- infarction (AMI) 238, 241, 242, 243, 387
- Ischemia 243
- pancreatitis 470
- panmyelosis 152
- promyelocytic leukemia (APL) 152, 153, 155
- respiratory syndrome Coronavirus-2 386
- tubular injury (ATI) 522, 528, 530
- Addison disease 215
- Adenocarcinomas 4, 27, 113, 122, 134, 251, 501
 - castrate-resistant prostate 4
 - cervical 27
 - gastric 357
 - ovarian 251
 - prostatic 501
- Adenomas 223, 228, 251, 290
 - adrenal 215
 - pleomorphic 290
 - secreting parathormone 223
- Adenosine 297, 467, 669
 - deaminase 467, 669
- Adenosine triphosphate 241, 297
 - increased myosin 241
- Adipocyte lipolysis 631
- Adipocytes 243, 258, 626, 629, 635, 637, 641, 642
 - insulin-resistant 637
 - murine 629
- Adipocytokines 626, 629
- Adipogenesis 604, 635, 642
- Adipokine 638, 639, 641
- Adiponectin 25, 626, 629, 635, 636, 639, 640
- Adiponectin production 626
- Adipose tissue 619, 620, 626, 627, 628, 629, 630, 632, 633, 634, 635, 637, 639, 641, 642, 643
 - dysfunction 634
 - functions 635
- Adiposity 600, 634, 640
- Adnexal masses, malignant 27
- Adrenalectomy 228
- Adrenal tumors 215
- Adrenocorticotrophic hormone 79, 215
- Adrenokortikotropik hormone 225
- Advanced oxidised protein products (AOPP) 558, 559, 606, 607
- Adverse drug reactions 313, 314
- Adverse effects 310, 321, 324, 354
 - systemic 324
- Adverse events 9, 314, 319, 350, 351, 655, 657
 - drug-related 314

- immune-related 9
- immunotherapy-related 9
- Aeroallergens 453
- Agents 7, 104, 107, 156, 159, 163, 187, 188, 192, 321, 323, 326, 345, 346, 347, 352, 354, 355, 358, 361, 362, 370, 569, 655, 656, 658
- alkylating 107, 156, 159, 163
- anti-inflammatory 370
- antimuscarinic 321, 323, 326
- antiretroviral 346, 347
- antiviral 188, 346
- demethylating 104
- immune therapy 7
- immunotherapeutic 187
- infectious 655
- Aggregation 570, 632
 - robust rank 570
- Aggressive systemic mastocytosis (ASM) 357
- Agnogenic myeloid metaplasia 164
- Alanine transaminase 494
- Albumin 119, 188, 247, 440, 441, 442, 443, 447, 463, 490, 504, 507, 511, 512, 614
 - glycated 440, 441, 447, 463
 - glycation 442
 - synthesis 504
- Alcoholic cirrhosis 497
- Aldehyde dehydrogenase 568
- Alkylating agent therapy 107
- Allergens 382, 453, 456, 457
- Allergic 277, 452, 455, 456, 457, 472
 - disease pathogenesis 452
 - disorders 452
 - rhinitis 452, 455, 456, 472
 - sensitization 277, 457
- Alpha-fetoprotein (AFP) 23, 24, 56, 57, 58, 59, 106, 217, 238, 247, 248, 508, 509, 510, 589
 - increased second-trimester serum 589
- Alzheimer's disease 253, 255, 256, 341
- Amide hydrolysis 322, 346
- Amino acids 45, 84, 246, 247, 409, 411, 415, 441, 501
 - nonproteinic 411
- Aminoglycosides 532
- Aminotransferases 493, 494, 495, 497, 500
 - alanine 490, 493, 494, 503, 507
 - concomitant 503
- Aminotransferases elevations 498
- Amiodarone 315, 324
- Amniotic cavity 588
- AMP-activated protein kinase 638
- Amphetamine 316, 326
 - narcolepsy 316
- Amplification 63, 174, 190, 380
 - proto-oncogene 63
 - method 380
- Amyloid fibrils 471
- Amyloidosis 471, 499
 - systemic 471
- Analysis 114, 133, 139, 168, 224, 317, 379, 445, 455, 565, 567, 568, 570, 604
 - biochemical 224
 - biological material 379
 - chimerism 455
 - genome-wide associations 445
 - histopathological 114, 133
 - immunohistochemical 139
 - lipidomic 565, 568, 570
 - mass spectrophotometer 604
 - proteomic 168, 565, 567, 568
 - retrospective 317
 - transcriptomic 568
- Anaplastic 77, 79, 80, 81, 88, 179, 352, 354
 - lymphoma kinase (ALK) 179, 352, 354
 - thyroid cancers (ATC) 77, 79, 80, 81, 88
- Androgen receptor coregulator 103
- Anemia 52, 151, 214, 161, 163, 215, 441, 461, 468, 472, 474, 615, 617
 - aplastic 151
 - hemolytic 214
 - macrocyte 615
 - megaloblastic 617
 - microcyte 615
 - normochromic 461
 - normocyte 615
 - refractory 163
 - refractory macrocytic 161
- Aneuploidy 42
 - single chromosome 42

- Angiogenesis 103, 278, 282, 288, 289, 604, 664
- Angiogenic factors 138, 547, 551
- Angiography 547, 551
coronary 547
- Angioimmunoblastic T-cell lymphoma 179, 181, 183, 184, 185, 186
- Angiopoietins 662, 664
- Angiotensin 527
- Ankylosing spondylitis 470
- Anthropometry 613
- Antiarrhythmics 316, 324
- Antiasthmatics 309
- Antibiotic therapy 659
- Antibodies 3, 47, 52, 85, 215, 361, 410, 416, 417, 454, 457, 458, 459, 461, 465, 467
anticardiolipin 459
anticeratin 461
anti-cyclic citrullinated peptide 458
anti-EGFR 361
anti-endomysial 417
cytoplasmic 457, 467
heterophile 215
heterophilic 85
tissue transglutaminase 417
- Anti-chromatin 458
- Antichymotrypsin 296
- Anticyclic 215, 297, 461
citrullinated peptide antibodies 461
hormone 215, 297
- Anti-double helix DNA 458
- Anti-endomysial and tissue transglutaminase autoantibodies 416
- Anti-estrogens 218
- Antigen(s) 3, 4, 5, 18, 39, 101, 103, 105, 107, 113, 138, 139, 157, 169, 176, 214, 217, 222, 253, 454, 455, 457, 465, 637, 667
carcinoembryonic 222
carcinoembryonic 253
human leucocyte 5
microbial 637
mycobacterial 669
nuclear 139
presenting cells (APCs) 3, 4, 39, 101, 107, 113
receptor genes 176
tissue peptide 138
tumour-associated 18
- Anti-gliadin autoantibody (AGA) 417
- Anti-glutamic acid decarboxylase 462
- Antimicrobial therapy 667
- Anti-nuclear antibodies (ANA) 458, 461, 466
- Antioxidant(s) 555, 556, 557, 560, 561, 616
defense mechanisms 556
non-enzymatic 557
response 560
- Antiphospholipid antibodies 459
- Antiproteases 426
- Antiribonucleoprotein 458
- Antisense 287, 343
oligonucleotide 343
transfection 287
- Anti-thyroglobulin antibodies 83
- Anti-thyropoxidase 460
- Anti-TNF therapies 429
- Anti-viral treatment 509
- Apoptosis 40, 106, 118, 119, 121, 244, 245, 285, 287, 290, 294, 295, 526, 527, 629, 667, 670
and DNA repair-based markers 40
induced 287
inhibiting 244
inhibitors 295
regulating 106
resistance 285
triggered 245
- Apoptotic protease 285
- Applications 217, 606
gastric band 606
of tumor markers in hepatocellular carcinoma 217
of tumor markers in pancreatic adenocarcinoma 217
- Arrhythmic events 544, 545, 548
- Arrhythmogenic 545, 551
right ventricular cardiomyopathy (ARVC) 551
- Arthritis 389, 460, 461, 466, 472, 473
chronic 460
inflammatory 460

- septic 472, 473
 - Arthrobacter luteus 101
 - Asparaginase 171
 - Aspartate transaminase 239, 494
 - Aspartic-glutamic transaminase 494
 - Aspergillosis phenotype in asthma 456
 - Assays 41, 42, 43, 44, 83, 85, 105, 106, 107, 138, 156, 167, 242
 - biomarker panel 24
 - cell-based urine 44
 - genomic microarray 156
 - immunometric 83
 - protein-based 44
 - sandwich ELISA micro 138
 - Assay tumor aggressiveness 49
 - Assessment, histological 114
 - Asthma 455
 - etiopathogenesis 455
 - exacerbations 455
 - Astrocytes 253, 254, 255, 256, 258, 259
 - fibrous 254
 - protoplasmic 254
 - transform 254
 - Astrocytosis 254, 255
 - Atherosclerosis 387, 425, 471, 472, 544, 546, 547, 631, 635, 637
 - coronary 387, 544, 546
 - ATP-dependent 103, 278
 - RNA helicase activity 103
 - transmembrane efflux pump 278
 - ATP synthesis 244
 - Atrial natriuretic peptide (ANP) 245, 246
 - Atrophy 343, 390, 409, 410
 - gastric 409, 410
 - spinal muscular 343, 390
 - Autism-related irritability 330
 - Autoantibodies 9, 139, 416, 417, 459, 460, 461, 462
 - anti-endomysial 417
 - antifilaggrin 461
 - in Sjögren Syndrome 461
 - Autoimmune diseases 378, 388, 389, 451, 454, 457, 458, 460, 461, 472, 661, 662
 - chronic 460
 - multiple 457
 - systemic 460, 461
 - Autoimmune hepatitis 497
 - Autoimmunity 2, 278, 457
 - Autooxidation reactions 556
 - Autosomal recessive 467
- B**
- Bacteria 348, 370
 - intestinal 370
 - resistant 348
 - Bacterial infections 468, 472, 473, 658, 659, 661, 662, 664, 665, 667, 668, 669, 670
 - diagnosis of 659, 668
 - Bacterial 411, 470, 663
 - endocarditis 470
 - overgrowth, intestinal 411
 - pneumonia 663
 - Balance 102, 248, 291, 367, 557, 606, 607, 614
 - chromosomal 102
 - electrolyte 614
 - pro-oxidant antioxidant 606, 607
 - Barrett's esophagitis 409
 - Base excision repair (BER) 99, 100
 - Behçet's 467, 470
 - disease 467
 - syndrome 470
 - Bence Jones protein 188, 189
 - Bergmann's glia 254
 - Bilateral lymphadenectomy 81
 - Bile flow obstruction 498
 - Biliary obstructions 215, 216, 496
 - Bilirubin retention 497
 - Bioinformatics data banks 381
 - Biological Markers of Recovery 534
 - for the Kidney (BioMaRK) 534
 - Biological 2, 451
 - surrogates 451
 - therapy 2
 - Biomarker(s) 7, 5, 37, 38, 41, 47, 48, 50, 51, 106, 115, 117, 140, 150, 177, 178, 179, 190, 193, 241, 247, 186, 381, 412, 419,

- 430, 468, 493, 500, 523, 524, 526, 532, 555, 559, 606, 611, 618, 619
- assays 51
- complementary 7
- conventional 150
- cytotoxic 186
- dietary 611, 619
- fetal 247
- for Acute Myocardial Infarction 241
- for hepatocellular injury 493
- for Malignant Upper Gastrointestinal System Diseases 412
- for Prognosis and Immunotherapy 186
- genetic 178, 179, 430, 555
- genomic 150, 190, 419
- immunotherapy 5
- in kidney injury 523
- independent prognostic 177
- infection 468
- liver 500
- methylation-based 106
- non-invasive 117, 381
- novel blood 606
- nutritional 618
- of inflammation 524, 526
- oxidative DNA damage 559
- pharmacodynamics 140
- protein oxidation 559
- surrogate 140
- tissue-based 39, 48, 50, 115
- transcriptional 532
- transcriptomic 193
- urine-based 37, 38, 41, 47, 50
- vasodilator 658
- Biopsies 46, 48, 49, 115, 116, 217, 220, 227, 411, 426, 428, 467, 505
 - bronchial 426, 428
 - gastric 411
 - reducing unnecessary prostate 46
- Biopsy-based techniques 114
- Bladder cancer (BC) 37, 38, 39, 40, 41, 42, 44, 59, 61, 62, 107, 357, 358
 - muscle-invasive 38, 39, 62
 - non-muscle-invasive 61
- Bladder tumor antigen (BTA) 42, 43
- Blastocyst implantation 573
- Blood 254, 255, 256, 318, 379, 391, 614, 616, 668
 - brain barrier (BBB) 254, 255, 256
 - clotting 616
 - leukocyte 428
 - lipids 614
 - neutrophils 668
 - plasma 391
 - pressure 318, 379
 - proteins 614
 - urea nitrogen 614
- Body 188, 507, 511, 498, 601, 606, 607, 613, 614, 634, 639, 640, 642
 - mass index (BMI) 507, 511, 601, 606, 607, 613, 614, 634, 639, 640, 642
 - isoenzyme 498
 - lesions 188
- Bone 79, 218, 293, 295
 - metastases 218
 - morphogenetic proteins (BMPs) 295
 - resorption 79, 293
- Bone marrow 98, 139, 151, 155, 156, 157, 160, 164, 165, 176, 188, 192, 428
 - fibrosis 164
 - hypercellular 157
 - microenvironment 157
- Bone marrow biopsy 153, 189, 191
 - cellularity 153
- Bradycardia 318
- Brain 51, 103, 245, 246, 550, 551, 617
 - and lung cancer 103
 - iron deficiency 617
 - natriuretic peptide (BNP) 245, 246, 550, 551
 - tumors 51
- Breast 84, 85, 101, 103, 104, 213, 215, 218, 219, 220, 243, 249, 357, 465
 - adenocarcinoma 357
 - biopsy 219
- Breast carcinomas 133, 138, 338
 - lumps, symptomatic 133
 - malignancies 388
- Breast cancer 107, 108, 133, 134, 135, 137, 138, 139, 140, 141, 142, 143, 217, 218, 219, 635

- circulating biomarkers in 134, 138
 - non-metastatic 140
 - postmenopausal 635
 - Bronchitis 215, 324, 325
 - chronic 324, 325
 - Bronchogenic carcinoma 669
 - Bronchospasm 224
 - Brucellosis 669
 - Bruton tyrosine kinase (BTK) 185
 - Bud-Chiari syndrome 491
 - Burkitt lymphoma (BL) 169, 177, 178, 180, 182, 184
 - Butyrylcholinesterase 322
- C**
- CAFs-associated proteins 289
 - Calcitonin 77, 78, 79, 84, 85, 86, 88, 215, 222, 223, 225
 - Calcium 48, 52, 79, 223, 240, 258, 358, 414, 616, 659
 - absorption 79
 - channel blockers, dihydropyridine 358
 - deficiency 616
 - non-glycosylated 414
 - Calcium-dependent 38, 255
 - proteinases 255
 - zinc-containing endopeptidases 38
 - Calprotectin 414, 415, 469, 527, 528, 535, 668
 - CALR mutations 164, 165
 - Cancer(s) 2, 5, 9, 10, 16, 25, 27, 37, 49, 51, 56, 60, 82, 95, 96, 100, 101, 102, 103, 104, 105, 106, 107, 123, 135, 213, 214, 215, 220, 222, 248, 249, 280, 282, 283, 287, 288, 289, 382, 383, 384, 409, 412, 463, 464, 465, 616, 670
 - anaplastic 220
 - associated fibroblasts (CAFs) 287, 289
 - biliary tract 217
 - bronchial 59
 - cervical 16, 27, 107
 - childhood 463, 464
 - epithelial 222
 - esophageal 409
 - growth 123, 135
 - head and neck 103, 220, 280, 282, 283, 287, 288
 - hematological 670
 - hepatocellular 106, 107, 248
 - intestinal-type intramucosal 409
 - laryngeal 284, 286, 287
 - myeloid 162
 - nasopharyngeal 465
 - oral cavity 283, 288
 - pulmonary 248
 - screening test 82
 - solid 9, 289
 - stomach 213, 409, 465
 - testicular 37, 56, 60, 104, 215
 - testis 56
 - tumor-node-metastasis 412
 - urothelial 5, 51
 - uterine 16, 25, 27
 - Cancer biomarkers 16, 37, 48, 64, 104, 247, 250
 - cervical 16
 - novel urine-based prostate 48
 - ovarian 16
 - Cancer cells 2, 3, 40, 86, 101, 134, 136, 141, 250, 281, 382, 413, 463
 - epithelial 136
 - gastric 413
 - necrotic 86
 - Cancer chemotherapy 310, 370
 - emetogenic 370
 - Cancer progression 136, 140, 285, 288, 289
 - gastric 413
 - Cancer tissues 49, 221, 287, 380
 - paraffin-embedded 287
 - Carbamazepin 316
 - Carbamazepine 315, 316, 328, 330, 331, 336, 337, 347, 350, 501
 - metabolization 337
 - Carbohydrate response element-binding protein (CREBP) 641
 - Carbonyl phosphate synthetase 663
 - Carboxylcytosine 99
 - Carboxylesterases 347, 353

- Carcinoembryonic antigen (CEA) 23, 79, 85, 113, 120, 122, 134, 135, 143, 215, 216, 225, 228, 238, 251, 252, 417, 418, 465, 511
- Carcinogenesis 40, 49, 54, 62, 95, 102, 106, 281, 282, 290, 506
- hepatocellular 106
- Carcinoids 223, 228
- Carcinoid syndrome 226, 228
- Carcinomas 5, 24, 27, 56, 215, 224, 251, 451, 464, 465, 511
- cervical squamous cell 27, 251
- embryonal 24, 56, 464
- endocrine 224
- microsatellite-unstable colorectal 5
- ovarian 215, 451
- Cardiac 243, 320, 387, 544, 546, 547
- arrest 544, 547
- arrhythmias 320
- hypertrophy 243, 387
- sympathetic function 546
- Cardiomyocytes 241, 242, 243, 244, 246
- Cardiomyopathies 387, 548, 549, 550
- arrhythmogenic 548
- chemotherapy-induced 548
- hypertrophic 548, 550
- Cardiovascular 316, 364
- death risk 364
- system drugs 316
- Cardiovascular diseases 317, 387, 429, 452, 471, 544, 549, 604, 614, 616, 620, 660
- wound healing 660
- Castration resistant prostate cancer (CRPC) 62
- Catecholamines 84
- CEA 123, 135, 251, 253
- expression in colorectal and breast cancers 253
- overexpression 251
- proteins 123, 135
- Celiac disease 83, 412, 414, 415, 416, 417
- Cell activation 4, 506
- hepatic stellate 506
- Cell adhesion molecules (CAMs) 251, 252, 571, 572, 573
- Cell cycle 103, 104, 122, 175, 180, 250, 280, 290, 389, 670
- regulation 104, 175, 180
- Cell cycle progression 138, 285
- estrogen-stimulated 138
- Cellular immunodeficiency 455
- Central nervous system (CNS) 47, 173, 254, 255, 258, 326, 329, 330, 467, 637, 638
- Cephalhematoma 469
- Ceramide synthases 631
- Ceruloplasmin 138, 557, 658
- Cervical carcinoma 27
- Chagas disease 656, 663
- Channelopathies 545
- Chemoimmunotherapy 187
- Chemokines 186, 426, 428, 429, 430, 455, 570, 628, 636, 661, 667
- mucosa-associated epithelial 455
- Chemoradiotherapy 27, 116, 117
- Chemotaxis 628, 661, 666, 667
- regulating 667
- Chemotherapy 6, 8, 38, 56, 62, 81, 113, 114, 116, 119, 121, 123, 124, 140, 151, 155, 156, 344, 345, 353
- adjuvant 116, 123, 124
- cisplatin-based 56
- neoadjuvant 38, 62, 113, 114, 140
- oxaliplatin-based 116
- resistance 121
- taxane-based 140
- Childhood 451, 455, 475
- asthma 455
- diseases 451, 475
- malignancies 463, 464
- Cholangiocarcinoma 216, 490, 507, 510
- intrahepatic 507
- Cholangitis 216, 217, 412
- Cholestasis 217, 490, 492, 493, 497, 498, 499, 503, 505
- extrahepatic 497
- intrahepatic 497
- Cholesteatoma 276, 291, 292, 293, 294, 295, 299
- pediatric 292
- Cholesterol 507, 636

- high-density lipoprotein 636
- Chondrocytes 246, 258
- Chorionic gonadotropin hormone (CGH) 225
- Chromatin dynamics 102
- Chromatography, high-performance liquid 442
- Chromogranins 79, 223, 224, 225, 228, 465
- Chromosomal 156, 157, 158, 159, 160, 161, 175, 178, 179, 181, 184, 190
 - abnormalities 156, 157, 158, 159, 160, 161, 181
 - translocations 156, 175, 178, 179, 184, 190
- Chromosome 42, 155, 156, 158, 159, 160, 164, 165, 166, 167, 172, 173, 174, 175, 177, 190
 - abnormalities of 155, 156
 - aneuploidies 42
- Chronic 136, 151, 159, 163, 164, 165, 166, 167, 168, 216, 245, 357, 443, 460, 469, 471, 492, 497, 510, 511, 523, 526, 535, 600, 612, 614, 615, 616, 617, 618, 620, 633, 672
 - diseases 469, 600, 612, 614, 615, 616, 617, 618, 620, 672
 - hepatitis 136, 216, 492, 497, 510, 511
 - illnesses 633
 - inflammation 245, 443, 460, 471
 - kidney disease (CKD) 523, 526, 535
 - myeloid leukemia (CML) 151, 159, 163, 164, 165, 166, 167, 168, 357
 - myelomonocytic leukemia 159
- Chronic renal 215, 616
 - failure 215
 - problems 616
- Chron's disease 470, 471
- Circulating tumor cells (CTCs) 38, 46, 86, 113, 114, 124, 134, 139, 140, 143, 191, 192, 219, 220
- Clarithromycin 316
- Clopidogrel, anticoagulant drugs 362
- CNS 174, 254, 256
 - relapse 174
 - traumas 254, 256
- Collagenases 252
- Collagen metabolism 505
- Colon cancers 85, 103, 113, 384, 465, 635
- Colonoscopy 116, 414
- Colorectal cancer 216, 353, 361
 - metastatic 353, 361
 - screening 216
- Colorectal carcinoma 215, 353
 - metastatic 353
- Combination 8, 25, 26, 81, 135, 142, 172, 192, 321, 323, 345, 346, 350, 351, 353, 358, 359, 360
 - chemotherapies 172
 - immunotherapy 8
 - therapies 192, 346, 360
- Concentrations 318, 322, 324, 329, 333, 335, 367, 618, 640
 - plasma flibanserin 329
 - plasma paroxetine 335
 - plasma selenium 618
 - plasma triglyceride 640
 - plasma vortioxetine 333
 - serum esomeprazole 367
 - therapeutic 318, 322, 324
- Conditions 119, 295, 409, 411, 416, 417, 452, 455, 468, 470, 498, 522, 523, 528, 531, 567, 570, 613, 614, 637, 655, 657, 670
 - allergic 452
 - autoimmune 670
 - diabetic vascular 637
 - harsh 455
 - ischemic 416
 - malignant 417
 - neoplastic 498
 - non-allergic 452
 - non-malignant 119
- Congenital 454
 - immunodeficiency 454
 - neutropenias 454
- Congestive heart failure (CHF) 242, 245, 246
- Conjugation reactions 326
- Constipation 321, 334
- Contraction 238, 240, 243, 246
 - cardiac 240
 - smooth muscle 246
- Coronary 363, 378, 387, 441, 545, 547, 549, 635

Artery Disease (CAD) 363, 378, 387, 441, 545, 547, 549, 635
 syndrome 545
 Coronavirus 656
 Corticosteroids 427, 657
 Corticotropin- 581, 585, 590
 releasing factor (CRF) 581, 585
 hormone (CRH) 581, 590
 COVID-19 386, 474, 656, 672
 outbreak 656
 pandemic 386
 sepsis 672
 virus 474
 Cow's milk allergy 453
 Cox survival analysis 23
 Creatinine kinase (CKs) 138, 239
 Crizotinib plasma concentrations 354
 Crohn's disease (CD) 60, 466, 469, 664
 CRP and systemic cytokine concentrations 633
 Cushing's syndrome 215, 228
 Cyanocobalamin 617
 Cycles 20, 566, 567, 568, 571, 573
 fertile-infertile 568
 menstruation 567
 Cyclic 246, 296
 adenosine monophos 296
 guanylate monophosphate 246
 Cyclooxygenase 120, 121
 Cystadenoma 17
 Cystatin, urinary 524, 534
 Cystectomy 39, 62
 Cysteine protease inhibitor cystatin 283
 Cystic carcinoma 287, 290
 cell 287
 Cystic nephroma 55
 pediatric 55
 Cystoscopy 37, 41
 Cytidine deaminase 353
 Cytogenetic abnormalities 154, 156, 159, 161, 164, 172, 174
 Cytogenetics 150, 151, 152, 161, 167, 171, 172, 174, 189, 190
 Cytokeratins 27, 134, 138, 142

Cytokine(s) 162, 252, 253, 259, 278, 298, 427, 585, 628, 630, 661, 663, 665
 anti-inflammatory 252
 endocrine 630
 function 661
 inflammation-related 585
 pro-inflammatory 253, 259, 427, 628, 665
 secretion 278, 663
 signaling pathways 162
 stress-associated 298
 Cytokinesis 105
 Cytology 27, 44, 222
 liquid-based 27
 Cytomegalovirus 386, 460
 Cytopenias 461
 Cytoskeleton 105, 138, 282
 intracytoplasmic 282
 Cytosol 413, 414, 668
 neutrophilic 414

D

Damage 45, 48, 242, 243, 259, 260, 416, 459, 472, 493, 523, 530, 546, 549, 556, 560, 606, 672
 cardiac myocyte 546
 glomerular 459
 hepatocyte 493
 intrinsic kidney 530
 ischemic 546
 ischemic brain 472
 neuronal 259, 260
 oxidative 606
 pathological cardiomyocyte 242
 renal parenchymal 523
 reperfusion 416
 Databases 381, 570, 619
 nutrient composition 619
 Deaminated gliadin peptide antibodies (DGPA) 417
 Death 16, 27, 113, 135, 140, 387, 415, 452, 507, 533, 534, 535, 544, 545, 546, 547, 548, 549, 550, 551, 656
 arrhythmic 551

- cancer-related 27, 113, 507
- cardiac 544, 545, 547, 550
- cardiovascular 545
- disease-related 387
- enterocyte 415
- gynecological cancer 16
- Decalcification 293
- Decarboxylation 617
- Decidualizing stroma prostaglandins 570
- Defects 96, 190, 388, 509
 - atrial septal 388
 - neural tube 509
 - ventricular septal 388
- Deficiencies 78, 79, 82, 327, 328, 339, 353, 360, 366, 370, 467, 500, 611, 612, 613, 615, 616, 617, 618, 666
 - deficient dihydropyrimidine dehydrogenase 353
 - homologous recombination 360
 - iodine 79, 82
 - iron 615, 617
 - magnesium 617
 - micronutrient 615
 - mineral 611
 - nutrient 611, 612, 618
 - oxygen 666
 - thyroid hormone 78
 - zinc 617
- Dementia 341, 617
- Demethylation 162
- Demyelination 254
- Dendritic cell(s) 3, 4, 169, 170, 186, 280, 660
 - follicular 186
 - neoplasm 169, 170
 - preparation 4
- Dengue Fever 656
- Depression 227, 309, 334, 340
 - fatal respiratory 340
- Dermatitis 227, 417
 - herpetiformis 417
- Detecting 494, 600
 - putative targets 600
 - tissue damage 494
- Detection 82, 83, 84, 86, 106, 107, 108, 123, 124, 138, 139, 167, 168, 381, 385, 493
 - chronic viral hepatitis 385
- Dextromethorphan 330, 340, 341
- Diabetes 227, 327, 440, 441, 445, 463, 507, 511, 601, 614, 618, 631, 635, 637, 640
 - Chlorpropamide 327
 - gestational 441
 - insulin-dependent 440
 - insulin-independent 440
 - remission 601
- Diarrhea 226, 227, 353, 357
 - watery 227
- Diazepam 327, 330, 338, 347, 368, 369
 - elimination of 338
- Diet-induced obesity (DIO) 634
- Diffuse large B-cell lymphoma (DLBCL) 177, 178, 180, 181, 182, 183, 184, 185, 186
- Digestion, chemical 413
- Dihydroceramide synthases 631
- Dihydropyrimidine dehydrogenase 313
- Disease activity 459, 471, 495, 506, 606
 - comorbidities 506
 - obesity-related 606
- Disorders 58, 151, 160, 164, 166, 183, 299, 331, 329, 330, 408, 411, 414, 416, 419, 443, 445, 454, 470, 601, 620, 640
 - antibody production 454
 - auto-immune 416
 - carbohydrate absorption 411
 - clonal hematopoietic 151, 166
 - degenerative 330
 - inflammation-related 470
 - lymphoproliferative 183
 - malignant 419
 - metabolic 601
 - monogenic 445
 - myeloid 160, 164
 - nutritional 620
 - obesity-related 640
 - pregnancy-related 58
 - relapsing 414
 - schizoaffective 331
 - thyroid hormone 443
- Diuresis 246
- Diuretic therapy 530

- DNA 39, 62, 97, 98, 99, 100, 113, 118, 120, 123, 134, 140, 141, 181, 276, 285, 458, 508, 559, 560, 566, 620, 662
and chronic diseases 620
and protein microarrays 566
cancer release 118
cell-free plasma 134
chaperone 662
circulating tumour 113, 120, 123, 141
demethylation 98, 99, 100
germline 62
hemi-methylated parental 99
methylated 98
methyltransferase 97, 181
replicated hemi-methylated 98
transcription 285
- DNA damage 53, 95, 107, 116, 117, 122
and induction of mutations 116
cellular 122
repairing 107
- DNA methylation 99, 100, 102, 104, 107, 620
and chromatin remodeling 620
biomarker approval for detection 107
in Cancer 100
pathways 99
regulation 100, 102, 104
- DNA repair 40, 63, 101, 116, 180, 662
genes 40, 63
protein functions 116
- Drug(s) 81, 104, 188, 247, 309, 310, 311, 312, 313, 314, 315, 316, 317, 319, 320, 321, 327, 330, 335, 336, 341, 345, 346, 347, 348, 349, 350, 351, 361, 362, 411, 414, 531
anti-angiogenic 81
antiarrhythmic 319, 320
anticonvulsant 336
antifungal 349
anti-inflammatory 414
antimuscarinic 321
antiretroviral 345, 348
antiulcer 309
epigenetic 104
immunomodulatory 188
induced kidney injury 531
non-steroid inflammatory 411
organic 247
toxicity 310
transporter genotypes 311
- Drug interactions 328, 336, 347, 350, 655, 657
of phenytoin 336
- Drug metabolism 116, 310, 311, 312
and drug transporter genotypes 311
- Drug therapy 309, 442
antidepressant 309
- Duchenne muscular dystrophy (DMD) 343
- Dysbiosis 279, 671
intestinal 671
- Dysfunction 411, 505, 530, 535, 546, 548, 617, 667
cardiac 530
immune 667
mechanical 548
myocardial 546
neurologic 617
renal 411, 535, 546
synthetic liver 505
- Dysgerminoma 23, 24
- Dyslipidemia 601, 603, 635
- Dysmetabolism 635
- Dyspareunia 329
- Dysplasia 156, 157, 161
- Dysproteinemia 472
- Dysregulation 96, 117, 164, 176, 182, 298, 560, 561, 626
epigenetic 176, 560
epigenome 96
of expression of miRNA 117
- Dystrophin 343
- ## E
- Eccentric hypertrophy 242
- Echocardiography 545, 548, 551
- ECM adhesion 282
- Effects 102, 283, 285, 321, 385, 440, 443, 504, 531, 547, 641, 630, 663
anti-arrhythmic 547
anticancer 283

- anti-inflammatory 641
- anti-metastatic 285
- antimicrobial 663
- antimuscarinic 321
- antioxidant 504
- antiviral 385
- cytoprotective 531
- hypoglycemic 443
- insulin 440
- oncogenic 102
- pro-inflammatory 630
- protective 531
- Efficacy 6, 8, 41, 328, 332, 334, 335, 337, 340, 354, 363, 364
 - atezolizumab 6
 - rosuvastatin 328
- Efficiency of warfarin 364
- Efflux 314, 318
 - adenosine triphosphate binding cassette 314
 - transporter p-glycoprotein pump, intestinal 318
- EGF, heparin-binding 571
- EGFR 121, 355
 - gene polymorphisms 121
 - kinase activity 355
- Ehrlichia infections 472
- Electrocardiography 379
- Electrolyte 618
- ELISA method 666
- Embolism 59, 219, 363, 364
 - pulmonary 59, 363, 364
- Embryo-epithelial interaction 572
- EMT processes 285
- Encephalopathies 255, 511
- Endocrine 80, 136, 218, 220, 224, 227, 327, 351
 - surgery 220
 - system drugs 327
 - therapy 136, 218, 351
 - tumors 80, 224, 227
- Endocrinological oncology 226
- Endocytosis 248, 249, 664
- Endogenous noncoding RNA molecules 527
- Endometrial 18, 25, 26, 219, 384, 388, 465, 570, 573, 574, 635
 - cancer (EC) 18, 25, 26, 219, 384, 465, 635
 - carcinomas 388
 - growth factors 573
 - receptivity, human gene expression 570
 - receptivity disorders 574
 - transcriptomic analysis 570
- Endometrioid 16, 23
- Endometriosis 17, 18, 21, 23, 216, 329, 571
- Endoproteinase 408
- Energy 297, 612, 631
 - homeostasis 631
 - metabolism 612
 - transfer 297
- Enolase 223, 225, 257, 258, 465
 - activity 257
- Entecavir treatment 510
- Enterocolitis 411, 414, 415, 416
 - necrotizing 414, 415, 416
- Environmental 151, 445, 556
 - factors 151, 445
 - toxins 556
- Enzalutamide 315
- Enzymatic 99, 312, 557
 - antioxidants 557
 - reactions 99, 312
- Enzymatic activity 136, 671
 - degenerative 136
- Enzyme(s) 78, 98, 99, 102, 162, 180, 244, 257, 258, 294, 295, 310, 312, 313, 315, 316, 317, 319, 320, 322, 346, 347, 358, 362, 410, 497, 495, 500, 527, 560, 570
 - angiotensin-converting 527
 - antioxidant 560
 - catabolic 258
 - catalytic 257
 - cholestatic 497
 - conjugating 313
 - degradative 570
 - drug-metabolizing 310
 - encode DNA methyltransferase 162
 - glutathione S-transferase 244
 - hepatic 312
 - histone-modifying 180

immunoassays 410
 inhibitor 315, 316, 346
 microsomal 362
 polymorphic 313
 thyroid peroxidase 78
 transferase 500
 Eosinophil-derived neurotoxin 453
 Eosinophilia 9, 174, 277, 428, 454
 Eosinophilic 277, 278, 426, 452, 453, 455, 456
 cathionic protein (ECP) 278, 426, 453, 456
 chronic rhinosinusitis 277
 esophagitis 452, 455
 Eosinophils 153, 174, 427, 428, 429, 453, 454, 455, 626, 627, 628, 634
 dysplastic marrow 153
 Epidermal 294
 barrier functions 294
 Epidermal growth factor (EGF) 8, 120, 121, 134, 137, 138, 280, 281, 282, 283, 290, 293, 351, 353, 354, 429, 524, 531, 571, 573
 receptor (EGFR) 8, 120, 121, 138, 280, 281, 282, 283, 353, 354, 531
 Epilepsy 215, 390, 472
 pediatric 472
 EPI-mediated activation 293
 Epinephrine 330, 338, 339
 Epithelial 16, 17, 18, 20, 21, 22, 23, 24, 284, 288, 465
 mesenchymal transition (EMT) 284, 288
 ovarian cancer (EOC) 16, 17, 18, 20, 21, 22, 23, 24
 tumors 465
 Epithelial cells 45, 136, 138, 220, 325, 427, 243, 429, 510, 527, 660, 668, 670
 follicular 220
 infected 670
 renal 243
 renal tubular 527
 Epstein-Barr virus (EBV) 102, 183, 187, 386, 460
 Erlotinib metabolism 355
 Erosive esophagitis 368
 Erythematosis 389, 457, 458, 459

 systemic lupus 389, 457, 458, 459
 Erythrocytes 425, 431, 454, 459, 460, 461, 466, 467, 468, 469, 472, 473
 sedimentation rate (ESR) 425, 431, 459, 460, 461, 466, 467, 468, 469, 472, 473

Erythrocytosis 166
 Erythroleukemia 153
 Erythromycin 315, 316, 356
 Estrogen 102, 217, 218, 219, 328, 573
 Eteplirsen 330, 343
 Ethosuximide 316
 Eukaryotic initiation factor 632
 Exacerbations, bacterial 430
 Exhaled breath condensate (EBCs) 427

F

Factor(s) 4, 5, 6, 7, 255, 382, 418, 427, 429, 461, 472, 458, 460, 504, 525, 545, 565, 566, 569, 570, 571, 581, 582, 585, 616, 620, 629, 632, 633, 634, 635, 671
 antiperinuclear 461
 autocrine 566
 binding protein 525
 chemotactic 427
 coagulation 504
 colony-stimulating 429
 corticotropin-releasing 581, 585
 demographic 418
 dietary 616, 620
 endometrial 570
 etiological 671
 hemodynamic-autonomic 545
 immunosuppressive 629
 inflammatory 472
 neurotrophic 255
 proinflammatory 382
 rheumatoid 458, 460
 vasoprotective 635
 FAHFAs in adipose tissue 641
 Failure 82, 84, 115, 215, 222, 241, 242, 584, 566, 573, 602, 616
 renal 82, 84, 188, 215, 222, 616
 tocolysis 584

- Fallop tetralogy 388
Fasting 225, 441, 442, 443, 444, 446, 462, 602, 636, 642
 blood glucose (FBG) 444, 636, 642
 glucagon 225
 glucose 442, 443
 insulin 225, 444, 446
 plasma glucose (FPG) 441, 462, 604
 salivary glucose 444
 somatostatin 225
Fatal arrhythmias 545
Fatty 242, 415, 416, 511, 524, 626
 acid binding proteins (FABPs) 242, 415, 416, 524
 acids homeostasis 626
 liver index (FLI) 511
FDA-approved biomarkers 533
Ferric reducing antioxidant power (FRAP) 558
Fetal 258, 469
 development gliosis 258
 distress 469
Fever 452, 460, 466, 470, 659, 669
 familial Mediterranean 470
 hay 452
 maternal 469
 prolonged 466
 typhoid 669
 yellow 656
Fibrinogen 428, 429, 462, 472, 504, 630
 production 630
Fibrinolysis 155
Fibroblasts 287, 289, 429, 462, 550, 588
 cancer-associated 287, 289
 interstitial 462
Fibrogenesis 505
Fibronectin 285, 462, 505, 507, 573
 regulating 285
Fibrosis 115, 325, 490, 505, 506, 524, 526, 527, 529, 546, 548, 549, 550, 632, 668
 cystic 325, 668
 interstitial 527
 myocardial 548, 549
 radiation-induced 115
 scores 506
FibroTest 507
Fibrothecoma 17
Flavonoids albumin 557
Flibanserin 327, 329
Flow 139, 150, 665
 cytometric techniques 665
 cytometry 139, 150
Fluid 45, 227, 257, 296, 426, 451, 583, 588, 589, 618
 amniotic 589
 cervicovaginal 583, 588, 589
 perilymphatic 296
Fluorescence *in situ* hybridization (FISH) 42, 44, 137, 139, 156, 160, 164, 167, 171, 173, 174, 186, 190
Fluoropyrimidine 117
FNA biopsy 220
Follicular 79, 88, 177, 178, 180, 182, 184, 185, 187, 290
 carcinoma 290
 lymphoma (FL) 177, 178, 180, 182, 184, 185, 187
 thyroid carcinoma (FTC) 79, 88, 290
Food 452, 453, 618, 619
 allergies 452, 453
 consumption 618, 619
 sensitization 452
Formation 96, 97, 99, 102, 244, 254, 295, 326, 338, 340, 389, 453, 462, 569, 572
 catalyzed norcodeine 340
 dysregulated bone 295
 glucuronide conjugate 338
 synapse 389
Fraction 86, 508, 638
 agglutinin-reactive 508
 stromal-vascular 639
Free fatty acids (FFAs) 547, 629, 630, 631, 633
Fridericia method 354
Fructosamine 463
Functions 285, 287, 387, 413, 501, 503, 524, 544, 618, 620, 666, 672
 anti-oncogenic 285
 cardiac 544
 endothelial 387

glomerular 524
 hepatic 501
 immune 618, 672
 immunological 666
 immunomodulatory 413
 metabolic 503, 620
 metastatic 287

G

- Gametogenesis 98
 Gas exchange 291
 Gastric 84, 105, 383, 409, 410, 412, 413, 635
 acidity 409, 410
 cancer 84, 105, 383, 409, 410, 412, 413, 635
 Gastrin 84, 409
 Gastrinomas 225, 226, 228
 Gastritis 409, 408, 410, 635
 atrophic 409, 410
 chronic 410
 Gastroenterology 366
 Gastroenteropancreatic neuroendocrine tumor 223
 Gastroesophageal reflux 367, 368, 369, 409, 635
 symptomatic 368, 369
 disease 635
 Gastrointestinal 10, 215, 408, 411, 412, 419, 453, 464, 465, 466
 biomarkers 419
 cancers 10, 465
 diseases 408
 disorders 419
 mucosa 411
 Gastrointestinal system 217, 407
 cancers 217
 diseases 407
 Gelatinase-associated lipocalin 51, 524
 Gene(s) 47, 48, 49, 55, 95, 101, 103, 105, 106, 107, 121, 162, 166, 181, 190, 191, 279, 298, 310, 317, 349, 358, 445, 455, 567, 568, 570, 632, 629, 671
 adipose-specific 629
 anti-apoptotic 160
 downregulated 191
 fusion test 48
 hypermethylated 181
 leptin 638
 leptin receptor 638
 oncogenic 101
 protein-coding 455
 silencing 95, 101, 103
 stress response 632
 Gene expression 7, 48, 49, 87, 116, 117, 162, 166, 168, 178, 182, 620
 signatures (GES) 7
 Gene expression 9, 41, 49, 168, 177, 179, 182, 184, 186, 190, 191, 671, 171
 assay 41, 671
 microarrays 171
 profiling (GEP) 9, 49, 168, 177, 179, 182, 184, 186, 190, 191
 Gene mutations 62, 80, 162, 175, 179, 353, 457
 somatic 62
 Generation 24, 664, 672
 superoxide 664
 Genetic 142, 153, 162, 311, 360, 506, 560
 biomarkers of liver fibrosis 506
 damage 560
 fingerprint 311
 heterogenicity 142
 mutations 153, 162, 360, 506
 polymorphisms 121, 279, 317, 349, 358
 Genital diseases 378
 Genome 103, 672
 integrity 103
 replication 672
 Genotype 311, 325, 336, 337, 344, 348, 358, 362, 547, 602
 drug target 311
 Germ cell tumors 17, 23, 24, 56, 58, 59, 215, 217, 464, 509
 non-seminomatous 56, 58
 Gestation 583, 584, 585, 587, 588, 633
 Gestational trophoblastic diseases 215
 GFAP 254, 255
 deficiency 254, 255

- secretion 254
- synthesis 255
- Giant cell arteritis (GCA) 466
- Gilbert's Syndrome 346
- GI tract disease 220
- Glands 136, 249, 284, 290, 291, 461, 570
 - exocrine 461
 - salivary 284, 290, 291
 - sweat 249
- Glial fibrillary acidic protein (GFAP) 238, 253, 254, 255, 256, 257, 663
- Glioblastoma 101, 102, 107, 253
- Gliososis 254, 255
- Global 548, 603
 - longitudinal strain (GLS) 548
 - protein expression 603
- Globulins 189, 589, 472
 - hormone-binding 589
- Glomerular filtration 524
- Glomerulonephritis 466, 526
- Glucagon 84, 222
- Glucagonomas 225, 226, 227
- Glucocorticoids 222, 277, 316
- Gluconeogenesis 257, 258, 635
 - catalyzing 258
- Glucose 279, 440, 441, 442, 444, 462, 507, 607, 628, 632, 638
 - airway surface liquid 279
 - homeostasis 628, 638
 - intolerance 632
 - postprandial blood 444
 - random plasma 441, 462
 - regulated protein (GRP) 632
 - salivary 440, 444
 - tolerance test 462
- Glucosyl hydrolases 297
- Glucuronidation 314, 317, 348, 352
 - reaction 314
- Glucuronide conjugate 339
- Glutathione 297, 349, 500, 557, 558
 - peroxidase 297, 557, 558
 - reductase (GR) 557, 558
- Glutathionylation 560
- Glycated haemoglobin 633
- Glycogen phosphorylase (GP) 243, 244, 255
- Glycogenolysis 243, 244
 - sarcoplasmic reticulum 244
- Glycolysis 257
- Glycolyzed hemoglobin 463
- Glycoprotein 58, 24, 85, 105, 135, 136, 139, 216, 218, 247, 251, 255, 278, 281, 353, 412, 417, 462, 658, 661, 665
 - adhesive 462
 - antigens 105, 412
 - glycosylated 85
 - hormone 24
 - mucin 139
 - oncofetal 216
 - transmembrane 136, 251, 281, 353
- Glycosylase 99
- Glycosylation 250
- Glycosyl transferases 285
- Gonadal carcinoma 220
- GPI anchor cleavage catalysis 135
- Granulomatosis 465, 466
 - eosinophilic 466
- Graves' disease 83, 222
- Growth 2, 51, 123, 248, 249, 251, 285, 293, 294, 611, 614, 617, 620, 664
 - endothelial 664
 - heparin-binding epidermal 293
 - inhibition 285
 - neoplastic 51
 - modulation functions 248
 - signal transduction 251
- Growth factor(s) 5, 116, 164, 250, 252, 278, 293, 505, 534, 569, 570, 571, 581, 583, 586, 664
 - binding protein 586
 - endothelium-derived vascular 664
 - hypersensitivity 164
 - keratinocyte 293
 - transforming 5, 278, 293
 - urinary hepatocyte 534
 - vascular endothelial 52, 252
- Growth hormone (GH) 25, 215, 227, 228
 - releasing hormone (GHRH) 228
- Guillain-Barré syndrome 215
- Gynecological 103, 388
 - cancers 103

- diseases 388
- Gynecologic 16, 17
 - diseases 17
 - malignancies 16
- H**
- Hashimoto's thyroiditis 82, 83
- HBV-related hepatocellular carcinoma 385
- HCV-associated chronic viral hepatitis 385
- Healing fracture Paget's disease 499
- Health 310, 495, 504, 529, 536, 603, 611, 612, 617, 618, 620, 621, 642
 - cardiovascular 603
 - impaired metabolic 642
- Hearing loss 291, 296, 297, 298
 - age-related 296
 - noise-induced 297
 - non-syndromic 296
- Heart diseases 238, 381, 387, 388, 545, 547, 600
 - congenital 388
 - congestive 238
 - coronary 600
 - ischemic 547
- Heart failure 242, 317, 547, 549, 550
 - congestive 242
- Heart rate 546, 549
 - turbulence (HRT) 546, 549
 - variation (HRV) 549
- Heart-type fatty acid binding protein 242, 243
 - in acute myocardial ischemia 243
- Helicobacter pylori* 102, 410, 667, 670
 - and *Mycoplasma* 667
 - infection 670
- Hematologic neoplasm 150, 188, 193
- Hematopoietic progenitors 164
- Hematuria 37, 43
 - painless macroscopic 37
- Hemoglobin 52, 188, 442, 614, 615, 617
 - glycated 441, 462, 642
 - glycosylated 642
- Hemoglobinopathy 441
- Hemolysis 59, 493
- Hepatic steatosis index (HSI) 511
- Hepatitis 182, 187, 214, 215, 216, 217, 329, 385, 491, 492, 49, 454, 460, 510, 511, 670, 672
 - B virus (HBV) 187, 385, 491, 492
 - C virus (HCV) 182, 329, 385, 511
 - ischemic 495
- Hepatobiliary 103, 104
 - and lung cancers 103
 - cancer 104
- Hepatoblastoma 215, 216
- Hepatocarcinoma 247
- Hepatocellular 106, 214, 215, 216, 217, 385, 464, 507, 508, 509, 510, 511
 - injury 490, 492, 493, 503, 505
 - carcinoma (HCC) 106, 214, 215, 216, 217, 385, 464, 507, 508, 509, 510, 511
 - injury 490, 492, 493, 503, 505
- Hepatocyte growth factor (HGF) 296, 354, 534
- Hepatotoxicity reactions 359
- Hereditary 18, 59
 - breast-ovarian cancer (HBOC) 18
 - tyrosinemia 59
- Heterogeneity 7, 50, 61, 156, 191, 501
 - clonal 156, 191
 - electrophoretic 501
 - genetic 151
 - temporal expression 7
- High-performance liquid chromatography (HPLC) 442
- Histaminase 79, 86
- HMGB1 662
 - gene in peripheral monocytes 662
 - proteins 662
- HMG-CoA reductase inhibitor 328
- Hodgkin lymphoma 220, 464
 - bone tumors germ cell tumor 464
- Homeostasis 165, 258, 259, 296, 390, 618, 631, 632
 - ion 672
 - metabolic 631
 - modulating calcium 165
- Homocysteine 547

- Homologous recombination deficiency (HRD)
 360
 Homotransplantation 365
 Hormones 25, 79, 86, 102, 221, 222, 224, 297,
 565, 569, 570, 581, 590
 hypophosphatemic 222
 thyroid-stimulating 79, 221
 thyrotropic 221
 HPV 280, 281
 infection 280, 281
 involvement in squamous oropharyngeal
 cancer 281
 transforming proteins 281
 Human 5, 20, 24, 40, 46, 56, 119, 134, 137,
 219, 248, 251, 255, 280, 293, 351, 329,
 430, 454, 464, 666, 667, 668, 670, 672
 carcinoembryonic antigen 251
 chorionic gonadotrophin 56
 chorionic gonadotropin 24, 464
 epidermal growth factor (HEGF) 40, 134,
 137, 219, 293, 351
 epididymis protein 20
 immunodeficiency virus (HIV) 255, 329,
 454, 666, 670, 672
 kallikrein-related peptidase 46
 leukocyte antigen (HLA) 5, 248
 neutrophil lipocalin (HNL) 667, 668
 papilloma virus infection 280
 Rhinovirus infection 430
 telomerase reverse transcriptase 119
 Humoral immunodeficiency 467
 Huntington's disease 255, 341, 342
 Hürthle cell carcinomas 222
 Hydroxylation, aromatic 318
 Hydroxyurea 168
 Hyperadiponectinemia 635
 Hyperbilirubinemia 362
 Hypercalcemia 52, 84, 222, 228
 Hyperdiploid 173
 Hyperdiploidism 190
 Hyperdiploidy and chromosomal
 translocations 190
 Hypergammaglobulinemia 461
 Hyperglycemia 440, 441, 462
 Hyperhomocysteinemia 617
 Hyperinsulinemia 637
 Hyperlipidemia 309
 Hypermethylation 52, 95, 101, 104, 106
 Hyperparathyroidism 80, 222
 Hypersensitivity 164
 Hypersomnia 340
 Hypertension 247, 316, 317, 318, 600, 635
 Hyperthyroidism 222, 255
 Hypertriglyceridemia 328
 Hypertrophic cardiomyopathy (HCM) 548,
 550
 Hyperuricemia 365, 366, 635
 asymptomatic 366
 Hyperviscosity 472
 Hypoadiponectinemia 635
 Hypoalbuminemia 443, 474
 Hypodiploidy 170, 171, 173, 190
 Hypofibrinogenemia 472
 Hypoglycemia 226, 227, 328
 Hypogonadism 59
 Hypokalemia 227, 544
 Hypomethylation 95, 102, 103, 106, 107
 Hyponatremia 466
 Hypotension 318, 329, 663
 sepsis-associated 663
 Hypothyroidism 136, 216, 500
- I**
- Imaging 80, 114, 123, 125, 139, 500, 502,
 509, 558
 magnetic resonance 114, 500, 502
 medical 80
 radiological 114
 techniques 558
 Imatinib 167, 358
 plasma concentration 358
 therapy 167
 Imbalances 617, 426, 556
 electrolyte 617
 intracellular redox 556
 protease-antiprotease 426
 Immune 1, 4, 7, 248, 588
 activation, cell-mediated 588

- based therapy approaches 1, 4
- checkpoint inhibitor therapy 7
 - modulation functions 248
- Immune responses 2, 7, 38, 83, 187, 247, 248, 289, 382, 410, 661, 665
 - humoral 410
 - innate 661
- Immune system 2, 3, 5, 61, 248, 381, 382, 385, 453, 454, 459, 615, 656, 659, 671
 - activation 459
 - anti-tumor effects 61
 - disorders 615
 - functions 248
- Immunity 295, 410, 471, 615, 661, 637, 665
 - humoral 661
 - innate 471, 637, 665
- Immunochemiluminometric assays 85
- Immunochemistry 410
- Immunodeficiency 47
- Immunofluorescence 139
- Immunohistochemistry 7, 120, 150, 177, 183, 185, 186, 187, 568
- Immunosuppressive 27
 - acidic protein (IAP) 27
- Immunotherapy-related biomarkers 192
- Impaired 254, 443
 - fasting glucose (IFG) 443
 - metabolic functions of astrocytes 254
- Infections 291, 292, 384, 385, 454, 469, 472, 584, 671
 - chronic 291, 292, 385, 454, 472
 - coronavirus 672
 - intestinal 469
 - intraamniotic 472, 584
 - mycobacterial 472
 - urinary system 348
- Infectious 414, 454, 458, 467, 469, 470, 472, 655, 656, 657, 667, 669, 670
 - colitis 414
 - diseases 454, 458, 467, 469, 470, 472, 655, 656, 657, 667, 669, 670
 - mononucleosis 669
- Infiltration 7, 278
 - immune cell 7
 - mucosal eosinophil 278
- Inflammation 244, 245, 255, 256, 415, 426, 428, 431, 456, 462, 471, 472, 584, 588, 614, 626, 633, 642, 660, 661
 - allergic 456
 - choriodecidual 588
 - eosinophilic 428
 - gastrointestinal luminal 415
 - intestinal mucosal 415
 - nasal 456
 - obesity-induced 626
 - underlying gastrointestinal 462
- Inflammatory 85, 280, 283, 293, 389, 411, 413, 414, 415, 418, 429, 457, 461, 462, 466, 468, 470, 469, 470, 526, 551, 581, 582, 583, 588, 626, 627, 628, 629, 632, 635, 660, 661, 665, 667
 - bowel diseases (IBD) 85, 389, 413, 414, 415, 418, 469, 470, 635
 - cytokines 283, 293, 461, 506, 588, 628, 632, 660
 - processes 280, 429, 461, 466, 468, 470, 526, 551, 581, 582, 583
 - response 411, 415, 457, 462, 626, 627, 629, 660, 661, 665, 667
- Inflammatory conditions 292, 472, 659, 661, 668
 - non-infectious 472
- Inflammatory diseases 216, 425, 451, 467, 470, 471, 559, 615, 667
 - pelvic 216
- Inflammatory disorders 455, 662
 - chronic 662
- Influenza virus co-infection 662
- Inhibition 103, 117, 157, 179, 239, 240, 241, 252, 285, 386, 387, 388
 - translational 117
- Inhibitors 63, 81, 141, 154, 188, 243, 295, 315, 318, 319, 326, 328, 329, 341, 346, 349, 354, 360, 361, 363, 365, 384,
 - acetylcholinesterase 341
 - antisense 384
 - mammary-derived growth 243
 - monoamine oxidase 326
 - protease 295, 329

proteasome 188
 thyroline kinase 63
 tyrosine kinase 81, 141, 154
 xanthine oxidase 365
 Inhibitory protein 121
 Injury 254, 255, 258, 296, 260, 503, 523, 522,
 523, 524, 525, 528, 527, 601, 606
 cellular 296
 cholestatic 503
 endothelial 601
 interstitial 522, 523
 ischemic 526, 606
 renal ischemia-reperfusion 527
 renal parenchymal 523
 Innate Lymphoid 278
 Inner hair cells (IHC) 7, 120, 137, 296, 297
 Insertion, mobile element 311
 Insulin 445, 446, 462, 507, 526, 606, 607,
 637, 638, 639, 641
 dependent diabetes mellitus 462
 exocytosis 445
 growth factors 526
 secretion 445, 446, 638
 sensitivity 635, 638, 639, 641
 Insulin resistance 440, 443, 446, 600, 606,
 632, 635, 637, 638, 639, 640, 641, 642
 fatty acid-induced 637
 indicators 446
 obesity-related 640
 Interleukin 2, 3, 9, 581, 585, 606, 607, 626,
 629, 658, 661, 662
 proinflammatory 629
 Interventions 408, 490, 523, 606, 611
 endoscopic 408
 therapeutic 490, 523, 606, 611
 Iron Binding Capacity (IBC) 617
 Ischemia 83, 239, 242, 416, 606, 607
 intestinal 416
 modified albumin (IMA) 83, 606, 607
 myocardial 239, 242
 Ischemic Cardiomyopathy 545
 Islet cell antibody (ICA) 462
 Isocitrate dehydrogenase 181, 493
 oncogene mutations 162

J

JAK-STAT pathways 175
 Juvenile 457, 458, 462
 dermatomyositis 457, 458
 Diabetes 462
 Juvenile idiopathic arthritis (JIA) 457, 458,
 460, 461

K

Kallikrein 24, 46
 protein biomarkers 46
 related peptidases 24
 Kawasaki disease 466, 469, 472
 Keratinocyte growth factor (KGF) 293
 Ketamine oxidase 442
 Kidney 37, 51, 216, 218, 246, 461, 464, 467,
 494, 495, 498, 522, 524, 525, 526, 528,
 529, 531
 cancer 37
 cysts 218
 disease improving global outcomes
 (KDIGO) 522
 diseases 526
 failure 216
 Kidney injury 522, 523, 525, 526, 528, 529,
 531
 drug-induced acute 522
 intrinsic 531
 intrinsic acute allograft 528
 mechanisms 532
 obstructive 526
 toxic 526
 transplantation 531
 Kinase 179, 244, 246, 280, 352
 activation 525
 anaplastic lymphoma 179, 352
 inhibiting myosin light chain 246
 phosphorylase 244
 threonine-protein 280

L

- Lactate Dehydrogenase (LDH) 52, 56, 57, 58, 59, 64, 189, 214, 239, 464, 493
- Lambert-Eaton myasthenic syndrome 330, 343
- Lateral sclerosis 255
- Legionnaires' disease 667
- Leiomyomas 17
- Leishmania 667
- Lesions 222, 284, 284, 292
 malignant thyroid 222
 neoplastic 288
 supraglottis 284
 tumoral 292
- Leucine aminopeptidase 498
- Leukemia 59, 154, 156, 159, 167, 174, 176, 214, 357, 382, 463, 464, 465, 470, 499
 chronic eosinophilic 357
 chronic neutrophilic 159, 167
 juvenile myelomonocytic 159
 lymphocytic 382
- Leukemogenesis 171
- Leukocyte 251, 454
 adhesion defect (LAD) 454
 diapedesis 251
- Leukocytosis 166, 454, 467, 472
- Lipid 298, 558, 568
 hydroperoxides 558
 mediators 568
 oxidation 558
 peroxidation products 298
- Lipogenesis 629
- Lipopolysaccharide binding protein 658, 660
- Lipoproteins 117, 603
- Lipoxygenase 556
- Liquid biopsy 77, 86, 87, 113, 114, 133, 134, 135, 219, 295
 analysis 219
- Liver 117, 214, 216, 226, 252, 385, 412, 418, 443, 469, 495, 496, 497, 501, 505, 506, 507, 510, 512, 669
 biopsy 505
 cancers 214, 512
 cirrhosis 216, 412, 418, 443, 496, 497, 669
 fibrogenesis 506
 fibrosis 385, 501, 505, 506, 507
 function tests 495, 501, 506
 inflammation 385, 506
 metastases 117, 226, 252
 neoplasia 469
 transplantation 510
- Liver diseases 215, 491, 495, 496, 497, 501, 506, 508, 509, 635
 alcoholic 215, 496, 497
 chronic 495, 496, 497, 506, 508, 509
 genetic 491
 non-alcoholic fatty 635
 parenchymal 501
- Liver injury 493, 495, 503, 506
 drug-induced 503
- Lobectomy 81
- Logistic regression (LR) 19, 21
- Lung 5, 8, 59, 101, 103, 104, 382, 383, 464
 and Gynecological cancers 103
 and Ovarian cancer 104
 cancers 5, 8, 59, 101, 103, 104, 382, 383, 426, 464, 465
 carcinoids 465
 parenchyma 426
- Lupus 250, 459
 anticoagulant 459
 drug-associated 459
 neonatal 459
 nephritis 459
- Lymphadenopathy 457
- Lymphoblastic leukemia, acute 156, 169, 357
- Lymphoblasts 169, 173
 leukemic 169
- Lymphocytes 2, 3, 4, 176, 187, 248, 251, 292, 454, 455, 460, 669
 nodular 187
 tumor-infiltrating 2
- Lymphocytopenia 474
- Lymphoid progenitors 169
- Lymphomas 176, 177, 178, 180, 181, 182, 183, 184, 186, 187, 214, 464, 465, 469
 follicular 177
 germinal center-related 177

lymphocytic 178
Lymphopoiesis 169
Lynch syndrome (LS) 18, 19

M

Macrocytosis 472
Macronutrients 611, 612, 626
Macrophage 533, 581, 585, 637
 infiltration 637
 inflammatory protein (MIP) 581, 585
 migration inhibitory factor 533
Maddrey's discriminant function 511
Magnetic resonance 114, 118, 500, 502, 548,
 551, 467
 angiography 467
 imaging (MRI) 114, 118, 500, 502, 548,
 551
Major 2, 251, 453
 basic protein (MBP) 453
 histocompatibility complex (MHC) 2, 251
Malabsorption 504, 616
Malignancies 54, 55, 56, 81, 82, 83, 84, 118,
 119, 151, 152, 160, 176, 214, 215, 216,
 217, 218, 220, 221, 222, 388, 280, 412,
 418, 463, 464
 colorectal 418
 epithelial 412
 gynecological 220, 388
 hematological 176, 463, 464
 hematopoietic 160
 pediatric 54, 463
 thyroid 81, 84, 221, 222
Malignant 50, 151, 407, 412, 417, 472
 Gastrointestinal System Diseases 407
 hematopoietic precursor cells 151
 masses 50
 neoplasms 472
 alignant Upper Gastrointestinal Diseases
 412
 Lower Gastrointestinal Disorders 417
Malnourishment 612
Malnutrition 454, 500, 611, 612, 613, 615
 Wilson's Disease 500
Mantle cell lymphoma (MCL) 177, 178, 182,
 183, 184, 185
Marginal zone lymphoma (MZL) 178, 185
Mass spectrometry 566
 gas chromatography/time-of-flight 22
 liquid chromatography-tandem 83
Mechanisms 96, 99, 102, 137, 139, 193, 240,
 241, 246, 248, 456, 545, 557, 559, 560,
 566, 626, 632, 635, 638, 643, 663
 allergic 456
 antioxidant 557
 arrhythmogenic 545
 compensation 245
 epigenetic 96, 102, 560
 inflammatory 626, 643
 pathogenetic 193
 pro-inflammatory 663
Medullary thyroid cancer (MTC) 78, 79, 80,
 81, 84, 85, 86, 88, 215, 222, 223, 465
Melanocytic lesion 103, 104
Melanoma 3, 4, 5, 6, 192, 220, 248, 464
Meniere's disease 276, 291, 297
Menopause 24, 219
Merkel cell carcinoma 223
Mesenteric ischemia 415, 416
 non-occlusive 416
 occlusive 416
Messenger RNAs, splicing 163
Metabolic 259, 617
 acidosis 617
 distress 259
Metabolic dysfunction 443, 626, 632, 634
 obesity-related 632
Metabolism 78, 243, 312, 313, 314, 316, 317,
 320, 321, 323, 324, 325, 346, 347, 349,
 358, 387, 556, 603, 632, 633, 642
 aerobic 556
 carbohydrate 243
 fatty acid 243
 intermediary 78
 lipid 387, 603, 632, 642
 lipoprotein 633
Metabolites 22, 226, 227, 318, 320, 325, 326,
 327, 328, 331, 332, 333, 348, 349, 351,
 352, 363, 446, 616, 618, 620

- antioxidant 616
 - glucuronide 363
 - intermediary plasma 446
 - nucleoside 348
 - oxidative 328, 349, 351
- Metabolization 329, 331, 332, 334, 335, 339, 340, 341, 342, 343, 344, 363, 364, 367
 - deutetrabenazine 341
 - donepezil 341
 - oxidative 334
- Metabolization 333, 363
 - of vortioxetine 333
 - pathway 363
- Metalloenzymes 292, 410, 616
- Metalloproteases 138
- Metalloproteinases 252, 283, 524, 589
- Metastectomy 81
- Metastasis 39, 80, 41, 57, 58, 59, 135, 136, 137, 139, 140, 225, 226, 250, 251, 252, 285, 418
 - cervical 80
 - lymphatic 418
 - non-pulmonary visceral 57, 58
- Metastatic 46, 50, 52, 57, 60, 81, 82, 87, 113, 124, 133, 134, 142, 360
 - carcinoma 134, 358
 - disease 46, 50, 52, 60, 81, 82, 87, 113, 124, 133, 142
 - germ cell cancer 57
 - pancreatic adenocarcinomas 360
- Metastatic breast 134, 135, 136, 140, 141, 143, 216, 218, 219, 351, 352, 353, 359
- cancer 134, 135, 136, 140, 141, 143, 216, 218, 219, 351, 352, 353, 359
- carcinoma 216
- Methemoglobinemia symptoms 345
- Methylated 97, 102
 - centromeric repetitions 102
 - cytosines 97
- Methylation 38, 39, 48, 49, 96, 98, 106, 107, 108, 180, 281
 - gene body 281
 - promoter 39, 181
- Methyltransferases 95, 106, 166
 - methylated-DNA-protein-cysteine 106
- MGMT methylation assay 107
- Microaneurysms 467
- Microbiome of airway 279
- Microcytic anemia 615
- Microcytosis 472
- Microenvironment 5, 102, 150, 186, 252, 259, 660
 - antimicrobial 660
 - inflamed 5
 - pro-inflammatory 259
 - tumor-preferred 102
- Micrometastases 136
- Micronutrients 611, 612, 615
- Microsatellite instability 1, 4, 6
- Microscopic colitis 414
- Microvascular density of cholesteatomas 292
- Mitochondrial 556, 626, 672
 - biomarkers, accessible 672
 - dysfunction 556, 626
- Mitogen-activated protein kinase (MAPK) 79, 185, 244, 288, 289, 294, 385
- Monoclonal 18, 51, 137, 188, 189, 218, 251, 353, 410
 - antibodies 18, 51, 137, 189, 218, 251, 353, 410
 - gammopathy 188
- Monocyte-derived macrophage infiltration 632
- Monoxygenases 312
- Monotherapy 8, 328, 338
- Mortality 24, 25, 37, 38, 39, 40, 425, 428, 429, 430, 526, 527, 529, 582, 603, 662, 663
 - cardiovascular 603
 - neonatal 582
- Mucosa-associated lymphoid tissue (MALT) 410
- Mucosal 80, 411, 414, 415
 - damage 411, 414, 415
 - neuromas 80
- Multiparameter flow cytometry (MFC) 151, 177, 191, 192
- Muscle dysfunction 425
- Muscular dystrophy 330
- Musculoskeletal system 425, 457, 467

- Myeloblastic leukemia 153
Myelodysplastic syndromes 151, 157, 159
Myelofibrosis 152, 164, 166
 chronic idiopathic 164
Myeloid 2, 152, 153, 160
 derived suppressor cells (MDSCs) 2
 leukemogenesis 160
 neoplasia 160
 sarcoma 152, 153
Myeloid leukemia 151, 152, 159, 166
 chronic 151, 159, 166
Myeloid neoplasms 151, 152, 157, 159
 therapy-related 152, 159
Myeloma 184, 188, 192, 454, 465
 multiple 184, 188, 465
 relapsed 192
Myeloperoxidase 426, 427, 465, 547, 556
Myocardial 59, 239, 242, 244, 316, 317, 363,
 544, 545, 546, 548, 634
 infarction (MI) 59, 239, 242, 316, 317, 363,
 544, 545, 546, 548, 634
 oxygen deficiency 244
Myocytes, cardiac 546
Myxoma resistance protein 670
- N**
- Nasopharyngeal carcinoma 282
Natriuretic peptides 245, 246, 546, 549, 550,
 551, 663
Natural killer (NK) 2, 170, 172, 192, 426, 626,
 627, 628
 cell lymphoblastic leukemia/lymphoma 170
Nausea 367, 370, 491
 chemotherapy-related 367
Neck cancer 103, 220, 280, 282, 283, 287,
 288, 353
Necrosis 336, 337
 experiencing Stevens-Johnson
 Syndrome/toxic epidermal 336, 337
Necrotizing arteritis 467
Neoadjuvant 40, 61, 81, 116, 125
 chemoradiotherapy 125
 chemotherapy efficiency 61
Neoplasms 55, 95, 136, 151, 163, 166, 169,
 193, 258, 284, 388, 412
 lymphoid 169
 lymphoproliferative 169
 myeloproliferative 151, 163
 ovarian 388
 pancreatic 412
Nephrectomy 52
Nephrotoxicity 522, 531, 532
Neural parenchyme 291, 292
Neuroblastoma 101, 214, 258, 464, 465
 malignant lymphoma Wilms tumor 464
 metastatic 258
Neurodegenerative diseases 253, 254, 255,
 259, 389
 chronic inflammatory 259
Neuroendocrine tumors 214, 215, 222, 223,
 224, 465
Neurofibromatosis 463
Neurogenesis 258
Neurohormonal dysregulation 547
Neuromuscular disorders 330
Neurons 225, 254, 255, 257, 258, 259, 465,
 604
 hypothalamic 604
Neuropeptide 465, 585
Neutropenia 353, 357, 454
Neutrophil granulocytes 527, 668
Neutrophilia 277, 474
Neutrophil-to-lymphocyte ratio (NLR) 38
NFAT pathways 185
Nicotinamide 638
 adenine dinucleotide (NAD) 638
 phosphoribosyltransferase 638
Nitroblue Tetrazolium test 455
Nitrosylation 559
Noninfectious Diseases 387
Nonischemic cardiomyopathy 548
Non-seminoma, metastatic 58
Non-seminomatous germ cell tumors
 (NSGCTs) 56, 58, 59
Non-small cell lung cancers (NSCLC) 5, 6, 7,
 8, 119, 352

Notch signaling pathways in relation to viral infections 385
Novel red blood cell indexes 617
Nuclear factor kappa-light-chain-enhancer 604
Nucleic acid 103
 binding and ATP-dependent RNA helicase activity 103
Nucleoside monophosphates 502
Nucleotidase 490, 498, 502, 503
Nucleotide polymorphisms 506
Nutrition 620
 and nutrition-related diseases 620
 related diseases 620

O

Obesity 606, 627, 631, 632
 aging-associated 631
 pathogenesis of 606, 627, 632
Occlusion, proximal acute coronary artery 545
Octreotide scanning 227
Olaparib concentration 361
Omentin genes 639
Oncofoetal glycoprotein 122
Oncogenes 40, 95, 102, 184, 190, 248, 285, 288, 289, 382, 390
 protein-encoding 382
Oncogenesis 247, 248, 388
Oncogenic 105, 177, 248
 dysregulated 177
 properties 248
Operator-dependent nature 44
Oral 161, 283, 287, 441, 442, 462
 antidiabetics 442
 cancer tissue specimens 283
 glucose tolerance test (OGTT) 441, 462
 lenalidomide therapy 161
 squamous cell cancer (OSCC) 283, 287
Orchidectomy 56
Organic anion 314, 346
 transporters (OAT) 314
 transporting polypeptides (OATPs) 314, 346

Osmoregulation 297
Osteoarthritis 365
Osteoclasts 293
Osteogenic sarcoma 464, 499
Osteomyelitis 472, 473
Osteoporosis 425, 430, 616, 635
Osteosarcoma 214
Otosclerosis 276, 295, 296, 299
Outer hair cells (OHCs) 296
Ovarian 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 360, 412
 and fallopian tube cancers 16
 cancer (OC) 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 360
 cysts 412
Ovary syndrome 388, 571
 polycystic 388
Oxidation 78, 243, 312, 313, 322, 326, 442, 559, 560, 616
 tyrosine 559
Oxidative 287, 289, 363, 446, 555, 556, 557, 558, 560, 561, 600, 601, 606
 biomarkers 555
 degradation of rivaroxaban 363
 reactions in phagocytic cells 556
 stress 287, 289, 446, 555, 556, 557, 558, 560, 561, 600, 601, 606
Oxymetazoline 330, 339
 vasoconstrictor 339

P

Paget's disease 296
Pain 114, 329, 333
 diabetic peripheral neuropathic 333
Pancreatic 224, 225, 226
 neuroendocrine tumors 224
 polypeptide 224, 225, 226
Pancreatic adenocarcinoma 217, 357
 metastatic 360
Pancreatic cancers 59, 213, 216, 217, 228, 355, 383
 metastatic 355

Subject Index

Pancreatitis 85, 215, 216, 217, 412, 418, 469, 635
Pancytopenia 156, 461
Papillary thyroid 77, 79, 88, 220, 221, 289, 290
 cancers (PTC) 77, 79, 88, 220, 221, 289, 290
 carcinomas 220
Papillomavirus 102
Paracrine interaction 293
Parafollicular cells 78, 79, 84, 88, 222
 calcitonin-producing 222
Paraganglioma 223, 225
Parkinson's disease 253, 255, 390
Pathophysiological mechanisms in synthesis and secretion 246
 of BNP 246
Pathways 39, 40, 51, 61, 98, 103, 121, 179, 244, 255, 276, 277, 278, 281, 287, 288, 296, 314, 320, 321, 322, 324, 345, 348, 381, 452, 506, 631, 632, 664, 672, 669
 alcohol dehydrogenase 345
 anaerobic 244
 apoptotic 121
 canonical 296
 cobalamin-dependent 98
 fibroblast growth factor 61
 inflammatory 277, 631, 632
 inhibiting mitochondrial 672
 mechanistic 452
 metabolic 324, 381
 nucleotide excision repair 40
 oncogenic 103, 179
 pro-thrombotic 664
 purine catabolic 669
 pyrimidine nucleotide biosynthesis 348
 rapamycin 39
 triggering autophagic 255
PCR 55, 179, 662
 based fragment analysis 55
 technique 662
 tests 179
PCR amplification 157, 176
 of antigen receptor genes 176
Pediatric 55, 450, 457, 470, 472, 475

Biomarkers in Medicine 705

 autoimmune diseases 457
 clear cell sarcoma 55
 diseases 450, 470, 472, 475
 rheumatology 457
 systemic sclerosis (PSS) 457
Pegloticase 362, 366
Pembrolizumab 3, 6, 9
Pentagastrin test 84
Peptic ulcer 216
Peptides 84, 86, 119, 120, 138, 224, 225, 227, 228, 239, 245, 426, 473, 501, 663
 amino acid 84, 663
 diuretic 245
 gastrin-releasing 86
 minimum inhibitory 239
 toxic 426
 vasoactive intestinal 86, 227
Peripheral blood 86, 104, 114, 134, 139, 157, 165, 174, 191, 277, 430, 467, 584
 cytopenia 157
 eosinophil 430
 granulocytes 165
Peripheral nervous system (PNS) 254
Peritonitis 216
PET scan imaging 20
Phagocytic cells 556
Phagocytosis 2, 664
Pharmacogenomic Biomarkers 339, 367
 for anesthesia 339
 for treatment 367
Pheochromocytoma 80, 223, 225, 465
Philadelphia chromosome 164, 357
Phosphatases 54, 62, 165, 462, 498
 anti-tyrosine 462
 inducible protein 165
Phosphate 290, 313, 330, 343, 498
 amifampridine 330, 343
 monoesters 498
Phospholipase 135
Phosphorylation 244, 250, 256, 287, 294, 348, 627
 inhibiting 256
 oxidative 287, 672
Pituitary adenoma 215, 227
PKA phosphorylates 240

- PKC signaling pathways 289
- Placental 24, 589
dysfunction 589
trophoblasts 24
- Plasma 21, 119, 228, 428, 503, 534, 603
creatinine 534
fibrinogen 428
growth hormone 228
peptides 119
preoperative 21
proteins 503, 603
- Plasmacytosis 188
- Plasma proteome 603
profiling technique 603
- Plasminogen 139
- Plasmodium* 667
falciparum 667
vivax 667
- Plasticity 259, 389
modulating synaptic 259
- Pleiotropic effects 3
- Pleural pericardial effusions 669
- Pneumonia 214, 412, 468, 666
pneumoniae 468
- POLG gene 338
- Polyangiitis 465, 466, 467
microscopic 467
- Polycythemia 468, 472
- Polycytosis 472
- Polymerase 120, 139, 154, 338, 360, 380
chain reaction 139, 154, 380
mitochondrial DNA 338
- Polymorphisms 116, 279, 298, 309, 311, 328,
364, 367, 445, 506
- Positron emission tomography (PET) 47, 114,
546
- Post 138, 279, 607
immunotherapy serum activities 279
sleeve gastrectomy 607
translational modifications (PTMs) 138
- Postoperative 81, 223, 525, 470
AKI in children 525
complications 470
parathyroid hormone 223
risk stratification 81
- Preeclampsia 587, 589
- Pregnancy 251, 583, 589
associated plasma 589
asymptomatic 589
nulliparous singleton 583
specific glycoproteins (PSGs) 251
- Pregnant women 581, 582, 583, 584, 585,
586, 587, 588, 589, 633
asymptomatic 586, 587, 588
- Preoperative 116, 223, 604
and postoperative parathyroid hormone 223
chemoradiotherapy 116
peroxisome 604
- Pre-proinsulin mRNA expression 443
- Pressure 246, 256, 291, 504
hydrostatic capillary 256
oncotic 504
- Primary 57, 80, 81, 85, 86, 191, 258, 353, 499
biliary cholangitis 499
sclerosing cholangitis 499
tumor 57, 80, 81, 85, 86, 191, 258, 353
- Primary liver 493, 507
carcinoma (PLC) 507
malignancy 493
- Process 39, 96, 99, 246, 248, 249, 250, 252,
254, 255, 257, 259, 277, 280, 282, 286,
294, 311, 312, 417, 503, 505, 506, 569,
572, 589, 603, 613
dynamic 39, 249, 505, 603
eosinophilic 277
lipid peroxidation 282
metabolic 294, 503
multifactorial 506
myelination 254
neoplastic 286, 417
neuroprotective 255
neutrophilic 280
nutrition care 613
suppress apoptotic 248
vascular remodelling 589
- Progenitor cells 156, 158, 258
normal hematopoietic 156
- Progesterone 26, 217, 218, 219, 316, 568, 569,
573, 581, 587
receptor (PR) 26, 217, 218, 219, 568, 587

- Prognosis of lymphomas 177, 181, 186
Prognostication 9, 117, 118, 133, 140, 143,
150, 161, 193, 533
Prognostic 23, 40, 50, 52, 57, 116, 151, 167,
189, 512, 560
 biomarkers 50, 52, 512, 560
 factors 23, 40, 57, 116, 151, 167
 systems 189
Prognostic markers 1, 4, 7, 151, 157, 162,
380, 385, 657, 660, 663
 of immunotherapy 4
Programmed-death ligand (PDL) 39
Progression 6, 20, 41, 42, 58, 61, 124, 157,
158, 161, 162, 168, 189, 190, 191, 192,
429, 430, 431, 450
 free survival (PFS) 6, 20, 58, 61, 168, 189,
191
Proinflammatory 582, 588, 627, 629, 661
 cytokines 582, 588, 629, 661
Prokalsitonin 430
Prolactinoma 215
Prolonged inflammatory processes 506
Propafenone 316, 317, 319, 320, 323
 metabolism 319
 pharmacokinetics 319
Properties 114, 187, 213, 223, 247, 280, 415,
419, 459, 557, 585, 638, 661
 angiogenic 585
 anti-inflammatory 280
 antimicrobial 415
 biomolecular 419
 cell growth promotion 247
 metastatic 638
 proinflammatory 661
Prostaglandin synthase 556
Prostate 18, 45, 46, 47, 48, 104, 214, 291, 383,
465
 biopsy 45, 46, 48
 health index (PHI) 46
 hypertrophy 214
 specific membrane antigen (PSMA) 47
 tissue 48
Prostate cancer 37, 40, 41, 44, 62, 102, 119,
214, 220, 360, 384, 451
 metastatic castration-resistant 360
Prostatectomy 41
Prostatic acid phosphatase (PAP) 4
Prostatitis 214
Proteases 280, 426, 461, 570, 628
 matrix metalloproteinases 280
Proteasome inhibitors (PIs) 188, 190
Protein 58, 503, 558, 632, 657
 carbonyl oxidation (PCO) 558
 disulfide isomerase (PDI) 632
 enzyme 58
 metabolism 503
 metabolites 657
Protein kinase 79, 185, 240, 244, 254, 281,
288, 294
 activating mitogen-activated 244
 mitogen-activated 79, 288, 294
 serine threonine 288
Proteinuria 459, 526
Proteoglycan 106, 462
 transmembrane heparan sulfate 106
Proteolysis 415, 666
Proteome 296, 566
 core perilymph 296
Proteomic(s) 86, 134, 139, 506, 508, 532, 565,
567, 568, 570, 600, 603, 671
 and Lipidomic Profiling 603
 analysis and serum metabolite biomarkers
 508
 information 86
 techniques 139
Prothrombin 349, 490, 503, 504, 507, 511
 time (PT) 349, 490, 503, 504, 507, 511
Proximal tubular reabsorption 524
Pseudocholinesterase 507
Psoriasis 389
Psoriatic arthropathy 470
PTS-inducing acoustic trauma 298
Pulmonary hemorrhage 81
- Q**
- Quinidine therapy 340

R

Radioactive iodine therapy 81
Radioimmunoassay 18, 83, 456
Radiological techniques 414
Radiotherapy 81, 286, 287, 411
RAS mutations 80, 163, 290, 354, 361
Reactions 312, 346, 382, 655
 autoimmune 382
 hydrolysis 312, 346
 inflammatory 655
Reactive oxygen species (ROS) 244, 245, 282,
 555, 556, 557, 558, 559, 560, 588, 629
Receptor tyrosine kinase (RTK) 288
Refractory cytopenias 159, 163
Regulating metabolic circadian rhythms 641
Regulation 471, 671
 inflammatory 471
 protein synthesis 671
Renal 3, 49, 50, 51, 52, 53, 54, 55, 62, 63,
 188, 245, 355, 356, 527, 528, 531
 angiomyolipoma 356
 cell carcinoma (RCC) 3, 49, 50, 51, 52, 53,
 54, 55, 62, 63, 355, 356
 functions 188, 245, 527, 528
 tubular dysfunction 531
Renal injury 532, 536
 predicting sepsis-associated 532
 tissue-defined 536
Renal tumors 54, 55, 63
 aggressive pediatric 55
 pediatric 54
Repair DNA methylation 98
Respiratory diseases 278, 656
Retinopathy 441, 442
Reverse transcriptase-PCR 154
Rheumatic 462, 470, 472
 carditis 462
 fever 470, 472
Rheumatoid 365, 388, 389, 458, 460, 461,
 470, 471, 668
 arthritis (RA) 365, 388, 389, 460, 461, 470,
 471, 668
 factor (RF) 458, 460, 461

Risk 9, 10, 16, 21, 25, 336, 337, 345, 363,
 364, 367, 368, 534, 535, 548, 549, 550,
 587, 588
 duodenal ulcer recurrence 367, 368
 of Ovarian Malignancy Algorithm
 (ROMA) 16, 21, 25
RNA 98, 117, 181, 282, 389
 binding proteins 87
 metabolism 282
 methyltransferase 98
 sequencing analysis 181, 389
 silencing 117

S

Salivary gland tumors 290, 291
Sarcoidosis 216, 250, 499
SARSCoV-2-infection 672
Scedosporiosis 349
Schizophrenia 330, 331, 332
Screening 16, 214, 458
 autoimmune disease 458
 neoplasia 214
 ovarian cancer 16
Secretion 409, 630
 gastric acid 409
 hepatic triglyceride 630
Seminomas 56, 57, 58, 59, 60
 metastatic 59
Sensitivity 21, 22, 25, 26, 43, 44, 106, 107,
 116, 142, 168, 217, 218, 240, 286, 287,
 510, 535
 to chemotherapy and radiotherapy 286
 tumour 116
Sepsis 85, 532, 533, 656, 659, 660, 661, 662,
 663, 664, 665, 666, 668, 669, 671, 672
 prognosis 85, 663
Serine 47, 296
 enzyme transmembrane protease 47
 protease 296
Serotonin syndrome 326
Sex hormone-binding globulin (SHBG) 589,
 603
Shigellosis 348

- Shock, septic 214, 386, 473, 656, 659, 663, 666
- Sickle cell anemia 472
- Signaling pathways 185, 288, 294, 314, 381, 386, 388, 390, 560, 640, 657
- immune-related 386
 - immune system-related 386
 - oncogenic 185
 - pro-inflammatory 640
- Signal 163, 180, 254, 314, 568, 666
- transduction 163, 180, 314, 666
 - transmission 254, 568
- Single nucleotide polymorphism (SNPs) 49, 171, 310, 602, 603, 620
- Sinonasal carcinoma 281
- Sjogren's syndrome (SS) 321, 389, 428, 457
- Skin diseases 227, 453, 456
- common chronic inflammatory 453
- Skin prick test (SPT) 452
- Sleep apnea, obstructive 326
- Small-cell lung cancer (SCLC) 8, 85, 464
- Smoldering multiple myeloma (SMM) 188, 189, 190, 192
- Sneddon syndrome 467
- and humoral immunodeficiency 467
- Sorbitol dehydrogenase 493
- Spermatogenesis 103
- Spherocytosis 472
- Spinal muscular atrophy (SMA) 343, 390
- Squamous cell carcinoma 27, 105, 284
- Squamous oropharyngeal cancer 281
- Staphylococcus aureus* 277, 279
- enterotoxins 277
- Stem cell transplantation 169, 176
- allogeneic hematopoietic 169
 - hematopoietic 176
- Stenosis 387
- Stimuli 84, 102, 297, 471, 664
- adrenergic 297
 - angiogenic 664
 - environmental 102
- Streptococcus pneumoniae* 658
- Streptomycin 247
- Stress 252, 254, 255, 259, 297, 550, 626, 632, 639
- cardiac 550
 - hormone 297
 - metabolic 639
- Stroke 256, 317, 363, 364, 441, 634, 635
- Subglottic carcinoma 284
- Succinate dehydrogenase 62
- Superoxide dismutase 557, 558
- Surgery 220, 525, 529, 533, 535, 587, 603, 615
- biliopancreatic 615
 - cardiac 525, 529, 533, 535
 - cardiovascular 527
 - cervical 587
 - diagnostic hemithyroidectomy 220
 - metabolic 603
- Symptoms 224, 226, 227, 229, 321, 322, 323, 328, 458, 461, 462, 463, 490, 491, 492, 655, 656, 659
- of urinary incontinence 321, 322, 323
 - premenstrual dysphoric disease 328
- Synaptic transmissions 254
- Syndrome 18, 25, 80, 152, 159, 161, 226, 227, 357, 458, 459, 463, 473, 536, 614, 535, 637, 656, 663
- antiphospholipid 459
 - cardiomyopathy 548
 - coronavirus 656
 - hypereosinophilic 357
 - macrophage activation 473
 - metabolic 25, 614, 635, 637
 - systemic inflammatory response 663
- Synthesis 78, 79, 246, 429, 468, 504, 588, 616, 638
- prostaglandin 588
- Systemic 389, 457, 458, 459, 460, 470, 472, 663, 666
- inflammatory response syndrome (SIRS) 663, 666
 - lupus erythematosus (SLE) 389, 457, 458, 459, 460, 470, 472
 - scleroderma 458
 - sclerosis 472
- Systolic dysfunction 548

T

- Testicular 37, 56, 57, 58, 59, 60, 63, 104, 215
- cancer (TC) 37, 56, 57, 58, 60, 63, 104, 215
 - germ cell tumors (TGCTs) 56, 59, 60, 63
- Testosterone 501
- Thalassemia 59
- Therapy 3, 4, 62, 116, 118, 119, 120, 121, 125, 137, 139, 140, 142, 143, 182, 216, 359, 442, 530, 582
- corticosteroid 582
 - epigenetic 182
 - hormonal 351
 - hormone 62, 359
 - insulin 442
 - oxaliplatin 116
- Thiamine 617
- deficiency 617
 - pyrophosphate 617
- Thrombocytopenia 163
- Thrombocytopenia 161, 181, 454, 461, 474
- Thrombocytosis 52, 156, 159, 166, 467
- Thromboembolism 470, 550
- Thrombosis 165, 166, 635
- Thromboxanes 568
- Thymic stromal lymphoprotein 278
- Thymidylate synthase (TS) 120, 121
- Thyroglobulin synthesis function 88
- Thyroid 25, 78, 79, 81, 82, 98, 213, 218, 220, 221, 223, 276, 460
- antibodies 460
 - follicle function 79
 - hormones 78, 79, 218
 - stimulating hormone (TSH) 25, 79, 82, 221
- Thyroid cancer 82, 289, 464
- cell growth 289
 - malignant 464
 - screening 82
- Thyroid carcinomas 79, 80, 221
- anaplastic 80
 - follicular 79
- Thyroid diseases 83, 221
- autoimmune 83
- Thyroidectomy 87, 222, 223
- Thyroiditis 221
- Tourette's disorder 331, 332
- Transaminases 493, 494
- Transcription 53, 55, 95, 96, 102, 246, 310, 343, 382, 389, 390, 662
- microphthalmia-associated 55
- Transcription factor(s) (TF) 51, 63, 158, 162, 218, 279, 282, 289, 296, 381, 632, 633, 641
- ligand-dependent 218
 - melanogenesis-associated 63
- Transcriptome profiling techniques 380
- Transformation 158, 159, 166, 167, 180, 181, 289, 506, 567
- malignant 167, 180, 181
- Transforming growth factor (TGF) 3, 5, 278, 289, 293, 295, 296, 429
- Transglutaminases 293, 417
- Transient abnormal myelopoiesis (TAMs) 152, 252, 253
- Transition 50, 96, 284, 288, 385
- epithelial-mesenchymal 284, 288
- Transketolase 617
- Translation 379, 390, 527
- inhibiting protein 527
- Translocations 154, 155, 156, 162, 164, 171, 172, 173, 174, 177, 179, 181, 184, 190
- Transmembrane proteins 3, 106, 314
- Transplantation 531, 603, 667
- hematopoietic cell 165
- Transporters 247, 314, 341, 346, 347, 360, 362, 603
- toxin extrusion 346
 - vesicular monoamine 341
- Trauma 255, 259, 408, 468, 472, 634, 660, 662
- surgical 660
 - thermogenic 255
- Treatment 21, 60, 64, 81, 117, 122, 124, 133, 134, 214, 317, 326, 336, 341, 343, 345, 353, 355, 359, 360, 368, 369, 442, 469, 657
- aggressive 81
 - hormonal 21

inefficient toxic 117
induced adaptation 133
insulin 442
Troleandomycin 315, 316
Trypanosoma brucei infection 667
Tuberculosis, multidrug-resistant 656
Tumor(s) 1, 2, 4, 5, 19, 23, 37, 38, 51, 52, 53,
54, 55, 56, 86, 95, 96, 172, 223, 224,
225, 226, 227, 247, 258, 290, 291, 413,
418, 450, 464, 499, 509, 510
angiogenesis 53
bladder 37, 38
carcinoid 225, 226
endodermal sinus 23, 464
fusion-dependent 55
hematopoietic 56
malignant 19, 51, 290, 291, 509, 510
malignant eosinophilic 52
metastatic 258, 499
non-carcinoid gastroenteropancreatic 223
pancreatic 227
pediatric 450
serotonin secreting 226
Tumor cells 3, 38, 86, 192, 219, 220, 247,
248, 249, 250, 252, 253, 353, 354, 355
mesenchymal 250
Tumor markers (TMs) 56, 59, 60, 213, 214,
215, 216, 217, 218, 224, 228, 229, 463,
464, 493, 507
for primary liver malignancy 493
in liver disease 507
Tumor necrosis 53, 252, 253, 283, 295, 298,
429, 466, 506, 616, 626, 658, 662
factor (TNF) 252, 253, 283, 295, 298, 429,
616, 658, 662
Tumor suppressor 95, 103, 105, 106, 107,
158, 179, 187, 280, 283, 285, 290, 382,
390
gene functions 179
gene mutations 290
pathways 103
protein 280
Tyrosine kinase inhibitors (TKIs) 81, 141,
154, 167, 168, 171, 172, 175

U

Ulcerative colitis (UC) 215, 366, 370, 389,
414, 469, 616
Ultrasonography 17, 77, 80, 88, 222, 500, 502,
509
transvaginal 17
Urinary 527, 531
angiotensinogen (UAGT) 527
biomarkers of renal tubular dysfunction
531
Urine microscopy 459
Urological tumours 37
Urothelial carcinoma 7, 39, 61, 62
metastatic post-platinum 61
muscle-invasive 62

V

Vaccine-based therapy 4
Vaginal 329, 586
dryness 329
swab 586
Vascular endothelial growth factor (VEGF)
52, 53, 63, 252, 278, 429, 664
Vasculitis 466, 467, 469
autoimmune 469
cryoglobulinemic 466
necrotizing 467
Vasculitis syndrome 467
Vasoactive intestinal peptides (VIP) 227
Vasodilation 245, 246, 663
systemic 246
Ventricular 240, 545, 546, 547
fibrillation 545
pumping function 240
tachycardia 545, 546, 547
Ventricular arrhythmias 546, 548, 549, 550,
551
malignant 549, 551
Verner-Morrison syndrome 227
Viral respiratory tract infections 472
Virus 27, 255, 329, 386, 666, 670
herpes 255

herpes simplex 386
human immunodeficiency 329, 666, 670
human papilloma 27
Virus infections 382, 468
vesicular stomatitis 382
Vitamin 85, 364, 499, 500, 504, 508, 557,
588, 589, 611, 612, 615, 616, 617
D binding protein (VDBP) 588, 589
deficiencies 615
low lymphocyte 616
reduced 616
zinc deficiency 500
Vomiting 367, 370, 491

binding protein 414
ion-binding proteins and ribo-somal
proteins 291
protoporphyrin 617
Zollinger-Ellison syndrome 215

W

Warfarin treatment 504
Wegener Granulomatosis 470
Wernicke-Korsakoff syndrome 617
Wheat allergies 453
White 173, 291, 473, 474, 606, 630, 657, 658,
662, 669, 671
adipose tissue deposition 606
blood cell (WBC) 173, 291, 473, 474, 630,
657, 658, 662, 669, 671
WHO classification of myelodysplastic
syndromes 159
Wilms tumor (WT) 54, 63
Wilson's disease 491
Wiskott-Aldrich syndrome and hyper IgM
syndrome 454
Wnt signaling pathway 249, 250
Women, obese post-menopause 636
World health organization (WHO) 50, 55,
151, 386, 474, 491, 600, 611, 656

X

Xanthine oxidase 556

Z

Zinc 291, 414, 615, 617



Pinar Atukeren

Prof. Dr. Pinar Atukeren is the Dean of the Faculty of Pharmacy of Istanbul University-Cerrahpaşa, Istanbul, Turkey. She is also a senior professor in the Department of Medical Biochemistry of Cerrahpaşa Medical Faculty, in the same university. Dr. Atukeren is the head of the Animal Welfare and Ethics Committee and also a member of the Scientific Research Projects Coordination Unit of Istanbul University-Cerrahpaşa. Her research interests are oxidative and nitrosative stress in health and diseases and antioxidants. She has published many papers in indexed journals and edited and authored many books and book chapters. At the community level, Dr. Atukeren is an active member in several governmental and non-governmental societies and committees.



Hafize Uzun

Hafize Uzun received her bachelor's degree from Yildiz Technical University in 1981, Chemical Engineering Degree in 1989 and doctoral degree in 1998 in Medical Biochemistry from the Istanbul University, Cerrahpasa School of Medicine, and Department of Medical Biochemistry. Prof.Uzun had been working at Istanbul University Cerrahpasa Medical School, Department of Medical Biochemistry from 1985 to 2021 (One of the best medical schools in Turkey, selecting student ranking in first 2000 among 1.5 million students). After retirement from Istanbul University-Cerrahpasa, Prof.Uzun is leading an academic life as a full time faculty member in the Faculty of Medicine at the Istanbul Atlas University.